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Abstract 
 
Nucleoside analogues are a pharmacologically diverse family that includes cytotoxic 
compounds, antiviral agents and immunosuppressive molecules. Considerable progress 
has been made in the search for novel nucleoside structures with anticancer and/or 
antiviral activity by modifications in the nucleobase and/or in the sugar moiety and 
several branched-chain sugar nucleosides have shown potent antitumor activity. These 
agents behave as antimetabolites that interact with a number of intracellular targets 
blocking the DNA chain elongation or interfering with biosynthesis of nucleosides and 
nucleotides, a limiting process in cell proliferation. Many of the enzymes involved in 
these pathways are highly active in cancer cells, such as ribonucleotide reductase 
(RNR). RNR is a multisubunit radical-containing enzyme involved in the conversion of 
ribonucleoside diphosphates to the corresponding 2'-deoxyribonucleotides, which are 
building blocks for DNA replication and repair. Increased RNR activity has been 
associated with malignant transformation and tumor cell growth; it is therefore an 
excellent target for cancer chemotherapy. In recent years, several nucleoside RNR 
inhibitors have entered clinical trial or application such as arabinosylcytosine (ara-C), 
gemcitabine, cladribine, fludarabine and clofarabine.  
A previous structure-activity relationship study reported by us, identified the 3'-C-
methyladenosine (3'-Me-Ado) as a mechanism-based RNR inhibitor endowed with a 
significant antitumor activity against a panel of human leukemia and carcinoma cell 
lines. 
To further investigate the structural determinants of 3'-Me-Ado required for the 
antitumor activity, in the first part of my PhD project, a number of 3'-C-methyl 
ribonucleosides with different purinic and pyrimidinic nucleobases and the 3'-C-methyl 
derivatives of the antitumor agents 5-fluorouridine and 9-(β-D-arabinofuranosyl)-
adenine were synthesized and evaluated on human tumor cell lines. 
The biological results showed that the structure of 3'-Me-Ado is crucial for the 
antitumor activity of this type of ribose-modified nucleosides.  
A further structure-activity relationship study of synthesized adenine 3'-C-methyl-
ribonucleosides containing different substituent at N6-amino group of nucleobase such 
 1
as a cycloalkyl, aryl or heteroaryl group confirmed that any modification in the structure 
of 3'-Me-Ado is detrimental for the antitumor activity. 
The obtained results have been rationalized by docking studies utilizing the X-ray 
structure of the subunit Rnr1 of the RNR from Saccharomyces cerevisiae complexed 
with ADP. 
The ribose recognition domain of adenosine derivatives appears to be of considerable 
importance not only for cytotoxic activity, but also for agonistic activity at adenosine 
receptors (ARs).  
The physiological agonist adenosine modulates a variety of functions through four 
receptor subtypes classified as A1, A2A, A2B and A3.  A1 adenosine receptors (A1 ARs) 
are expressed in high density in the brain, in adipose tissue and in medium to low levels 
in many peripheral organ and tissues such as heart, lung and kidney. Thus, A1 agonists 
have many therapeutic potentials; however the clinical application of A1 full agonists is 
hampered by several side effects. In this respect, it has been reported that A1 partial 
agonist may be therapeutically advantageous.  
Among the adenosine derivatives, some 5'-chloro-5'-deoxy-N6-cycloalkyl(bicycloalkyl)-
analogues were found A1 agonists with high affinity and selectivity for rat A1 AR or 
partial agonists for this AR subtype. 
In the search for potent and selective A1 AR agonists we have previously investigated a 
series of 2'-C-methylribofuranosyl analogues of selective A1 AR agonists and 2-chloro-
2'-C-methyl-N6-cyclopentyl-adenosine (2'-Me-CCPA) emerged as a potent and highly 
selective full agonist at rat, bovine and human A1 vs A2A, A2B and A3 ARs.  
On the base of these findings, in the second part of my work, a series of 5'-substituted 
derivatives of potent and selective A1 AR agonists were synthesized and tested for 
affinity and selectivity at different model of adenosine receptor subtypes.  
In particular, a series of 5'-carbamoyl or 5'-thionocarbamoyl derivatives of 2'-Me-CPA, 
2'-Me-CCPA, N6-[(R)-3-tetrahydrofuranyl]adenosine and 2-chloro analogue were 
synthesized and evaluated for binding affinity at ARs from bovine, porcine and human 
species. 
Moreover, a series of 5'-chloro-5'-deoxy-N6-cycloalkyl(bicycloalkyl)-substituted 
adenosine and 2'-C-methyladenosine derivatives and 2-chloro analogues were 
synthesized and evaluated for affinity and efficacy at all cloned human AR subtypes.  
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In this study, two adenosine derivatives displayed the highest affinity in the 
subnanomolar range and relevant selectivity for hA1 vs the other human receptor 
subtypes. This result was rationalized by a molecular modeling analysis.  
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Chapter 1. 
 
Introduction 
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1.1 Nucleoside analogues as therapeutic agents 
 
Nucleoside analogues are important component of treatment regimes for various 
malignancies. These are a pharmacologically diverse family, which includes cytotoxic 
compounds, antiviral agents, and immunosuppressive molecules. The anticancer 
nucleosides include several analogues of physiological pyrimidine and purine 
nucleosides and nucleobases. The growing importance of nucleoside analogues as 
cytotoxic agents has stemmed both from the development of newer compounds with 
broad applicability to common cancers and from an understanding of their mechanisms 
of action, enabling pharmacological intervention to potenziate the antitumor effects of 
these compounds.  
Cytotoxic nucleoside analogues are antimetabolites that interfere with the synthesis of 
nucleic acids. These agents can exert cytotoxic activity by being incorporated into and 
altering the DNA and RNA macromolecules themselves, by interfering with various 
enzymes involved in synthesis of nucleic acids, or by modifying the metabolism of 
physiological nucleosides. 
Several nucleoside analogues developed as antitumor agents are adenosine derivatives 
in which the nucleobase and/or the β-D-ribofuranosyl moiety were modified.  
The natural nucleoside is a crucial factor in determining the cell progression pathway, 
either in the apoptotic or in the cytostatic state.1 In fact, adenosine plays an important 
role in cancer growth and tumor diffusion interfering on neovasculogenesis, immune 
system anticancer activity, and improvement of tumor cell vitality and proliferation, 
which are events at the heart of all tumor development. 
Adenosine can be released from a variety of cells throughout the body, and is generated 
by the degradation of ATP, in concentration that can profoundly influence the 
immunoescaping and growth of tumors. It is recognized that the concentration of 
adenosine is increased in cancer tissues. In particular, it is recognized that significant 
levels of adenosine are found in the extracellular fluid of solid tumors,2 suggesting a 
role of adenosine in tumor growth.  
Adenosine has been shown to interfere with the proliferation of many cell types: it 
markedly inhibits proliferation of tumor cell whilst stimulates the proliferation of 
normal cells.3-5  
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Concerning the nervous system-derived cells, it was underlined that adenosine has been 
demonstrated to protect damaged neuronal cells against cell death.6
In vivo studies have shown that adenosine exerts a profound inhibitory effect on the 
induction of mouse cytotoxic T-cells, without substantially affecting T-cell viability.7,8  
The ability of adenosine to specifically inhibit tumor cell growth in vitro and in vivo 
suggests that the activation and/or blockade of the pathways downstream of adenosine 
receptors may contribute to tumor development. Furthermore, the extracellular 
adenosine concentration may be a crucial factor in determining the cell progression 
pathway, either in the apoptotic or in the cytostatic state. 
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1.2 Importance of conformational issues of nucleosides and nucleotides 
for biological activity 
 
The conformational behaviour of natural and modified nucleosides, especially the sugar 
puckering, has demonstrated to be of great importance in terms both of their metabolic 
pathway and of their interaction with the biological targets.9     
The sugar puckering of natural ribo- and deoxyribonucleosides are known to exist in 
dynamic equilibria between two major conformers: the North (N) and the South (S) 
types. Conformational studies of nucleosides in solution indicate that the North/ South 
interconversion is rapid.10 However, when a nucleoside or a nucleotide bind to an 
enzyme (anabolic or catabolic) or its pharmacological target, only one conformer would 
be expected to be present within the active site. Although the binding conformation is 
probably modified by the enzyme to achieve optimal fitting, any conformation-activity 
study would be very useful in order to identify conformational preferences of enzymes 
involved in the metabolism of nucleos(t)ides and to study the interactions of such 
compounds with their enzymatic (or pharmacological) target. 
The complete definition of the conformational behaviour of natural or modified 
nucleosides involves the determination of four structural parameters (Figure 1): 
1) The glycosidic torsion angle χ  determines the syn or anti disposition of the base 
relative to sugar moiety 
2) The torsion angle γ determines the position of the 5′-OH with respect to C-3′ as 
represented by the three main rotamers γ+, γt and γ- 
3) The pseudorotational phase angle P  
4) The maximal puckering amplitude νmax 
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       Fig. 1.  Nucleoside conformation parameters (angle χ, angle γ, pseudo-rotational  
         P angle). 
 
 
 Torsion Angle  χ  
 
The torsion angle χ is determined by the orientation of the base towards the glycosidic 
bond. While in purinic nucleosides the torsion angle is defined as the dihedral angle 
between the O4′-C1′-N9-C4 atoms, in pirimidinic nucleosides this angle is between the 
O4′-C1′-N1-C2 atoms. Therefore, the origin of the angle is given by the O4′-C1′ and N9-
C4 in purinic nucleosides and by the O4′-C1′ and N1- C2 in the pirimidinic ones. 
The nucleobase can have two extreme conformations, syn (180 ± 90°) and anti (0 ± 90°). 
Pirimidinic nucleosides prefer anti conformation, while the two purinic nucleoside 
conformations are in rapid equilibrium in solution. 
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The nucleobase orientation towards the glycosidic bond can be determined by measuring 
the Nuclear Overhauser Enhancement  (NOE) effects in 1H-NMR experiments.                   
 
γ Angle  
 
The orientation of the 5′-hydroxymethylic group is given by the torsion angle γ, which is 
the dihedral angle between C3′-C4′-C5′-O5′.11  
The 5′-hydroxymethylic group can adopt three main conformations, ap (trans), +sc 
(gauche), e -sc (gauche), with a γ value of approximately 180°, 60° and -60°, respectively 
(Figure 2). 
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                         Fig. 2. Main conformations of γ angle. 
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Pseudorotational Angle P  
 
The sugar bending is described by two parameters: 
- the phase pseudorotational angle P, known as Altona-Sundaralingam (AS) angle, 
- bending width (ν max). 
The phase angle P can be determined from the endocyclic torsion angle showed in 
Figure 3. 
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   Fig. 3. Torsion angle. 
 
 
 
When the phase angle P equals 0°, the obtained conformation is C2′-exo/C3′-endo or 3T2 
(Figure 4). This is a twist conformation where the C1′, O4′ and C4′ atoms are on a plane 
and the C3′ and C2′ atoms are below (endo) or over (exo) the plane. 
The next conformation C3′ endo is due to a value of the P angle of 18°. This is an envelope 
conformation 3E where the C1′, O4′, C4′ and C2′ atoms are on a plane and the C3′ atom is 
below the plane. Thus every increase of the phase angle P of 18° determines a new 
conformation which is in turn twist (T) or envelope (E). 
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  Fig. 4. Pseudorotational parameters of the sugar moiety. 
 
The dynamic equilibrium between the two conformations depends on the nature of the 
sugar and the substituents.  While in solid state one conformation is prevalent, in solution, 
both conformations exist in a dynamic equilibrium. The energy barrier between these two 
states is low (4.7 kcal mol-1 is observed experimentally) and a rapid transition from one to 
the other proceeds through the East (0E, O4′-endo) rather than the West (0E, O4′-exo) 
conformation. The relative position of the equilibrium is determined by the 
stereoelectronic gauche and anomeric effects, which are modulated by electronegativity, 
steric hindrance and stereochemistry of the substituents on the furanose ring. For example, 
amounts of N conformers increase linearly with the electronegativities of the substituent in 
the 2′-position in 2′-deoxyribonucleoside derivatives, owing to their preferential axial 
orientations due to the gauche effect.12 In addition, the less favourable conformation in 
terms of steric interactions is W (0E, O4′-exo) in which C2′- and C3′- substituents are 
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eclipsed, while 5′-CH2OH and the base are in axial positions. The bases have their least 
steric hindrance when in the pseudoequatorial positions of the S conformation, while the 
5′-CH2OH moiety has minimal hindrance in the N conformation. Lastely, the anomeric 
effect promotes the N conformation over the S one, where the base is in a pseudoaxial 
orientation. This short survey of the conformational behaviour of nucleosides clearly 
shows that an infinite number of conformations are possible, varying from a particular 
sugar puckering to distinct rotamers, such as syn/anti orientations of the bases or γ+/-/t 
orientations of 5′-CH2OH . 
Many NMR and Raman spectroscopy studies show that the conformation of crystalline 
nucleosides is not necessarily the one preferentially adopted in solution.  
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Chapter 2.  
 
 
Ribonucleotide Reductase: a critical enzyme 
for cancer chemotherapy 
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2.1 Role of Ribonucleotide Reductase in the synthesis of DNA 
 
In normal cells, when conditions such as age or state of cell health dictate, programmed 
cell death (apoptosis) is triggered by the nucleus to prevent the development of 
abnormal cells.  However, cancerous cells are unable to experience this mechanism, 
which promotes the proliferation of abnormal cells and the development of tumors in 
the neighbour tissues.  
The increased knowledge of its molecular mechanisms and the absence of an effective 
treatment for tumor eradication, stimulate an intense exploitation of apoptosis as a 
strategy to specifically eliminate neoplastic cells. 
A key point in the pathways involved in apoptosis was found by Irwin Rose13 when he 
first observed that deoxyribonucleotides (dNTPs) cannot be directly obtained from cell 
metabolism, but are synthesized from ribonucleotides (NTPs) through catalytic 
reduction performed by a specific enzyme, named ribonucleotide reductase (RNR  E.C. 
1.17.4.1).  
Ribonucleotide reductase (RNR), (systematic name 2′-deoxyribonucleoside-
diphosphate: thioredoxin-disulfide-2′-oxidoreductase), is an ubiquitous cytosolic 
radical-containing enzyme. It plays a central role in cell growth and proliferation. It is 
involved in the conversion of both purinic and pyrimidinic ribonucleotides 
disphosphates into their corresponding 2′-deoxyribonucleotides (dNTP), which are the 
building blocks for DNA replication and repair in all living cells.  
RNR is regulated in the mammalian cell at several different levels, e.g. by allosteric 
control of activity and specificity by nucleoside triphosphates, by enhanced 
transcription of RNR gene encoding this enzyme during S-phase of cell cycle and by 
rapid, proteasome-dependent proteolysis of its small subunit (R2) during the late phase 
of mitosis.14
As maximal DNA synthesis requires high dNTP concentrations, RNR activity is central 
to cell proliferation. Increased RNR has been associated with malignant transformation 
and tumor cell growth and RNR long considered as excellent target for anticancer 
therapy.15
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2.2 Three different classes of RNR 
 
Three main classes of RNR have been described based on different metal cofactors for 
the catalytic activity (Table 1):16 class I enzymes contain a diiron-oxygen cluster,17  
class II a cobalt containing cobalamin cofactor (vitamin B12), and there is a 4Fe-4S iron-
sulfur cluster coupled to S-adenosylmethionine (SAM) in class III.  
 
Table 1. Different classes of RNR. 
 
 
 
 
Class I enzymes, which are found in practically all eukariotic organisms, from yeast and 
algae to plants and mammals, are further divided into three subclasses (Ia, Ib and  Ic) 
based on polypeptide sequence homologies and their overall allosteric regulation 
behaviour.18,19
Class I RNRs are characterized by a tyrosyl radical that is stabilized by an oxo-bridged 
binuclear Fe(III) complex and requires oxygen for its generation. The enzyme is a 
holoenzyme α2β2. The substrate binding active site is located in the large α2-homodimer 
which is called R1. The small β2-homodimer contains a binding site for two iron ions in 
each polypeptide chain and is called R2. In the active form these R2 proteins contain a 
stable tyrosyl radical close to the iron centres and the iron centres are found in the 
diferric state with a μ-oxo bridge. 
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Class II RNRs are restricted to prokaryotes (both aerobic and anaerobic) and use 
adenosylcobalamine to generate a free radical. In this class of enzymes the radical 
generator and a reductase are located in the same subunit. 
Class III RNRs, only function in anaerobic conditions and require a glycyl radical that is 
generated by a process that involves a [4Fe-4S] cluster and an S-adenosylmethionine. 
The α2 dimer is the active form and contains the active glycyl radical and the binding 
sites for the aerobic reductases. The β2 subunit is a small iron sulfur containing protein, 
which is essential for glycyl radical production. 
It is interesting to note that despite the large differences between RNR classes, the 
common catalytic and similar allosteric mechanisms, as well as retention of critical 
residues in the protein sequence, suggest similar structures.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. The figure shows an overlay of the substrate binding active sites in the three 
classes of RNR. The common cysteine radical sites are indicated, and the relative 
positions of the different radical generation systems in the three classes are 
indicated by the last tyrosines of the radical transfer pathway for class I, the B12-
derivative adenosylcobalamin for class II (magenta sphere: cobalt), and the glycyl 
radical site for class III (cyan sphere).  
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2.3 Catalytic mechanism  
 
The mechanism of generation of the radical as well as the reduction pathway has 
already been extensively studied. However, although a great effort is being made 
toward the understanding of the reactivity of the di-iron cluster and the tyrosyl radical 
generation and pathway, the overall process still remains elusive, and further studies 
need to be performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. The postulated reaction mechanism for reduction of a ribonucleotide by class I 
RNR. The involved amino acid residues are given with E. coli numbering. The reaction 
scheme is believed to be very similar for class II RNR. For class I, the substrate is a 5′-
diphospho(PP)ribonucleoside, whereas class II mainly utilises 5′-triphospho(PPP)- 
ribonucleosides. 
 
The involvement of cysteine residues in the reduction of ribonucleotides was first 
recognized by Thelander in 1974.20 A scheme for the catalytic cycle in R1 in E. coli 
starting from a thiyl radical at C439 has been proposed based on experimental data from 
several biochemical studies, active site mutants, as well as advanced EPR methods.21,22 
The thiyl radical is generated by a long-range radical transfer from the tyrosyl radical 
Y122 in R2. In the first step of the substrate turnover (Figure 6) the thiyl radical C439 
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(state 1) will abstract the 3′-hydrogen atom from the ribose ring of the substrate and 
thereby generate a substrate radical (state 2). The abstraction of 3′-hydrogen has been 
verified by 3H-labelling of a substrate analogue, where a 3H label was found on the 
protein after a quenched turnover reaction.23
The ribose radical makes the 2′-OH –group more accessible to acid catalysis, and the 2′-
OH-group is therefore protonated by C225 and then leaves as a water molecule. The 
substrate is thereby converted to a 2′-ketyl radical (state 3). The two cysteine residues, 
C225 and C462, are then oxidized to a disulfide anion radical when they transfer a 
hydrogen atom to the substrate (state 4). The excess radical electron is then transferred 
via a chain of hydrogen bonded active site residues, N437 and E441, to the substrate 3′-
position, thereby regenerating a substrate radical (state 5). This substrate radical then 
abstracts the hydrogen from C439, which results in completion of the 
deoxyribonucleotide product and a thiyl radical on C439 (state 6). The radical state is 
then transferred via the long range radical transfer chain back to the R2 subunit 
reforming the stable tyrosyl radical Y122*. 
For a complete turnover, the active site disulfide bridge between C225 and C462 must 
be reduced. The electron needed for this reduction is provided via a redox chain which 
involves a cysteine pair at the surface of R1 (C754 and C759), thioredoxin (or 
glutaredoxin), and finally the NADPH binding flavoprotein thioredoxin reductase.24 
Thus, NADPH ultimately provides the reducing power of class I RNR.  
The reduction of the disulfide bridge at the active site in R1 would be very difficult to 
accomplish if a radical state were still located close by e.g. at C439. In that case, the 
radical, rather than the disulfide bridge, would probably be reduced. This might be an 
explanation for why RNR utilizes a separate protein, R2, for storage of the radical, since 
the thioredoxin reduction system cannot access the tyrosyl radical inside the R2 protein. 
 
2.4 Regulation of  Ribonucleotide Reductase activity 
 
Synthesis of deoxyribonucleotides is an extremely well regulated reaction. A failure in 
the control of the dNTP levels and/or their relative amounts leads to cell death or 
genetic abnormalities. The are multiple levels of regulation of RNR activity in the 
mammalian cell: transcriptional and allosteric regulation.25
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2.4.1 Allosteric regulation  
 
RNR is regulated by allosteric control of the activity and specificity of the enzyme. The 
overall enzymatic activity is regulated by ATP (activation) and dATP (feedback 
inhibition at high concentrations) binding to a general activity site (A- site) in R1.25  In 
order to obtain a balanced supply of dNTPs for DNA synthesis, his specificity for each 
of the four substrates is determined by the binding of an allosteric effector (dATP or 
ATP, dTTP, and dGTP) to the so-called specificity site, or S-site,26 which is located at a 
different site from the substrate binding catalytic site.  Recently, it has been proposed 
that the activity of class Ia RNR also is regulated by a third site called the 
hexamerizaton site (H-site). ATP binding to this H-site promotes the formation of an 
R16R26 hexamer which is suggested to be the major active form of RNR in mammalian 
cells.27,28 The location of the allosteric sites in the three classes of RNR  has been 
identified by site-directed mutagenisis studies and by cocrystallisation of allosteric 
effectors with the rispective protein.  
 
 
 
 
E. coli R1 protein dimer
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7. E. coli R1 protein dimer with the active and allosteric sites. 
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2.4.2 Transcriptional regulation and protein degradation regulation 
 
Large amounts of deoxyribonucleotides are required in proliferating cells during the S-
phase of the cell cycle where genome duplication takes place, whereas in the other 
phases requirement is low. The level of RNR in mammalian cells is therefore closely 
linked with the cell cycle and growth control mechanisms. Enzyme activity and the R1 
and R2 mRNAs reach maximal level during S-phase. In human and mouse cells, the 
genes encoding the R1 and R2 proteins are located on different chromosomes.29,30
The transcription on the R1 and R2 genes is cell cycle-regulated with undetectable 
mRNA levels in G0/G1 phase cells. Enzyme activity and the R1 and R2 mRNAs reach 
maximal levels during S-phase.31-33 The R1 protein has a long half life of 18-24 hours 
and its levels are almost constant and in excess throughout the cell cycle in proliferating 
cells. The R2 protein, in contrast, shows an S-phase specific expression and has a 
shorter half-life of about 3-4 h, probably regulated by a controlled degradation.34 R2 
protein synthesis starts in early S phase, and it slowly accumulates in the cell up to late 
mitosis when it is rapidly degraded.35 Enzyme activity is therefore determined by R2 
protein levels.  
 
2.5 p53R2 
 
A homologue of R2, called p53R2, has been identified in human and mouse cells.36  
p53R2 is induced by the key signalling protein p53, and  is suggested that p53R2 is 
important for supplying deoxyribonucleotides to the DNA damage repair system in 
phases of the cell cycle where the normal RNR is not functional. As much as 80% of 
human tumours have been found to contain mutations in p53 or pathways that either 
regulate or are regulated by this protein. The discovery of the p53R2 thus created a link 
between one of the most important tumour suppressors and the synthesis of 
deoxyribonucleotides. Recently, it was reported that p53 binds both the R2 and p53R2 
subunit in resting cells but, upon exposure to UV  irradiation, they dissociated from p53 
and bound to R1. Perhaps the regulation of RNR activity by p53 is more complex than 
only activation of p53R2; however, how this might effect cell cycle progression is not 
clear.37 A study using p53R2 knockout mice showed the importance of p53R2 in DNA 
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repair.38 These mice had severe alterations in the dNTPs pools in kidney cells suffering 
from oxidative stress. This imbalance in the dNTP pool presumably resulted in higher 
mutation rate in the kidney cells. The increased interest in RNR following the discovery 
of p53R2 has not so much been the role of RNR in cancer development, but rather as a 
target for cancer treatment. The possibility of designing specific inhibitors to the normal 
RNR is discussed in a review by Eklund et al.39 The hypothesis is that the cancers often 
have mutations in the p53 pathway and thus presumably are unable to make p53R2. As 
all cells are dependent on the supply of deoxyribonucleotides, cancer cells would die if 
the normal RNRs were inhibited, whereas normal cells with p53 could survive on the 
deoxyribonucleotide pool supplied by p53R2. This appears as a good strategy, but 
unfortunately the picture seems to be more complex. Some preliminary studies on breast 
cancer cells with mutations in p53 showed that in some cell lines p53R2 is present 
throughout the cell cycle and also in relatively high amount (Graff, P.; Pettersen, E. O.; 
Anderson, K. K. unpublished data). This implies that there might exist an additional 
p53-indipendent induction pathway for p53R2.  
Also, a recent study on the response of p53R2 in cells treated with DNA-damaging 
agents showed that cells with mutated p53 might still induce p53R2, suggesting a p53 
indipendent pathway for activation of p53R2.40 This shows how complex the control of 
DNA repair and deoxyribonucleotide synthesis is with respect to cancer development 
and that it is not straightforward to use p53R2 strategies in cancer treatment. 
 
2.6 Human Ribonucleotide Reductase inhibitors 
 
Inhibitors of RNR have been widely investigated as potential anti-tumoral, anti-viral 
and anti-bacterial chemotherapeutic agents.41-43 Some RNR inhibitors have been 
approved for clinical treatment of cancer; other are being in clinical trials.44  
The majority of the known and deeply studied RNR inhibitors act when the enzyme is 
already formed and active. These inhibitors consist on substrate analogues, radical 
scavengers, metal chelators and some small molecules or peptides that will directly or 
indirectly inhibit subunits R1 or R2, inactivating by this way the enzyme and leading to 
cell apoptosis.  
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The RNR inhibitors are grouped in three different categories: translation inhibitors, 
dimerization inhibitors and catalytic inhibitors. 
The catalytic inhibitors are further sub-divided in two sub-categories, depending on their 
main binding site, i.e., subunit R1 (specific R1 binding inhibitors) or subunit R2 (specific 
R2 binding inhibitors). 
 
2.6.1 Translation inhibitors 
 
The translation inhibitors are several molecules capable of inhibiting or even destroying 
the messenger RNA (mRNA), produced during the transcription process, which prevents 
the formation of an active RNR. Although they are not new, they only started to be 
developed very recently, and therefore their application is still limited.  
Translation inhibition is characterized by the binding of antisense oligonucleotides (ODNs) 
to the mRNA chain. Lee et al.45 studied GTI-2040, a 20-mer oligonucleotide that is 
complementary to a coding region of mRNA of RR subunit R2. In vivo studies have 
already shown that GTI-2040 significantly inhibits the growth of a wide range of tumors, 
as human colon, pancreatic, liver, lung, breast, kidney and ovary tumors.46 GTI-2501 is 
another translation inhibitor of RNR, whose target is subunit R1. In the preclinical trials, 
GTI-2501 was an effective anticancer agent when tested in standard mouse models bearing 
a variety of different human cancer lines including tumor cells from lung, breast, colon, 
kidney, ovary, pancreas and skin cancers.  
The main disadvantage of these inhibitors is related with their low rate of transport across 
cellular membranes and their sequestration within endocytic-like vescicles that 
complicates their use as therapeutic agents. Moreover the inhibition effect of these 
antisense inhibitors is dependent both on the initial concentration and half-life of the target 
enzyme and on the half-life of the cell. 
 
2.6.2 Dimerization inhibitors 
 
Another type of inhibitors prevents the formation of an active RNR by competing with 
subunit R2 during complexation with subunit R1.47,48 Generally these inhibitors are 
oligopeptides with similar sequences to the flexible C-terminus of R2, which is responsible 
for interaction with R1.49 RNR peptide inhibition began with the discovery, by Dutia et 
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al.,50,51 of a nonapeptide corresponding to the nine C-terminal residues of subunit R2 of 
herpes simplex virus (HSV). The first work with mammals was reported by Yang et al.52 
which demonstrated that the heptapeptide, FTLDADF, identical in sequence to the last 
seven aminoacid residues of the C-terminus of the R2 subunit of mouse ribonucleotide 
reductase (NSFTLDADF), and its N- alphaacetylderivative (N-Ac-FTLDADF) were able 
to inhibit calf thymus RNR. Taking in account the results obtained with herpes simplex 
virus, several systematic structure-function studies, including residues modification and 
deletions53 were also performed with these organisms in order to understand the inhibition 
mechanism and to achieve better inhibitory activity.  
   
2.6.3 Catalytic inhibitors 
 
These inhibitors interact with the active form of RNR, promoting the inactivation of one or 
both enzyme subunits. The inhibition can occur through several ways: by the destruction of 
the radical that is essential for RNR activity and is located at the R2 subunit (specific R2 
inhibitors), by association of small molecules that are capable of inactivating the active site 
or induce allosteric malfunction (specific R1 inhibitors), or by substrate analogues that, 
depending on their nature, can lead to the specific inhibition of subunit R1 or/and subunit 
R2. The inhibitors were grouped in two subcategories, according to the subunit where they 
bind to, i.e., specific R2 binding inhibitors, that interact directly with and inhibit subunit 
R2, and specific R1 binding inhibitors that interact with subunit R1 and can inhibit one or 
both subunits. 
 
2.6.3.1 R1 Protein inhibitors  
 
Depending on the mechanisms of inactivation, R1 protein inhibitors can be divided in 
two sub-groups: nucleoside analogues (including substrate and allosteric effector 
analogues) and inactivators of sulfhydryl groups. 
 
2.6.3.1.1 Nucleoside analogues in clinical use and clinical trials 
 
The derivatives of the natural purinic and pyrimidinic nucleosides are effective in the 
clinical treatment of  human cancer or viral diseases. Cytarabine (ara-C, I), gemcitabine 
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(II), tezacitabine (III), fludarabine (IV), cladribine (V), and clofarabine (VI) are 
examples of this class of drugs that have therapeutic activity against human 
malignancies (Figure 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. Structures of R1 protein inhibitors. 
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analogues. These substrate analogues, modified at the carbon 2′ in the sugar moiety 
ibose or arabinose), are known as suicide inhibitors because they are recognized by 
NR as normal substrates and react in the active site leading to abnormal products that 
ytarabine (1-β-D-arabinosylcytosine, ara-C) CYTOSAR-U®. 
ytarabine is one of the first inhibitors that showed antitumor properties and is the most 
P inhibits RNR 
ck inhibitor of dCK 
in tumor cells. Furthermore, the rapid degradation by 
eamination causes ara-C to be ineffective against solid tumors. 
emcitabine (2′,2′-difluoro-2′-deoxycytidine, dFdC) GEMZAR®. 
th the natural dCTP for incorporation into replicating DNA. 
l cell lung cancer and 
le 
alignancies.73
(r
R
inactivate the enzyme.54-57
C
C
active drug in acute myeloid leukemias (AML).58-59 Ara-C is a good substrate of dCK 
and further metabolized to ara-CDP and ara-CTP in vivo. Ara-CTP inhibits DNA 
synthesis after incorporation into DNA by DNA polymerase α. Ara-CD
activity. However, at high concentration ara-CTP acts as a feedba
and has a short half-life 
d
 
G
Gemcitabine is metabolized intracellulary by deoxycytidine kinase to its 
monophosphorylated form, and further by other intracellular kinases to the 
metabolically active forms, gemcitabine diphosphate (dFdCDP) and gemcitabine 
triphosphate (dFdCTP).60-62 The cytotoxic effect is attributed to a combination of two 
actions performed by those two metabolites. First dFdCDP inhibits RNR;63 second, 
dFdCTP competes wi
Gemcitabine has been approved for treatment of non-smal
pancreatic cancer.64 In Europe it was approved for the treatment of bladder cancer.65 
Moreover, it continues to be employed in multip trials that assess the clinical benefit 
of different therapeutic approaches and combinations in these solid tumors.66-68  The role 
of gemcitabine as a single agent or in combination with other anti-tumor drugs in the 
treatment of breast cancer,69 ovarian cancer,70 squamous cell carcinoma of the head and 
neck,71 and malignant pleural mesothelioma72 has also been investigated. Gemcitabine 
has shown activity in clinical trials in patients with hematologic m
 
Tezacitabine ((E)-2′deoxy-2′-(fluoromethylene)cytidine, FMdC)  
Tezacitabine, a deoxycytidine analogue, is an irreversible RNR inhibitor and DNA 
chain terminator.74,75 After intracellular phosphorylation to a diphosphate form, the drug 
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irreversibly inhibits the enzyme RNR.76 The FMCDP inhibits both R1 and R2 subunits 
of RNR, by destroying the essential tyrosyl radical in R2 and alkylating the active site 
in R1. Tezacitabine is also phosphorylated intracellulary to a triphosphate form that has 
significant DNA chain termination activity by inhibiting DNA polymerase α with 
consequences for cell cycle arrest and apoptosis.77 This dual mechanism of action is 
similar to that of gemcitabine. However, at least two significant features differentiate 
tezacitabine from gemcitabine. First, unlike that by gemcitabine, the inhibition of RNR 
by tezacitabine is irreversible. Second, tezacitabine is approximately 30-fold more 
resistant than gemcitabine to metabolic inactivation through deamination by cytidine 
deaminase. Tezacitabine shows potent antitumor activity against leukemia (HL-60, 
MOLT-4, L1210 leukemia, and both MDR-resistant and sensitive P388 cell lines) and 
lid tumors (breast, lung, stomach, colon, ovary, bladder, pancreas, glioma, and 
er repair of DNA  stand breaks, which activates poly (ADP-
bose) synthetase, and NAD+ is depleted, leading to apoptosis.80 Fludarabine 
tor of several important enzymes including DNA 
olymerase,  DNA ligase, DNA primase, and RNR.82 Although the DNA termination 
so
melanoma cell lines).25 
 
ii) Allosteric effector analogues 
 
dATP is an allosteric inhibitory effector of RNR activity. Some synthetic 
deoxyadenosine analogues have even higher affinity towards R1 with respect to 
deoxyadenosine and have low affinity for nucleotide-catabolizing enzymes such as 
adenosine deaminase. 
 
Cladribine (2-chloro-2′-deoxyadenosine, CdA) LEUSTATIN® and Fludarabine (9-β-D-
arabinofuranosyl-2-fluoroadenine 5′-monophosphate, Fara-A) FLUDARA®. 
Cladribine and Fludarabine are deoxyadenosine analogues and require intracellular 
phosphorylation for their cytotoxic actions. In proliferating cells, cladribine triphosphate 
inhibits RNR as well as DNA polymerase.78 CdATP is also incorporated into DNA, 
producing strand breaks and inhibition of DNA synthesis.79 In resting cells, CdATP 
interferes with the prop
ri
triphosphate is a potent inhibi
81p
may be a major mechanism for the cytotoxicity of fludarabine triphosphate, the 
depletion of dNTP pools in tumor cells after fludarabine exposure confirms that RNR 
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inhibition has a significant role in fludarabine cytotoxic mechanism. Fara-ATP is also 
incorporated into DNA resulting in premature termination of the RNA transcript and 
pairing its functioning as a template for protein synthesis.83 Cladribine is the current 
grade non-
as active in myeloid malignancies and was well tolerated 
 phase I-II trials.92
im
treatment of choice in hairy cell leukemia (HLC).84 It has also shown efficacy in other 
lymphoproliferative disorders, such as chronic lymphocytic leukemia, low-
Hodgkin’s lymphomas and Waldenström’s macroglubinemia, as well as in childhood 
acute myelogenous leukemia.85 CdA also has impressive clinical activity against 
multiple sclerosis.86 Fludarabine is in the treatment of chronic lymphocytic leukemia 
(CLL), acute myelogenous leukemia (AML), low-grade lymphoma and other 
hematologic malignancies.87 
 
Clofarabine (2-chloro-2′-fluoro-2′-deoxy-9-β-D-arabinofuranosyl-adenine, Cl-F-ara-A) 
CLOLAR®.  
Clofarabine, a deoxyadenosine analogue, has been approved by the US FDA in 
december 2004 for the treatment of pediatric patients with relapsed or refractory acute 
lymphoblastic leukemia (ALL).88 Like fludarabine and cladribine, clofarabine requires 
intracellular phosphorylation by deoxycytidine kinase to its active triphosphate form. 
Clofarabine triphosphate inhibits both DNA polymerase and RNR, and has high affinity 
to the enzyme deoxycytidine kinase, the rate-limiting step in nucleoside 
phosphorylation.89 Clofarabine has shown cytotoxicity to a variety of human 
hematologic and solid tumor cell lines and tumor xenograft models (leukemia, colon, 
renal, and breast tumor models).90 In addition to having been approved for treatment of 
pediatric ALL, clofarabine has also demonstrated antitumor activity against childhood 
and adult AML (acute myeloid leukemia) in Phase I and II trials.91 The combination of 
clofarabine with cytarabine w
in
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2.6.3.2 Specific R2 binding inhibitors 
 
The target of these inhibitors is protein R2, and from the inhibition results: 1) the 
destruction of the radical that is settled in the tyrosine residue (radical scavengers) or 2) 
the inactivation of the radical preventing its generation by chelating the iron of the 
binuclear cluster (iron chelators). 
As the radical is buried c.a. 10 Ǻ from the surface of the protein, these kinds of 
inhibitors are generally small and planar molecules in order to facilitate their approach 
to the free radical. The first inhibitor of this kind that was able to preclude RNR activity 
as Hydroxyurea (VII) (Figure 9). Its chemical name is hydroxycarbamide and is 
ademarked by the commercial name of Hydrea and Droxia®. This compound is cell 
ycle phase-specific (S-phase) and acts primarily as an inhibitor of RNR. It has already 
een indicated by FDA for the treatment of a variety of cancers, e.g. chronic myeloid 
ukemia, polycythemia vera and hypereosinophilic syndrome. Although its anti-tumor 
ctivity is still controversial,93 it is a fact that is able to promote temporary remissions in 
olid tumors like carcinomas of the head, 
eck, genitourinary system, cervix, and lung.  
4 The compound belongs to a class of powerful iron 
damaged DNA.94 Phase I clinical trials 
w
tr
c
b
le
a
metastatic malignant melanomas and other s
n
 
Triapine (3-Aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP) 
Triapine (VIII) is a new potent inhibitor for RNR currently in phase II clinical trials for 
cancer chemotherapy (Figure 9).9
chelators, heterocyclic carboxaldehyde thiosemicarbazones (HCTs), which coordinate 
with iron through the N*-N*-S* tridentate ligand system to form a 2:1 ligand to iron 
molar ratio octahedral complex. Triapine inhibits the enzymatic activity and the tyrosyl 
radical of both small subunits R2 and p53R2.94,95 Triapine is not only a potent inhibitor 
of DNA synthesis and repair through RNR inactivation, but also a DNA damaging 
agent. The two functions can combine synergistically causing cell cycle arrest and 
apoptosis. The compound is fully active against wild-type and hydroxyurea-resistant 
tumors and has broad spectrum antitumor activity in tumor xenograft models. 
Combinations of Triapine with various classes of DNA-damaging agents (such as 
etoposide, cisplatin, doxorubicine) produce synergistic inhibition of cancer cell growth, 
possibly resulting from preventing repair of 
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suggest that Triapine is a promising cancer chemotherapeutic drug in patient with 
her anticancer advanced cancers not only as monotherapy but also in association with ot
drugs such as gemcitabine.96 
 
 
 
 
 
 
 
 
 
Fig. 9. Structures of R2 binding inhibitors. 
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Chapter 3. 
 
 Study of  nucleoside analogues as RNR 
inhibitors 
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3.1 Introduction 
 
As previously reported, a large number of nucleoside analogues has been synthesized and 
some of them have demonstrated potent antitumor activities. Considerable progress has 
been made in the search for novel nucleoside structures with anticancer and/or antiviral 
activity by modifications in the base or in sugar portion of the molecule. These anticancer 
nucleosides act as antimetabolites after metabolic activation by phosphorylation to the 
corresponding 5′-di- or 5′-triphosphates. As so, they interact with one or more key 
enzymes in DNA/RNA biosynthesis, thus interfering with cell proliferation.  
Several branched-chain 2′-deoxynucleosides97,98 and some β-D-ribo-pentofuranosyl 
nucleosides, like 1-(3-C-ethynyl-β-D-ribopentofuranosyl)cytosine and its uracil 
congener99 have shown a broad spectrum antitumor activity.  
On the base of these findings, the research group in which I attended my PhD course was 
interested in the investigation of adenosine derivatives modified at carbon atom on 2′ or 3′ 
position of the sugar moiety by introduction of a methyl group, as potential antitumor 
agents. Therefore 2′-C-methyladenosine (2′-Me-Ado, 1) and 3'-C-methyladenosine (3′-
Me-Ado, 2) were synthesized and tested against a panel of tumor cell lines showing a 
different activity.  
As reported by Franchetti et al.,100 2′-C-Me-Ado showed a cell growth inhibitory activity 
only against human leukemia K562, while 3′-Me-Ado showed the best activity in both 
leukemia and carcinoma cell lines with IC50 values ranging from 17.5 to 38.3 μM. 
 
 
N
N N
N
NH2
O
OHHO
HO
R1 R
1 R = CH3,R1= H     (2'-Me-Ado) 
2 R = H,    R1= CH3 (3'-Me-Ado)
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The antiproliferative activity of 3′-Me-Ado appears to be related to its ability to deplete the 
levels of both intracellular purine and pyrimidine deoxynucleotides mediated by 
mechanism-based inhibition of RNR. 
As reported in 2.3, the initial step in the mechanism of action of RNR is the homolytic 
cleavage of the 3'-carbon-hydrogen bond mediated by a protein radical (Figure 6).23
Such carbon-hydrogen bond cleavage is not possible in the case of  3'-C-methyladenosine-
5'-diphosphate (3′-Me-ADP); thus, this ADP analogue cannot function as a substrate of 
RNR but behaves as an inhibitor of ADP reduction.  
In this respect, 3′-Me-Ado is the first example of a β-D-ribonucleoside able to inhibit 
human RNR functioning as mechanism-based inhibitor of the enzyme.  
Further structure-activity relationship studies showed that the substitution of a hydrogen 
atom of the amino group at the 6-position of nucleobase in 3′-Me-Ado with a methyl or 
cyclopropyl group, the introduction of a chlorine atom at the 2-position, or the shifting of the 
methyl group from the 3′-C position to the other C-positions of the ribose ring result into a 
decrease or loss of activity.100
 
On the basis of the 3′-C-methyladenosine biological activity, the aim of the first part of my 
PhD research project was to investigate the structural determinants of  3′-Me-Ado required 
for the antitumor activity. 
Thus the research work comprised: 
1) synthesis and biological evaluation of 3′-C-methyl ribonucleosides containing different 
purinic and pyrimidinic nucleobases;  
2) synthesis and biological evaluation of new derivatives of 3′-C-methyladenosine  
substituted at the N6-amino group with a series of cycloalkyl, aryl, arylalkyl,  or heteroaryl  
groups, based on the fact that several adenosine derivatives monosubstituted at the N6-
position with an cycloalkyl, aryl, heterocyclic or benzyl groups demonstrated significant 
antitumor activity.101  
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3.2 Synthesis and biological evaluation of purine and pyrimidine 
nucleoside analogues of 3′-C-methyladenosine as antitumor agents102
 
3.2.1 Aim of the research 
 
To further investigate the role of a methyl group at 3′-C position of ribonucleosides, a 
number of 3′-C-methyl ribonucleosides containing different purinic and pyrimidinic 
nucleobases, such as 3′-C-methylguanosine, (3′-Me-G, 3), 3′-C-methyluridine (3′-Me-UR, 
4), 3′-C-methylthymidine (3′-Me-T, 5), and 3′-C-methylcytidine (3′-Me-C, 7) were 
synthesized. 3′-C-methyl-5-fluorouridine (3′-Me-5-FUR, 6) as a novel ribose-modified 
analog of the antitumor agent 5-fluorouridine and the 3′-C-methyl analog of the antiviral 
and antitumor agent 9-(β-D-arabinofuranosyl)adenine (3′-Me-ara-A, 8) were also 
synthesized and evaluated against human leukemia and carcinoma cell lines.  
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3.2.2 Chemistry 
 
3′-C-Methyladenosine (2) and ara-A103 were synthesized as reported in literature as 
reference compounds for biological evaluation.100 3′-C-Methyluridine (4) and 3′-C-
methylcytidine (7) were synthesized according to Mikhailov et al.104 by glycosylation of 
the silylated uracil  and cytosine with 1,2,3-tri-O-acetyl-5-O-benzoyl-3-C-methyl-D-
ribofuranose (9). 
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The synthesis of 3′-C-methylguanosine (3), 3′-C-methylthymidine (5), and 3′-C-methyl-5-
fluorouridine (6) was carried out starting from 1,2,3-tri-O-acetyl-5-O-benzoyl-3′-C-
methyl-D-ribofuranose (9) as reported in Scheme 1. Compound 9 (mixture of α and β 
anomers) was synthesized following the method described by Ong et al.105 with minor 
modifications.100  
Stereoselective coupling of 9 with 2-amino-6-chloropurine (10) was performed by 
trimethylsilyl trifluoromethanesulfonate (TMSiOTf) mediated N-glycosylation in 
acetonitrile in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to obtain the 
protected 2-amino-6-chloropurine derivative 11. Deprotection of 11 gave the 
ribonucleoside 12 which was converted to 3′-C-methylguanosine (3) by substitution of the 
6-chloro substituent with OH group by treatment with 2-mercaptoethanol and sodium 
metoxide 0.5 M in methanol. 3′-C-Methylguanosine was previously synthesized by 
Beigelman L. N. et al.106 using a different route and with a lower overall yield.  
The pyrimidinic nucleoside analogues 5 and 6 were obtained by glycosylation of silylated 
thymine 13a and 5-fluorouracil 13b with 9 in the presence of SnCl4 in 1,2-dichloroethane. 
The protected compounds 14a and 14b were deprotected with ammonia in methanol to 
give the desired  5 and 6. 
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Scheme 1 
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Reagents and conditions: (i) DBU, TMSiOTf, CH3CN; (ii) NH3/CH3OH, r. t.; (iii) C2H6SO, 0.5 M 
CH3ONa, CH3OH; (iv) SnCl4, ClCH2CH2Cl. 
 
The arabino analog of 3′-Me-Ado (3'-Me-ara-A, 8) was obtained by a stereoselective 
synthesis as depicted in Scheme 2. 9-(3,5-Di-O-benzyl-3′-C-methyl-β-D-ribofuranosyl)-
adenine (15), was prepared in two steps starting from 1,2-di-O-acetyl-3,5-di-O-benzyl-D-
ribofuranose and 6-chloropurine as described by Eldrup et al.107  Compound 15 was 
converted into the corresponding 2′-O-triflate derivative 16 with trifluoromethanesulfonyl 
chloride in dichloromethane in the presence of triethylamine and 4-
(dimethylamino)pyridine (DMAP). SN2 displacement of the 2′-O-triflate group with 
tetrabutylammonium benzoate afforded the 2′-O-benzoyl arabino derivative 17. 
Debenzoylation of intermediate 17 with methanolic ammonia, and then deprotection of 18 
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by catalytic transfer hydrogenation with ammonium formate in methanol in the presence of 
10% Pd/C, gave 3′-Me-ara-A (8). 
 
Scheme 2 
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Reagents and conditions: (i) CF3SO2Cl, TEA, DMAP, CH2Cl2; (ii) Bu4NH+BzO-, toluene/H2O 
(1:0.4 v/v); (iii) NH3/CH3OH, r. t.; (iv) HCOO-NH4+, 10% Pd/C, CH3OH. 
 
 
The assignment of the β-configuration of nucleosides 3-7 was performed by proton NOE 
experiments. In particular, selective irradiation of the H-1′ signal increased the intensity of 
the H-4′ signal; this indicates that H-1′ and H-4′ are located on the same face of the ribosyl 
ring.108  
 
 
3.2.3 Biological evaluation  
 
The 3′-C-methyl-β-D-ribonucleosides 3-7 and 3′-Me-ara-A (8) were evaluated for their in 
vitro cytotoxicity against human myelogenous leukemia K562, human colon carcinoma 
HT-29 and CaCo-2 cell lines (Table 2). 3′-Me-Ado (2) and ara-A103,109 were used as 
reference compounds.  
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Table 2. In vitro activity of 3′-C-methylnucleoside analogues 3-8 against human myelogenous 
leukemia K562 cells, human colon carcinoma HT-29 and CaCo-2 cell lines, and stability in 
fetal calf serum. 
     
                                                           IC50 (μmol/l)a
             Half-life (h) 
   Compd K562 HT-29 CaCo-2  in serum 
 
 3 (3′-Me-G) >100 >100 >100 26.5 
 4 (3′-Me-UR)    43 >100 >100   4  
 5 (3′-Me-T)  >100 >100 >100 10 
 6 (3′-Me-5-FUR) >100 >100 >100 31.5 
 7 (3′-Me-C)  >100 >100 >100   8 
 8 (3′-Me-ara-A) >100 >100 >100 31.5 
 2 (3′-Me-Ado)   18.2   23.2   24.3 43.5 
 ara-A 184 >100   753 ND 
 
aIC50 values represent the drug concentration required to inhibit cancer cell replication by 50%.  
The compounds were tested up to a concentration of 100 μmol/l (1 mmol/l in the case of ara-
A). ND = not determined. 
 
3′-Me-Ado (2) confirmed to be cytotoxic against leukemia K562 and carcinoma HT-29,100 
and showing a similar  activity also against CaCo-2 cells.  
Ara-A was found to be moderately active against K562 cells and marginally active against 
CaCo-2 cells. Among 3′-Me-Ado analogues, only 3′-C-methyluridine (4) showed a 
cytotoxic effect against human leukemia K562 with an IC50 value of 43 μM, but not 
against the carcinoma cell lines at the highest tested concentration (100 μM).  
The poor or no activity of these nucleosides might be due to one or more of the following 
reasons: a) inefficient intracellular phosphorylation to the 5'-diphosphate derivatives, the 
metabolites that could act as mechanism-based RNR inhibitors; b) reduced inhibitory 
activity of the 5'-diphosphates against human RNR; c) instability in cell culture medium.  
The stability of tested compounds has been determined in minimal essential medium-alpha 
(MEM) containing 10% fetal bovine serum in order to mimic their behavior under the 
experimental conditions of the in vitro assays. From the half-life values of the tested 
nucleosides, the stability of 3′-C-methyladenosine analog appears not to be related to the 
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cytotoxicity because 3′-Me-UR (4), active against K562 cells, resulted the less stable 
compound (Table 2).  
On the contrary, the 5-fluoro analog 6, which was found to be inactive against all tested 
cell lines, showed a half life of 31.5 h, the same half life of 3′-Me-ara-A and similar to that 
of 3′-Me-G. Under the same conditions, 3′-Me-Ado (2) was found the most stable 
compound with a half life of 43.5 h.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 38
3.3 Synthesis, antitumor activity and molecular modeling of N6-
substituted 3′-C-methyladenosine derivatives110  
 
3.3.1 Aim of the research 
 
The results discussed in 3.2.3 showed that the substitution of the adenine  in 3′-Me-Ado 
with other purinic and pyrimidinic nucleobases or the inversion of configuration of the OH 
group at the 2′-position induces the loss or a significant decrease in cytotoxicity in both 
human leukemia and carcinoma cell lines.102 However, by a survey of the literature we 
noticed that some adenosine derivatives monosubstituted at the N6-position of the base 
with an cycloalkyl, aryl, heterocyclic or benzyl groups demonstrated significant antitumor 
activity.101  
Among these, N6-benzyladenosine (BnA) is the most interesting compound showing 
activity against human promyelocytic HL-60 leukemia cells and ability to trigger apoptosis 
through caspase inhibition.111 Moreover, some BnA derivatives with high cytotoxic 
activity against various cancer cell lines have been reported.112 Based on these  findings 
and on the results reported in 3.2.3, we have investigated new derivatives of 3′-Me-Ado 
substituted at the N6-amino group of the base with a series of cycloalkyl, aryl, arylalkyl,  or 
heteroaryl  groups (compounds 19-29). Moreover, to obtain information on the influence 
of the substituents in the 2-position of nucleobase, the 2-chloro-N6-cyclopentyl derivative 
of 3′-Me-Ado (2) was also synthesized (compound 30). 
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R   19  R = cyclopropyl,              
  20  R = cyclobutyl,                
  21  R = cyclopentyl,              
  22  R = cyclohexyl,               
  23  R = cycloheptyl,              
  24  R = (±)-endo-norbornyl,  
  25  R = phenyl,                    
  26  R = benzyl,                     
  27  R = 2-thienylmethyl,      
  28  R = 1-H-pyrazol-3-yl,      
  29  R = 2-furanylmethyl,       
  30  R = cyclopentyl,
R1
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3.3.2 Chemistry 
 
The synthesis of 3'-C-methyl-ribonucleosides 19-30 was carried out starting from 1,2,3-tri-
O-acetyl-5-O-benzoyl-3-C-methyl-D-ribofuranose (9), as reported in Scheme 3.  
Coupling of 9 with 6-chloropurine (31) or 2,6-dichloropurine (32) was performed by 
TMSiOTf mediated N-glycosylation in acetonitrile and in the presence of DBU to obtain 
compounds 33 and 34, respectively, in high yields. Nucleophilic displacement of 6-
chlorine atom in the protected ribofuranosides 33 and 34 with cyclopropyl-, cyclobutyl-, 
cyclopentyl-, cyclohexyl-, cycloheptyl-, (±)-endo-2-norbornyl-, phenyl-, benzyl-, 1-H-
pyrazol-3-yl-, 2-furanylmethyl-, or 2-thienylmethyl-amines, followed by sugar  deblocking 
in basic conditions furnished compounds 20-30. The cyclopropyl derivative 19 was 
obtained directly by treatment with aqueous cyclopropylamine.  
A series of the  corresponding sugar-unmodified ribonucleosides N6-cyclopentyl-, N6-
cyclohexyl-, N6-(±)-endo-2-norbornyl-, N6-phenyl-, N6-benzyl-, N6-2-furanylmethyl-, and 
N6-2-thienylmethyl-adenosine  were also synthesized as reference compounds using the 
methods reported in the literature.100,113-115 
 
 
Scheme 3 
O
OAcAcO
BzO
H3C
OAc
9
N
N NH
N
Cl
R1
31 R1 = H
32 R1 = Cl
N
N N
N
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O
OAcAcO
BzO
H3C
R1
N
N N
N
HN
O
OHHO
HO
H3C
R
R1
33 R = H
34 R = Cl
19-30
i ii, iii
Reagents and conditions: (i) TMSiOTf, CH3CN, DBU, Δ; (ii) RNH2, EtOH a, Δ; (iii) NH3/CH3OH, r. t. 
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3.3.3 Biological evaluation and discussion 
 
The antitumor activity of the N6-substituted derivatives of 3′-C-methyladenosine 19-30 
was evaluated in human myelogenous leukemia K562, human colon adenocarcinoma 
CaCo-2, human colon carcinoma HT-29 and human breast carcinoma MCF-7 cell lines 
(Table 3).  
The cytotoxicity of a series of unmodified ribose analogues, namely cyclopentyladenosine 
(CPA), cyclohexyladenosine (CHA), 2-chloro-cyclopentyladenosine (CCPA), N6-(±)-
endo-2-norbornyladenosine (±)-(ENBA), N6-phenyladenosine (PhA), N6-benzyladenosine 
(BnA), N6-(2-furanylmethyl)adenosine (FMA) and N6-(2-thienylmethyl)adenosine (TMA) 
was also determined. 2′-Me-Ado (1), 3′-Me-Ado (2) and gemcitabine (I), a clinically well 
established inhibitor of RNR, were used as reference compounds. Most of these 
compounds have not been previously evaluated against these types of tumor cell lines. 
The biological evaluation was carried out by Prof. Jayaram H.-N. (Indiana University 
School of Medicine and Richard Roudebush VA Medicinal Center, Indianapolis, Indiana, 
USA) for cytotoxic assay and by Prof. Szekeres T. (Clinical Institute of Medical and 
Chemical Laboratory Diagnostic, Medical University of Vienna, Austria) for RNR assay.  
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Table 3. In vitro activities of nucleosides 19-30 against human myelogenous leukemia K562, human colon
adenocarcinoma CaCo-2, human colon carcinoma HT-29 and human breast carcinoma MCF-7 cell lines. 
 
                                                       
N
N N
N
HN
O
OHHO
HO
R3
R
R1
R2
 
 
                                                                                                              GI50 (μM)a  
Compd R1       R2   R3          R         K562   CaCo-2  HT-29   MCF-7 
 
19100        H H   CH3   cyclopropyl   73  >250    >250   >250 
20 H H CH3 cyclobutyl 246  >250    >250
         >250 
21 H H CH3 cyclopentyl 145  >250         >250
         >250 
22 H H CH3 cyclohexyl    50    223   >250   >250 
23         H H CH3 cycloheptyl    83  >250     106          200 
24       H H CH3     (±)-endo-2-norbornyl  32.5     56     65.8     56 
25         H H CH3 phenyl   98    246     137          207 
26     H H CH3 benzyl                          >250   >250   >250 >250 
27  H H         CH3 2-thienylmethyl           >250   >250   >250 >250 
28 H H CH3 1-pyrazol-3-yl              >250   >250   >250 >250 
29 H H CH3 2-furanylmethyl           >250   >250   >250 >250 
30 Cl H CH3   cyclopentyl                  >250   >250   >250 >250 
CPA        H H         H       cyclopentyl                  >250   >250   >250 >250 
CCPA     Cl H         H    cyclopentyl                  >250   >250    >250  >250 
CHA       H H         H     cyclohexyl                   >250   >250    >250     >250 
(±)-ENBA H H H      (±)-endo-2-norbornyl     116   >250    >250     >250 
PhA         H H         H     phenyl                          >250   >250   >250 >250 
BnA  H H         H     benzyl       4.6             7.4     22.3   61 
FMA  H H H      2-furanylmethyl   3.3     45.6     60.2   45.6  
TMA      H H H      2-thienylmethyl  3.1       3.3        53.4   51.5 
1 2'-Me-Ado    H     CH3 H      H     9.4      23.2     26.1   22.4 
     2 3'-Me-Ado H H CH3  H                                      16           >100    >100      >100 
Gemcitabine                                                                         0.32 0.18     0.03           0.01 
 
aGI50 values represent the drug concentration required to inhibit cancer cell replication by 50%.
Compounds were tested up to a concentration of 250 μM.  
 
Among the N6-cycloalkylamino-3'-C-methyl nucleosides, cyclohexyl derivative 22 showed 
K562 cell growth inhibition with a GI50 (50% of growth inhibitory concentration) of 50 
μM, while the cycloheptyl analogue 23 showed a moderate activity also against HT-29 and 
MCF-7 cells. The size of cycloalkyl substituent influences on antileukemic activity as 
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follow: cyclohexyl > cyclopropyl ≥ cycloheptyl >cyclopentyl > cyclobutyl. The 2-chloro 
modification in 3′-Me-CPA (compound 30) resulted in the loss of activity.  
The N6-(±)-endo-2-norbornyl derivative 24 proved to be the most active compound, 
showing cytotoxicity against all tested tumor cells with GI50 values ranging from 32.5 to 
65.8 μM, turning out to be only 2.5-3.5-fold less active than 3′-Me-Ado, while the N6-
phenyl analogue 25 showed a moderate to marginal activity. In general these nucleosides 
proved to be less active than gemcitabine. However, it should be pointed out that the 
cytotoxicity of gemcitabine is due not only to the inhibition of RNR through its metabolite 
dFdCDP, but also to the ability of dFdCTP to inhibit DNA polymerase.116 
Furthermore, the mechanism of RNR inhibition of this drug is different from that of other 
known RNR suicide inhibitors.117
The GI50 values of the N6-substituted derivatives of 3′-Me-Ado could be conditioned by 
their cellular uptake properties and/or metabolic activation. The lack or very modest 
cytotoxicity showed by some compounds may be the result of their inability to be activated 
by the appropriate enzymes to the monophosphate level and then up to the di and/or 
triphosphate levels. 
It is interesting that among the N6-substituted adenosine derivatives, BnA, FMA and TMA 
displayed a significant activity, similar to that of 3′-Me-Ado against all tested cell lines. On 
the contrary, N6-cyclopentyl-, N6-cyclohexyl-, and N6-phenyladenosine analogues resulted 
to be inactive against these types of tumor cells, despite these nucleosides were previously 
found active or to induce apoptosis in HL-60 cells.101,118 The N6-(±)-endo-2-
norbornyladenosine ((±)-ENBA) showed moderate activity only against K562 cells with a 
GI50 value of 116 μM, 3.5 fold higher than that of corresponding 3′-C-methyl analogue 24. 
From the cytotoxicity data it may be stated that the 3′-C-methyl modification at the ribose 
moiety of compounds 26, 27 and 29 abolishes activity. 
Although the cytotoxicity of N6-benzyladenosine and its bioisosters 2-furanylmethyl- 
(FMA) and 2-thienylmethyl-adenosine (TMA) was already known, their mechanism of 
action is not well understood. It has been suggested that the intracellular phosphorylation 
of BnA is necessary for its cytotoxicity,118 and in the active form, this compound and 
similar nucleosides could be able to inhibit several human protein kinase among which 
CDKs.  
From a survey of the literature we found that BnA, FMA and TMA behave as agonists at 
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human A3 adenosine receptor subtype with Ki of 41.3, 22 and 60 nM, respectively.119
In recent reports it was well-documented that adenosine A3 receptor agonists are able to 
inhibit cell growth and/or induce apoptosis in various tumors both in vitro and in vivo.120
These findings prompted us to hypothesize that the cytotoxicity of BnA, FMA and TMA 
might be due to the stimulation of adenosine A3 receptor in target cells.  
To check this hypothesis we decided to experimentaly verify if the tumor growth inhibitory 
effect of N6-benzyladenosine could be antagonized by MRS 1334 {1,4-dihydro-2-methyl-
6-phenyl-4-(phenylethynyl)-3,5-pyridine-dicarboxylic acid 3-ethyl-5-[(3-nitrophenyl)-
methyl]ester}, a selective adenosine A3 receptor antagonist.121  
The obtained data showed that the K562 cell growth inhibition exhibited by BnA was not 
reversed or modified by MRS 1334 treatment. Thus, the cytoxicity of BnA does not appear 
to be related to the ability of nucleoside to stimulate A3 adenosine receptor. Therefore, the 
inactivity of 3′-C-methyl-N6-benzyladenosine cannot be attributed to the lower affinity at 
A3 AR induced by the 3′-C-methyl modification.122
Further studies are needed to identy the biological target(s) of  N6-benzyladenosine. 
It has been demonstrated by Franchetti et al.100 that the antitumor activity of 3′-Me-Ado 
appears to be related to its ability to deplete intracellular purine and pyrimidine 
deoxyribonucleotides through RNR inhibition. In fact, treatment of HL-60 human 
promyelocytic leukemia cells with 3′-Me-Ado significantly decreased all dNTP 
concentrations (Figure 10). 
 
To confirm that N6-substituted derivatives of 3′-Me-Ado that showed antitumor activity, 
retain the ability to inhibit the RNR, the effect of nucleoside 24 on cellular RNR was 
evaluated by measuring the level of intracellular deoxyribonucleoside triphosphate pools in 
HL-60 human promyelocytic leukemia cells before and after treatment with compound 24. 
This indirect method was already utilized to evaluate the RNR inhibition in tumor cells 
owing to poor stability of the human enzyme after purification.100,123  In HL-60 cells, the 
cytostatic effect of N6-(±)-endo-norbornyl derivative (24) proved to be higher than that of 3'-
Me-Ado (GI50 4.5 and 11100 μM, respectively), but lower than that of gemcitabine (GI50 0.33 
μM) (Figure 11). 
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Treatment of HL-60 cells with 3'-C-methyl-N6-(±)-endo-norbornyladenosine significantly 
depleted intracellular dATP pools (Figure 12). Incubation for 24 h with 2.5, 5, and 10 μM 
of  24 decreased dATP pools to 65%, 28%, and 10% of control values, respectively. 
Changes in intracellular dCTP and dTTP concentrations were not significant. Intracellular 
dGTP pools were below the detectability of the method used. The fact that intracellular 
dCTP and dTTP concentrations were not changed is not surprising because other 
nucleosides that behave as RNR inhibitors are able to induce only the depletion of 
dATP.123 Gemcitabine, in a similar experiment, decreased intracellular dCTP and dATP 
pools to 6.1% and 13.9% of control values, respectively. These findings confirm that also 
N6-substituted derivatives of 3′-Me-Ado behave as RNR inhibitors. 
 
 
 
 
 
Fig. 10. Concentration of dNTPs in HL-60 cells after treatment with 3′-Me-Ado as measured by 
HPLC. Values marked with an asterisk (*) are significantly different from the control (P < 0.05). 
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Fig. 11. Concentration of dNTPs in HL-60 cells after treatment with gemcitabine (dFdC) as 
measured by HPLC. Values marked with an asterisk (*) are significantly different from the control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ig. 12. Concentration of dNTP pools in HL-60 cells after treatment with N6-(±)-endo-norbornyl-
′-C-methyladenosine. Values marked with an asterisk (*) are significantly different from the 
ntrol (P < 0.05). 
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3.4 Conformational analysis and molecular modeling of ribose modified 
ucleosides 
odate different ligands. However, it is known that there are cases where 
dding a methyl group to a drug molecule can significantly decrease bioactivity or change 
lectivity; so, there are limits to how much an enzyme can adapt its shape to achieve 
ffinity to different ligands.124  
 fact, it is known that nucleosides bearing modified-ribose moiety can be used as tools 
r studying the enzyme modulation processes, as well as for preparation of bioanalogous 
 properties of 2′- and 3′-Me-Ado has been investigated.  
ethyl groups were placed on the ribose ring of adenosine at the 2′ and 3′ positions to 
e edominant solution conformations of 2′-Me-Ado, and 3′-
t with irradiation of methyl proton of 2′-Me-Ado moiety showed the complete 
plete lack of H-8 
form
e-Ado was obtained by the coupling constant values. The 2′-
n
 
Most enzymes have some degree of flexibility in the backbone and especially the side 
chains to accomm
a
se
a
In
fo
systems.  
On this basis, the effect of methylation at the ribose moiety of adenosine on the 
conformational
M
obtain 2′-Me-Ado (1) and 3′-Me-Ado (2), respectively. Like the methanocarba 
modification of ribose,125,126 this approach is a means of conformational control of the 
ribose ring that Franchetti et al.127 has proven effective to improve selectivity in A1 
adenosine receptor agonists. 
Informations concerning th pr
Me-Ado,  were obtained via 1H-NMR experiments and Nuclear Overhauser Enhancement 
(NOE) effects, determined in DMSO-d6 + D2O (5:1). A one-dimensional differential NOE 
experimen
lack of H-2 enhancement in the purine ring supporting a spatial arrangement where H-2 
and the protons of methyl group are not proximate. Moreover, the com
enhancement in the purine ring of 2′-Me-Ado when H-1′ was irradiated, supports a spatial 
arrangement where H-8 and H-1′ are not proximate, as would be the case in the anti 
conformer. The anti con ation was confirmed by the observation of NOE effects on 
O5’-H and on H-3′ when purine H-8 was irradiated. Further information concerning the 
solution conformation of 2′-M
C-substitution precludes getting information from J1’2’ and J2’3’ values leaving only J3’4’ as 
a clue to the sugar puckering. It was found that in 2′-Me-Ado the J3’4’ value is 7.7 Hz, 
indicating that this nucleoside is N-puckered predominantly (North).128
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The energy of conformer type for 2′-Me-Ado was also calculated. This nucleoside 
displayed a strong preference for North conformation in solution as reported by Franchetti,  
et al.127 and Eldrup, et al.107 1H NMR and NOE data showed that 2′-Me-Ado in solution 
has a marked preference for the North (3T2)-anti conformation. 
On the contrary, irradiation of H-1′ of 3′-Me-Ado showed the complete lack of H-2 
enhancement in the purine ring, as would be the case in the syn conformer. On the basis of 
correlation reported by Rosemeyer et al.,129 the observed H-1´ enhancement translates into 
a 60% population of syn conformer. Information concerning the conformation of the 
ribosyl moiety of 3′-Me-Ado was obtained by the coupling constant value. The 3′-C-
substitution precludes getting information from J2’3’ and J3’4’ leaving only J1’2’ as a clue to 
sugar puckering. It was found that the J1’2’ value of 3′-Me-Ado is on the range of 7.7-8.2 
2'-C-MeAdo                         3'-C-MeAdo 
North (3T2)-anti                               South (2T3)-syn 
Hz, indicating that it is S-puckered (South) predominantly. 
In general it may be concluded that 2′-Me-Ado has a market preference for the North (3T2)-
anti conformation in solution, while 3′-Me-Ado showed a preference for the South (2T3)-
syn conformation as shown in the Figure 13. 
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Fig. 13. Conformations of 2′-Me-Ado and 3′-Me-Ado. 
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3.4.1 Molecular Modeling 
o explain why 3′-Me-Ado has a higher antitumor activity compared to that of 2′-C-methyl 
nalogue (2′-Me-Ado), as previously reported by Franchetti et al.,100 and why the N6-
substitution in 3′-C-m thyladenosine induces a decrease of the antitumor activity (with the 
exception of N6-((±)- collaboration with 
rof. Lavecchia (Dip , University of 
Naple “Federico II”, Italy) a docking study was carried out 
′-Me-Ado, 2′-Me-Ado, and N -substituted 3′-Me-Ado 
24-26, 29, and 30 at the RNR recognition site. To this end, molecular models 
ntly solved crystal structure of the eukaryotic R1 subunit (Rnr1) of 
visiae complexed with the effector-substrate pair 
diphosphate (ADP) (PDB code: 2CVX). 
e enzyme. The 
 
T
a
e
endo-norbornyl derivative 24 in HL-60 cells), in 
P artimento di Chimica Farmaceutica e Tossicologica
in order to elucidate the 
6hypothetical binding mode of 3
analogues 
were built using the rece
RNR from Saccharomyces cere
deoxyguanosine triphosphate-(dGTP)-adenosine 
Although the antitumor activity of our compounds was evaluated on human cell lines, the 
use of the crystal structure of eukaryotic Rnr1 from Saccharomyces cerevisiae for docking 
studies is justified by the fact that the human RNR structure is unavailable and that human 
and yeast Rnr1 share 66% sequence identity and 83% sequence similarity.  
The nucleoside analogues must to be first intracellularly converted to their corresponding 
5′-diphosphates for inhibiting RNR. So, the ligands were docked into the RNR binding 
pocket as 5′-diphosphate metabolites (3′-Me-ADP, 2′-Me-ADP, and diphosphates of 
compounds 24-26, 29, and 30). The X-ray crystal structure of RNR showed six water 
molecules directly involved in the formation of H-bonds that bridge ADP to the enzyme 
(W5, W9, W18, W144, W163, and W214).130 To reproduce the observed binding mode of 
ADP, it was necessary to include all six water molecules in the docking experiments. 
3′-Me-Ado was found to be in the same location as ADP in the crystal structure. As 
illustrated in Figure 14 the Nε2 atom of Q288, which belongs to loop 2, H-bonds to the N1 
atom of the adenine. The N3 and N6 atoms on the adenine participate in a second-sphere 
H-bond, via two water molecules (Wat214 and Wat18, respectively), with th
N3 atom of the base also accepts an H-bond from the NH backbone of G247. The 2′-OH of 
the ribose H-bonds to the S217 CdO oxygen as well as to the conserved water molecule 
Wat214, whereas the 3′-OH forms a H-bond with the Sγ atom of C218. The α phosphate of 
the ligand binds to the NH backbone of T608 and A609, whereas the β phosphate binds to 
the NH backbone of S610, T611, and S202 as well as to the OH of S202 side chain. Wat9 
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and Wat144 contribute to further stabilize the network of H-bonds formed between the 
ligand diphosphate and the enzyme. 
Although 3′-Me-ADP differs from ADP only by the presence of one methyl at 3′ position 
of the ribose ring, it adopts a different conformation when binding to RNR. In the 
RNR/dGTP(2′-deoxyguanosine-5′-triphosphate)/ADP complex (Figure 14a), the 2′ and 3′ 
OH of the ribose are near the catalytic N426, E430, and C428, where the thiyl radical is 
generated on Rnr1 by a series of coupled electron and proton transfers, and C218 of the 
reduced catalytic redox pair (C218 and C443). Moreover, a water molecule (Wat5) is 
found to bind the 2′ OH of the ribose, the amide nitrogen of L427, the side chain of N426, 
and the carbonyl of G247. In contrast, in the RNR/dGTP/3′-Me-ADP complex, both the 
ribose and the base of the ligand appear to be significantly displaced (rmsd 6.51 Å) from 
those of ADP (Figure 14b). A possible reason for these differences in the binding mode of 
3′-Me-ADP could be given by the fact that the ribose ring in ADP adopts a 3′-endo 
 
conformation, whereas in 3′-Me-ADP it adopts a South (2T3)-syn conformation in which 
the 3′-methyl projects toward the catalytic residues C428, E430, and N426, altering the H-
bonding pattern of 2′- and 3′-OH of 3′-Me-ADP and RNR (Figure 14a). So, the presence of 
3′-methyl in place of 3′-hydrogen impedes the abstraction of the ligand’s 3′ hydrogen atom 
by the thiyl radical generated at C428 by a series of coupled proton and electron transfers 
from Y183• of Rnr2,29 thus explaining why the 3′-Me-ADP behaves as a mechanism-
based inhibitor of the RNR. 
Docking of 2′-Me-ADP into the RNR catalytic pocket resulted in a posing strongly 
resembling the one reported for ADP with a rmsd value less than 3.0 Å with respect to the 
crystallographic pose of ADP (Figure 14d). Likely, this is due to the North (3T2)-anti 
conformation of the furanose  ring, which corresponds to the 3′-endo one of ADP. 
As depicted in Figure 14c, with the exclusion of the H-bond between the ligand 3′-OH and 
the enzyme catalytic N426, all the polar interactions observed in the ADP/RNR 
crystallographic complex were preserved in the 2′-Me-ADP/RR complex. The 2′ and 3′ 
OH of the ribose were still close to the catalytic N426, E430, C428, and C218 of the 
reduced catalytic redox pair of cysteines (C218 and C443). So, 2′-Me-ADP should still 
function as a substrate of the enzyme, rationalizing its reduced inhibitory activity against 
RNR. 
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Fig. 14. a) Docked structure of 3'-Me-ADP (magenta) in the RNR active site. The residues 
involved in H-bonding to 3'-Me-ADP are also indicated, with their residue type and sequence 
numbers written in white. Structural water molecules are represented as red balls. H-bonds are 
symbolized with dashed yellow lines. b) Superimposition of the docked structure of 3'-Me-ADP 
(magenta) on the crystallographic enzyme-bound conformation of ADP (yellow) within the RNR 
active site. c) Docked structure of 2'-Me-ADP (green) in the RNR active site. d) Superimposition 
of the docked structure of 2'-Me-ADP (green) on the crystallographic enzyme-bound conformation 
of ADP (yellow) within the RNR active site. 
 
 
Docking of 24-DP and 25-DP to the RNR crystal structure provided well-clustered 
solutions; the top-ranked results (GOLD fitness scores of 90.5 kJ/mol for 24-DP and 85.3 
kJ/mol for 25-DP) strongly resembled that previously described for 3′-Me-ADP, except for 
the adenine nucleus of 24-DP, which was found rotated by 180°. As shown in Figure 15, 
e ligands had very strong H-bond networking interactions with RNR. In addition, the N6- th
norbornyl and -phenyl substituents of both ligands projected just underneath the loop 2 of 
the enzyme adapting themselves in a hydrophobic cleft made up residues P294, A296, 
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F329, and Y742. In particular, the phenyl ring of 25-DP was favorably oriented to establish 
a π-π stacking interaction with F329 ring. These interactions contribute to further stabilize 
the inhibitor binding, in agreement with the higher cytotoxic activity showed by 
pounds 24 and 25. 
6
com
In fact, extending the N -substituent by one methylene unit in 26 (benzyl), 27 
(thienylmethyl), and 29 (furanylmethyl), largely increases its conformational flexibility, 
which would generate very unfavorable steric interactions with loop 2, leading to a 
repositioning of the entire molecule in the RNR binding pocket and concomitant disruption 
of favourable  protein-ligand interactions. 
This rationalizes the lack of RNR inhibitory activity of  26, 27 and 29. 
 
 
Fig. 15. a) Docked structure of norbornyl derivative 24 (orange, a) and phenyl derivative 25 (pink, 
b) in the RNR active site. 
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3.5 Conclusions 
  
The work developed in the first part of my PhD project was devoted to the study of 
inhibition of RNR  by 3′-C-substituted nucleoside analogues. The main objectives were to 
clarify the structural determinants of the modified nucleosides related to their antitumor 
activity and to inhibition of the enzyme ribonucleotide reductase. 
The obtained results confirmed that the structure of 3′-Me-Ado is crucial for the antitumor 
activity of this type of ribose-modified nucleosides. In fact, the substitution of adenine in 
3′-Me-Ado with other purinic and pyrimidinic nucleobases or the inversion of 
configuration of OH group at the 2′-position (3′-Me-ara-A), induces the loss or a 
significant decrease in cytotoxicity in both human leukemia and carcinoma cell lines.   
s concern the N6-cycloalky-3′-C-methyl-purineribonucleosides 19-23, the antitumor 
ith a cyclopropyl, cyclohexyl or a cycloheptyl ring provided the most active compounds; 
lbeit at lower levels. The N6-(±)-endo-2-norbornyl derivative 24 proved to be the most 
ytotoxic compound against K562 and carcinoma cell lines with GI50 values slightly higher 
an that of 3′-Me-Ado, and displayed 2.7 fold higher cytotoxicity than 3′-Me-Ado against 
uman promyelocytic leukemia HL-60 cells. These results confirm that an unsubstituted 
6-amino group in the purinic nucleobase is essential for optimal cytotoxicity of 3′-Me-
do against both human leukemia K562 and carcinoma cell lines.  
oreover, N6-(±)-endo-2-norbornyl-3′-C-methyladenosine (24) significantly depleted 
ATP pools in HL-60 cells, proving to be RNR inhibitors. 
arried out on the eukaryotic α subunit (Rnr1) of RNR from 
ccharomyces cerevisiae, which shares 66% sequence similarity with human Rnr1, 
A
activity of these derivatives appears to be modulated by the ring size. The N6-substitution 
w
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Docking studies, c
Sa
whose structure is unavailable, showed that the activity of N6-substituted derivatives of 3′-
Me-Ado is largely dependent on the conformational flexibility of the  N6-substitutent with 
greater flexibility resulting in decreased favorable protein-ligand interactions. 
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3.6 Experimental section 
 
3.6.1 Chemistry 
 
Elemental analyses were determined on an EA 1108 CHNS-O (Fisons Instruments) 
analyzer. Thin layer chromatography (TLC) was run on silica gel 60 F254 plates (Merck); 
silica gel 60 (70-230 and 230-400 mesh, Merck) for column chromatography was used. 
Nuclear magnetic resonance 1H NMR spectra were determined with a Varian Mercury 
AS400 at 400 MHz. The chemical shift values are expressed in δ values (parts per million) 
re measured 
n a Perkin-Elmer 241 polarimeter at 20 °C; [α]D values are given in 10  deg cm2 g-1. 
-Chloro-9-(2,3-di-O-acetyl-5-O-benzoyl-3-C-methyl-β-D-ribofuranosyl)-9H-purin-2-
mine (11). To a precooled (0 °C) solution of 1,2,3-tri-O-acetyl-5-O-benzoyl-3-C-methyl-
-ribofuranose (9) (1 mmol), 2-amino-6-chloropurine (10) (1.1 equiv.) and 1,8-
DBU) (3 equiv.) in anhydrous acetonitrile (12 mL) was 
ethylsilyl triflate (4 equiv.) dropwise. The reaction mixture was heated at 50 °C 
e to room temperature, poured into saturated aqueous sodium 
hydrogen carbonate (80 mL) and extracted with dichloromethane (4 x 40 mL). The 
vacuo. The residue was purified by chromatography on a silica gel column eluting with 
relative to tetramethylsilane as an internal standard. All exchangeable protons were 
confirmed by addition of D2O. Stationary NOE experiments were run on degassed 
solutions at 25 °C. A presaturation delay of 1 s was used, during which the decoupler low 
power was set at 20 dB attenuation.  Mass spectroscopy was carried out on an HP 1100 
series instrument. All measurements were performed in the positive ion mode using an 
atmospheric pressure electrospray ionization (API-ESI). Optical rotations we
-1o
 
6
a
D
diazabicycl[5.4.0]undec-7-ene (
added trim
for 2 h, allowed to com
combined organic phase was dried over anhydrous sodium sulfate and evaporated in 
hexane-ethyl acetate (6:4) to give 11 as a foam (65% yield). 1H-NMR (DMSO-d6): 1.75 (s, 
3H, CH3); 2.04 and 2.1 (2s, 6H,  CH3CO); 4.60-4.80 (m, 3H, overlapped H-5'); 5.97 (d, J = 
7.0 Hz, 1H, H-2'); 6.05 (d, J = 7.01 Hz, 1H, H-1'); 7.06 (br s, 2H, NH2); 7.52 (m, 2H, H-
arom.); 7.66 (m, 1H, H-arom.); 7.96 (m, 2H, H-arom.); 8.32 (s, 1H, H-8).  Anal. calcd. for 
C22H22ClN5O7: C, 52.44; H, 4.40; N, 13.90. Found: C, 52.35; H, 4.22; N, 14.0.  
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6-Chloro-9-(3-C-methyl-β-D-ribofuranosyl)-9H-purin-2-amine  (12). A solution of 11 
(0.5 mmol) in saturated methanolic ammonia (30 mL) was stirred at room temperature for 
4 h. The solvent was removed in vacuo and the residue was purified on a silica gel column 
eluting with CHCl3-MeOH (92:8) to afford 12 as a foam (80% yield). 1H-NMR (DMSO-
d6): 1.24 (s, 3H, CH3); 3.56 (m, 2H, H-5'); 3.82 (t, J = 3.2 Hz,  1H, H-4'); 4.32 (dd, J =  6.4, 
.1 Hz, 1H, H-2'), 4.9 (s, 1H, 3'-OH); 5.2 (t, J = 4.9Hz, 1H, OH-5’); 5.52 (d, J = 6.4 Hz, 
. 
2
er nitrogen 
8
1H, OH-2’); 5.78 (d, J = 8.1 Hz, 1H, H-1'); 6.95 (br s, 2H, NH2); 8.32 (s, 1H, H-8). Anal
calcd. for C11H14ClN5O4: C, 41.88; H, 4.47; N, 22.18. Found: C, 41.68; H, 4.38; N, 22.31.  
 9-(3-C-Methyl-β-D-ribofuranosyl)guanine (3). To a solution of 12 (1 mmol) and 2-
sulfanylethan-1-ol (5 equiv.) in methanol (30 mL) was added 0.5 M sodium methoxide (5 
equiv.) in methanol and the mixture was heated under reflux for 7 h. The solution was 
cooled to room temperature and neutralized with acetic acid. The solvent was evaporated 
in vacuo and the residue was crystallized from water to afford 3 as a white solid (75% 
yield); 1H-NMR (DMSO-d6): 1.24 (s, 3H, CH3); 3.5 (m, 2H, H-5'); 3.78 (t, J = 3.1 Hz, 1H, 
H-4'); 4.26 (d, J = 8.1Hz, 1H, H-2'); 4.80 (br s, 1 H, 3'-OH); 5.3 (br s, 1H, OH-5’); 5.44 (br 
s, 1H, OH-2'); 5.66 (d, J = 8.1 Hz, 1H, H-1'); 6.8 (br s, 2H, NH ); 7.85 (s, 1H, H-8); 11.4 
(br s, 1H, NH). MS: m/z 296.2 [M – H]. Anal. calcd. for  C11H15N5O5:  C, 44.44; H, 5.08; 
N, 23.56. Found: C, 44.60; H, 5.18; N, 23.40.  
General procedure for glycosylation of pyrimidine bases with the protected sugar 9.   
To thymine or 5-fluorouracil (1 mmol) in dry 1,2-dichloroethane (5 mL) und
was added hexamethyldisilazane (HMDS) (0.8 equiv.) and chlorotrimethylsilane (TMSCl) 
(0.8 equiv.) were added. The reaction mixture was heated at 80 °C for 5 h. After cooling to 
room temperature, a solution of 9 (1 equiv.) in dry dichloroethane (5 mL) was added to the 
persilylated nucleobases 13a and 13b followed by 1 M SnCl4 in dry dichloromethane (2 
equiv.) dropwise. The mixture was stirred at room temperature or 85 °C as reported below, 
and then the solution was quenched by saturated solution of NaHCO3 and extracted with 
chloroform. The organic phase was dried over anhydrous sodium sulfate and, after 
filtration, the solvent was evaporated to dryness and the residue was purified by 
chromatography to obtain compounds 14a or 14b as foams. 
1-(2,3-Di-O-acetyl-5-O-benzoyl-3-C-methyl-β-D-ribofuranosyl)thymine (14a). The 
reaction of 9 with silylated thymine 13a at room temperature for 1 h, followed by 
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chromatography on a silica gel column (CH2Cl2-C2H5OH 99.5:0.5) gave 14a as a foam 
(39% yield). 1H-NMR (DMSO-d6): 1.55 (s, 3H, CH3); 1.70 (s, 3H, CH3); 2.1 (s, 6H, 
CH3CO); 4.5 (m, 2H, H-5'); 4.7 (m, 1H, H-4'); 5.45 (d, J = 7.7 Hz, 1H, H-2'); 6.05 (d, J = 
7.7 Hz, 1H, H-1'); 7.52 (m, 3H, H-6 and H-arom.); 7.65 (m, 1H, H-arom.); 8.0 (m, 2H, H-
arom.); 11.4 (br s, 1H, NH). Anal. calcd. for C22H24N2O9: C, 57.39; H, 5.25; N,  6.08. 
Found: C, 57.25; H, 5.10; N, 6.18. 
5-Fluoro-1-(2,3-di-O-acetyl-5-O-benzoyl-3-C-methyl-β-D-ribofuranosyl)-uracil (14b). 
 
phy to give the deprotected 
 5.92; N, 10.29. Found: C, 48.70; H, 6.0; N, 10.15.  
 
The reaction of 9 with silylated 5-fluorouracil 13b at room temperature for 2 h, followed
by chromatography on a silica gel column (hexane-EtOAc, 6:4) gave 14b as a foam (70% 
yield). 1H-NMR (CDCl3): 1.6 (s, 3H, CH3); 2.10 (s, 6H, CH3CO); 4.63 and 4.75 2 (m, 3H, 
H-4', H-5'); 5.40 (d, J = 7.7Hz,  1H, H-2'); 6.0 (dd, J = 1.8 , 7.7 Hz,  1H, H-1'); 7.54 (m, 
2H, H-arom.); 7.65 (m, 1H, H-arom.); 7.97 (m, 2H, H-arom.); 8.1 (d, J = 7.0 Hz, 1H, H-6); 
11.9 (br s, 1H, NH). Anal. calcd. for C21H21FN2O9: C, 54.31; H, 4.56; N,  6.03. Found: C, 
54.48; H, 4.61; N, 5.92.  
General procedure for deprotection of nucleosides 14a and 14b. 
Protected nucleosides 14a or 14b were treated with methanolic ammonia (saturated at 0 
°C) and the mixtures were stirred at room temperature overnight. Then the solvent was 
evaporated and the residue was purified by chromatogra
nucleosides 5 and 6.  
1-(3-C-Methyl-β-D-ribofuranosyl)thymine (5). Compound 5 was obtained from 14a and 
purified by chromatography on a silica gel column eluting with CHCl3-MeOH (92:8), as a 
white solid (50% yield); 1H-NMR (DMSO-d6): 1.20 (s, 3H, CH3); 1.78 (s, 3H, CH3); 3.54 
(m, 2H, H-5'); 3.74 (t, J = 2.7 Hz, 1H, H-4'); 3.86 (dd, J = 6.6, 8.1 Hz, 1H, H-2'); 4.74 (s, 
1H, OH-3’); 5.16 (t, J = 4.0 Hz, 1H, OH-5’); 5.30 (d, J = 6.6 Hz, 1H, OH-2’); 5.84 (d, J = 
8.1 Hz, 1H, H-1'); 7.87 (s, 1H, H-6); 11.25 (br s, 1H, NH). MS: m/z 271.1 [M – H].  Anal. 
calcd. for C11H16N2O6: C, 48.53; H,
5-Fluoro-1-(3-C-methyl-β-D-ribofuranosyl)uracil (6). Compound 6 was obtained from
14b. Chromatography on a silica gel column eluting with CHCl3-MeOH (86:14) gave 6 as 
a white solid (52% yield); 1H-NMR (DMSO-d6): 1.2 (s, 3H, CH3); 3.55 (m, 2 H, H-5'); 
3.76 (t, J = 2.6 Hz, 1H, H-4'); 3.82 (d, J = 8.1 Hz,  1H, H-2'); 4.76 (s, 1H, OH-3'); 5.3 (t, J 
= 3.7 Hz, 1H, OH-5'); 5.38 (d, J = 6.2 Hz, 1H, OH-2’); 5.85 (dd, J  = 2.2, 8.1 Hz , 1H, H-
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1'); 8.35 (d,  J = 7.3 Hz, 1H, H-6); 11.75 (br s, 1H, NH). MS: m/z 275.1 [M – H]. Anal. 
calcd. for C10H13FN2O6: C, 43.48; H, 4.74; N, 10.14. Found: C, 43.40; H,  4.61; N, 10.30. 
9-[3,5-Di-O-benzyl-3-C-methyl-2-O-(trifluoromethylsulfonyl)-β-D-ribofuranosyl]-
18.5 mL) was treated 
.3 equiv.) was added  in two portions over 
al. 
1  
 J = 
, 4H, CH2C6H5); 
adenine (16). A solution of 15 (1 mmol) in dry dichloromethane  (
with triethylamine (1.08 equiv.) and 4-dimethylaminopyridine (0.98 equiv.) and chilled in 
an ice bath. To the stirred solution was added trifluoromethanesulfonyl chloride (1.08 
equiv.) with a syringe. The reaction mixture was stirred at room temperature for 1.5 h. 
Additional trifluoromethanesulfonyl chloride (0
the next 3 h with cooling prior to the addition. After 3 h the solvent was removed in vacuo, 
and the residue was chromatographed on a silica gel column eluting with CHCl3. 
Evaporation of the appropriate fractions gave 16 as a foam (73% yield).  
1H-NMR (DMSO-d6): 1.6 (s, 3H, CH3); 3.74 (dd, J = 11.3, 3.1 Hz, 1H, H-5');  3.86 (dd, J 
= 11.3, 3.1 Hz, 1H, H-5'); 4.64 (d, J = 10.6 Hz, 2H, (CH2C6H5); 4.67 (t, J = 3.3 Hz, 1H, H-
4'); 4.72 (d, J = 11.7 Hz, 2H, CH2C6H5); 5.88 (d, J = 7.8 Hz, 1 H, H-2'); 6.42 (d, J = 7.8 
Hz, 1H, H-1'); 7.28-7.42 (m, 10H, H-arom); 8.10 (s, 1H, H-2); 8.13 (s, 1H, H-8). An
calcd. for C26H26F3N5O6S: C, 52.61; H, 4.41; N, 11.80. Found: C, 52.58; H, 4.55; N, 11.60.  
9-(2-O-Benzoyl-3,5-di-O-benzyl-3-C-methyl-β-D-arabinofuranosyl)adenine (17). 
Compound 16 (2.5 mmol) was dissolved in 10 mL of toluene containing 10 mmol of 
tetrabutylammonium benzoate and water (4 mL). The mixture was heated under reflux and 
stirred rapidly for 6 h. The solvent was removed in vacuo and the residue was purified by 
chromatography on a silica gel column eluting with CHCl3 to give 17 (73% yield) as a 
foam. H-NMR (DMSO-d6): 1.42 (s, 3H, CH3); 3.82 (d, J = 5.1 Hz, 2H, H-5');  4.48 (t, J =
5.7 Hz, 1H, H-4'); 4.65 (m, 4H CH2C6H5); 5.58 (d, J = 4.0 Hz, 1H, H-2'); 6.65 (d,
4.4Hz,  1H, H-1'); 7.2-7.7 (m, 15H, H-arom); 8.0 (s, 1H, H-2); 8.08 (s, 1H, H-8). Anal. 
calcd. for C32H31N5O5: C, 67.95; H, 5.52; N, 12.38. Found: C, 67.80; H,  5.40; N, 12.48.  
9-(3,5-Di-O-benzyl-3-C-methyl-β-D-arabinofuranosyl)adenine (18). Compound 17 (2.0 
mmol) was treated with saturated methanolic ammonia and stirred at room temperature 
overnight. The solvent was removed in vacuo, and the residue was purified by 
chromatography on a silica gel column eluting with CHCl3-MeOH (99:1) to give 18 as a 
foam (54% yield). 1H-NMR (DMSO-d6): 1.4 (s, 3H, CH3); 3.7 (m, 2H, H-5');  3.95 (dd, J 
= 3.7, 5.9 Hz, 1H, H-2'); 4.32 (dd, J = 5.12, 7.0Hz, 1H, H-4'); 4.58 (m
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5.95 (d, J = 5.9 Hz, 1H, OH-2'); 6.42 (d, J = 3.7 Hz, 1H, H-1'); 7.2-7.4 (m, 10H, H-arom); 
7.98 (s, 1H H-2); 8.1 (s, 1H, H-8).  Anal. calcd. for  C24H27N5O4: C, 65.06; H, 5.89;  N, 
15.17. Found: C, 65.26; H, 5.96; N, 15.0.  
9-(3-C-Methyl-β-D-arabinofuranosyl)adenine (8). To a mixture of 18 (1 mmol) and 
ammonium formate (8 equiv.) in anhydrous methanol (11 mL) under nitrogen was added 
10% Pd/C (1.2 g). The mixture was heated at reflux for 1 h, cooled to room temperature, 
5 
H, H-2'), 6.28 (d, J = 7.3 Hz, 1H, H-1'), 7.50, 
δ
Ac), 4.56 (dd, J ), 4.85 ( J = 3.5, 12.6 Hz, 1H, H-5'), 5.06 (t, J 
= 3.7 Hz, 1H, H-4'), 5.94 (d, J = 7.3 Hz, 1H, H-2'), 6.26 (d, J = 7.3 Hz, 1H, H-1'), 7.45, 
and filtered. After evaporation, the crude material was purified by chromatography on a 
silica gel column eluting with CHCl3-MeOH (87:13) to give 8 as a white solid (40% yield); 
[α]D = +29.6 (c 0.25, CH3OH). 1H-NMR (D2O): 1.3 (s, 3H, CH3); 3.71 (d, J = 5.1 Hz,  2H, 
H-5');  3.95 (d, J = 3.7 Hz, 1H,  H-2');  4.03 (t,  J = 4.9 Hz, 1H, H-4'); 6.37 (d, J = 3.7 Hz, 
1H, H-1'); 7.98 (s, 1H, H-2); 8.1 (s, 1H, H-8). MS: m/z 280.1 [M – H]. Anal. calcd. for 
C11H15N5O4: C, 46.97; H, 5.37; N, 24.90. Found: C, 47.0; H, 5.47; N, 24.80.  
General procedure for the synthesis of compounds 33 and 34. 
To a stirred mixture of 9 (2.03 mmol) 6-chloropurine (31) or 2,6-dichloropurine (32)  (2.2
mmol) and DBU (6.08 mmol) in anhydrous acetonitrile (4 mL) at 0 °C, TMSiOTf (8.11 
mmol) was added. After 3 h at 60 °C, the mixture was cooled at room temperature, poured 
into aqueous NaHCO3 (1M, 15 mL) and extracted  with CH2Cl2 (3 x 10 mL). The 
combined organic phase was dried over Na2SO4 and evaporated to dryness.  
6-Chloro-9H-(2,3-di-O-acetyl-5-O-benzoyl-3-C-methyl-β-D-ribofuranosyl)purine 
(33). Compound 33 was purified by flash chromatography on silica gel (n-hexane/EtOAc, 
75:25) as a white foam (72%). 1H-NMR (CDCl3): δ 1.82 (s, 3H, CH3), 2.05, 2.15 (2s, 6H, 
2 Ac), 4.56 (dd, J = 4.6, 12.6 Hz, 1H, H-5'), 4.82  (dd, J = 3.3, 12.8 Hz, 1H, H-5'), 5.0 (t, J 
= 3.8 Hz, 1H, H-4'), 6.10 (d, J = 7.3 Hz, 1
7.65, 8.05 (3m, 5H, arom.), 8.25 (s, 1H, H-2), 8.63 (s, 1H, H-8). Anal. calcd. for 
C22H21ClN4O7: C, 54.05; H, 4.33; N, 11.46. Found: C, 54.27; H, 6.03; N, 21.73. 
2,6-Dichloro-9H-(2,3-di-O-acetyl-5-O-benzoyl-3-C-methyl-β-D-ribofuranosyl)purine 
(34). Compound 34 was purified by flash chromatography on silica gel (n-hexane/CHCl3, 
95:5) as a white solid (78%). 1H-NMR (CDCl3):  1.84 (s, 3H, CH3), 2.17, 2.23 (2 s, 6H, 2 
 = 4.0, 12.5 Hz, 1H, H-5' dd, 
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7.60, 8.03 (3m, 5H, arom.), 8.24 (s, 1H, H-8). Anal. calcd. for C22H20Cl2N4O7: C, 52.33; 
H, 5.96; N, 21.79. Found: C, 52.27; H, 6.03; N, 21.73. 
General procedure for the amination of 33 into compounds 19-30. 
in vacuo. The 
100
.07 (br s, 
otection and chromatography on a 
% yield). 1H-NMR 
 
for 2 h followed by chromatography on a silica gel column (CHCl3-
To a stirred solution of 6-chloro-9H-(3-C-methyl-2,3-di-O-acetyl-5-O-benzoyl-β-D-
ribofuranosyl)purine (33) or 2,6-chloro-9H-(3-C-methyl-2,3-di-O-acetyl-5-O-benzoyl-β-
D-ribofuranosyl)purine (34) (1.0 mmol) in absolute ethanol (20 mL) and Et3N (3 mmol) 
only in the case of compound 24, the appropriate amine (1.6 mmol) was added. The 
reaction mixture was refluxed for the time reported below and concentrated 
residue was dissolved in methanolic ammonia (10 mL) and stirred at room temperature 
overnight. The solution was evaporated to dryness and the residue was purified by column 
chromatography.  
N6-Cyclopropyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (19).  Reaction of 33 
with 40% aqueous cyclopropylamine at 40°C for 22 h followed by chromatography on a 
silica gel column (EtOAc-CHCl3-MeOH, 70:25:5) gave 19 as a white solid (60% yield). 
1H-NMR (DMSO-d6): δ 0.60-0.80 (2m, 4H, cyclopropyl), 1.30 (s, 3H, CH3), 3
1H, CH-NH), 3.60 (m, 2H, H-5'), 3.88 (t, J = 2.6 Hz, 1H, H-4'), 4.45 (t, J = 7.3 Hz, 1H, H-
2'), 4.85 (s, 1H, OH-3'), 5.40 (d, J = 6.6 Hz, 1H, OH-2'), 5.85 (d, J = 8.1 Hz, 1H, H-1’), 
5.92 (dd, J = 3.5, 7.9 Hz, 1H, OH-5'), 8.08 (br s, 1H, NH), 8.22 (s, 1H, H-2), 8.35 (s, 1H, 
H-8). MS: m/z 322.34 [M+H]+. Anal. calcd. for C14H19N5O4: C, 52.33; H, 5.96; N, 21.79. 
Found: C, 52.27; H, 6.03; N, 21.73. 
N6-Cyclobutyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (20). Reaction of 33 with 
cyclobutylamine at reflux for 1.5 h followed by depr
silica gel column (CHCl3-MeOH, 95:5) gave 20 as a white solid (87
(DMSO-d6): δ 1.28 (s, 3H, CH3), 1.65 (m, 2H, cyclobutyl), 2.10-2.22 (2m, 4H, 
cyclobutyl), 3.52 (m, 1H, H-5'), 3.65 (m, 1H, H-5'), 3.85 (t, J = 2.6 Hz, 1H, H-4'), 4.42 (t, J
= 7.5 Hz, 1H, H-2'), 4.70 (m, 1H, NHCH), 4.82 (s, 1H, OH-3'), 5.40 (d, J = 6.8 Hz, 1H, 
OH-2'), 5.80 (d, J = 8.1 Hz, 1H, H-1'), 5.88 (dd, J = 3.0, 8.1 Hz, 1H, OH-5'), 8.15 (s and d, 
2H, H-2, NH), 8.35 (s, 1H, H-8). MS: m/z 336.4 [M + H]+. Anal. calcd. for  C15H21N5O4: 
C, 53.72; H, 6.31; N, 20.88. Found: C, 53.77; H, 6.24; N, 20.93.  
N6-Cyclopentyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (21). Reaction of 33 with 
cyclopentylamine 
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MeOH, 97:3) gave 21 as a white solid (83% yield). 1H-NMR (DMSO-d6): δ 1.30 (s, 3H, 
CH3), 1.50-2.00 (2m, 8H, cyclopentyl), 3.60 (m,2H, H-5'), 3.88 (br s, 1H, H-4'), 4.45 (t, J 
=7.3 Hz, 1H, H-2'), 4.80 (s, 1H, OH), 5.40 (d, J = 7.0 Hz, 1H, OH), 5.80 (d, J = 7.7 Hz, 
1H, H-1'), 5.93 (dd, = 3.3, 8.4 Hz, 1H, OH), 7.82 (d, J = 7.0 Hz, 1H, NH), 8.15 (s, 1H, H-J 
2), 8.32 (s, 1H, H-8). MS: m/z 350.39 [M + H] . Anal. calcd. for C H : C, 55.00; H, 
6
 1.60-1.96 (m, 5H, cyclohexyl), 3.60 (m, 2H, H-5’), 
loheptyl), 1.86 (m, 2H, 
 mmol) and Et3N (3 mmol) for 7 h 
+
16 23N5O4
6.64; N, 20.04. Found: C, 55.09; H, 6.71; N,   20.11.  
N6-Cyclohexyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (22). Reaction of 33 with 
cyclohexylamine for 3 h followed by chromatography on a silica gel column (CHCl3-
MeOH, 98:2) gave 22 as a white solid (89% yield). 1H-NMR (DMSO-d ): δ 1.10-1.40 (m, 
5H, cyclohexyl), 1.32 (s, 3H, CH ),3
3.90 (t, J = 3.1 Hz,1H, H-4'), 4.45 (t, J = 7.0 Hz, 1H, H-2'), 4.80 (s, 1H, OH), 5.40 (d, J = 
5.9 Hz, 1H, OH), 5.82 (d, J = 8.1 Hz, 1H, H-1’), 5.90 (dd, J = 3.3, 8.4 Hz, 1H, OH), 7.70 
(d, J = 8.4 Hz, 1H, NH), 8.15 (s, 1H, H-2), 8.35 (s, 1H, H-8), MS: m/z 364.42 [M + H]+. 
Anal. calcd. for C17H25N5O4: C, 56.18; H, 6.93; N, 19.27.  Found: C, 56.11 ; H, 6.88; N, 
19.32. 
N6-Cycloheptyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (23). Reaction of 33 with 
cycloheptylamine at reflux for 2 h followed by deprotection and chromatography on a 
silica gel column (CHCl3-MeOH, 95:5) gave 23 as a white solid (80% yield). 
1H-NMR 
(DMSO-d6): δ 1.26 (s, 3H, CH3), 1.40-1.66 (2m, 10H, cyc
cycloheptyl), 3.52 (m, 1H, H-5'), 3.62 (m, 1H, H-5'), 3.86 (t, J = 2.6 Hz, 1H, H-4'), 4.25 
(m, 1H, NHCH), 4.40 (d, J = 8.1 Hz, 1H, H-2'), 4.88 (s, 1H, OH-3'), 5.40 (d, J = 6.8 Hz, 
1H, OH-2'), 5.80 (d, J = 7.7 Hz, 1H, H-1'), 6.0 (dd, J = 3.0, 8.1 Hz, 1H, OH-5'), 7.75 (d, J 
= 7.7 Hz, 1H, NH), 8.15 (s, 1H, H-2), 8.32 (s, 1H, H-8). MS: m/z 378.5 [M + H]+. Anal. 
calcd. for C18H27N5O4: C, 57.28; H, 7.21; N, 18.55. Found: C, 51.20; H, 7.27; N, 18.59. 
N6-(±)-endo-Norbornyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (24). Reaction of 
33 with (±)-endo-2-norbornylamine hydrochloride (2
followed by deprotection gave 24 which was purified by chromatography on a silica gel 
column (CHCl3-MeOH, 95:5) as a white solid (93% yield). 
1H-NMR (DMSO-d6): δ 1.25 
(m, 3H, norbornyl), 1.28 (s, 3H, CH3), 1.43 (m, 3H, norbornyl), 1.60 (m, 1H, norbornyl), 
1.90 (m, 1H, norbornyl), 2.15 (br s, 1H, norbornyl), 2.52 (s, 1H, norbornyl), 3.55, 3.65 
(2m, 2H, H-5'), 3.86 (br s, 1H, H-4'), 4.34 (m, 1H, NHCH), 4.44 (t, J = 7.4 Hz, 1H, H-2'), 
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4.83 (s, 1H, OH-3'), 5.40 (dd, J = 2.1, 6.8 Hz, 1H, OH-2'), 5.82 (dd, J = 3.0, 8.1 Hz, 1H, H-
1'), 5.9 (dd, J = 3.0, 8.1 Hz, 1H, OH-5'), 7.85 (br s, 1H, NH), 8.18 (s, 1H, H-2), 8.30 (s, 
1H, H-8). MS: m/z 376.4 [M + H]+. Anal. calc. for C18H25N5O4): C, 57.59; H, 6.71; N, 
18.65. Found: C, 57.62; H, 6.75; N, 18.60. 
ve 27 as a white solid (72% yield). 1H-NMR 
N, 18.61. 
N6-Phenyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (25). Reaction of 33 with 
phenylamine for 4.5 h followed by deprotection and chromatography on a silica gel 
column (CHCl3-MeOH, 94:6) gave 25 as a white solid (65% yield). 
1H-NMR (DMSO-d6): 
δ 1.30 (s, 3H, CH3), 3.52 (m, 1H, H-5'), 3.65 (m, 1H, H-5'), 3.90 (t, J = 2.8 Hz, 1H, H-4'), 
4.45 (t, J = 7.1 Hz, 1H, H-2'), 4.90 (s, 1H, OH-3'), 5.47 (d, J = 6.6 Hz, 1H, OH-2'), 5.67 
(dd, J = 3.8, 7.1 Hz, 1H, OH-5'), 5.90 (d, J =  8.1 Hz, 1H, H-1'), 7.05 (t, J = 7.5 Hz, 1H, 
arom.), 7.32 (t, J = 7.9 Hz, 2H, arom), 7.90 (d, J = 7.7 Hz, 2H, arom.), 8.38 (s, 1H, H-2), 
8.50 (s, 1H, H-8), 10.0 (s, 1H, NH). MS: m/z 358.4 [M + H]+. Anal. calcd. for 
C17H19N5O4: C, 57.14; H, 5.36; N, 19.60. Found: C, 57.19; H, 5.33; N, 19.65. 
N6-Benzyl-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (26). Reaction of 33 with 
benzylamine for 2 h followed by chromatography on a silica gel column (CHCl3: MeOH, 
96:4) gave 26 as a white solid (79% yield). 1H-NMR (DMSO-d6): δ 1.30 (s, 3H, CH3), 3.60 
(m, 2H, H-5'), 3.90 (br s, 1H, H-4'), 4.45 (t, J = 7.5 Hz, 1H, H-2’), 4.70 (m, 2H, CH2Ph), 
4.80 (s, 1H,OH), 5.4 (d, J = 7.0 Hz, 1H, OH), 5.80 (d and t, J = 8.1 Hz after exchange with 
D2O, 2H, H-1', OH), 7.30 (m, 5H, Ph), 8.18 (s, 1H, H-2), 8.35 (s, 1H, H-8), 8.50 (br s, 1H, 
NH). MS: m/z 372.40 [M + H]+. Anal. calcd. for  C18H21N5O4: C, 58.21; H, 5.70; N, 18.86. 
Found: C, 58.17; H, 5.73; N, 18.77. 
N6-(2-Thienylmethyl)-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (27). Reaction of 33 
with 2-thiophenemethylamine for 6 h followed by deprotection and chromatography on a 
silica gel column (CHCl3-MeOH, 93:7) ga
(DMSO-d6): δ 1.30 (s, 3H, CH3), 3.55 (m, 1H, H-5'), 3.65 (m, 1H, H-5'), 3.86 (t, J = 2.6 
Hz, 1H, H-4'), 4.42 (t, J = 7.3 Hz, 1H, H-2'), 4.82 (s and br s, 3H, OH-3', CH2NH), 5.40 (d, 
J = 6.8 Hz, 1H, OH-2'), 5.80 (dd, J = 3.2, 7.9 Hz, 1H, OH-5'), 5.82 (d, J = 8.1 Hz, 1H, H-
1'), 6.90 (dd, J = 3.4, 5.1 Hz, 1H, arom.), 7.0 (d, J = 2.6 Hz, 1H, arom), 7.32 (d, J = 5.1 Hz, 
1H, arom.), 8.22 (s, 1H, H-2), 8.38 (s, 1H, H-8), 8.58 (br s, 1H, NH). MS: m/z 362.3 [M + 
H]+. Anal. calcd. for C16H19N5O4S: C, 50.92; H, 5.07; N, 18.55. Found: C, 50.87; H, 5.13; 
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N6-(3-Pyrazolyl)-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (28). Reaction of 33 with 
3-aminopyrazole for 3 days followed by deprotection and chromatography on a silica gel 
column (CHCl3-MeOH, 90:10) gave 28 as a white solid (61% yield). 
1H-NMR (DMSO-
deprotection and chromatography on a silica 
 as a white so
d ): δ 1.30 (s, 3H, CH ), 3.55 (m, 1H, H-5'), 3.65 (m, 1H, H-5'), 3.86 (t, J = 2.6 Hz, 1H, H-
4'), 4.42 (t, J = 7.1 Hz, 1H, H-2'), 4.68 (br s, 2H, CH NH), 4.82 (s, 1H, OH-3'), 5.40 (d, J = 
-
yclopentylamine for 3 h followed by chromatography on a silica gel column 
 
d6): δ 1.30 (s, 3H, CH3), 3.55 (m, 1H, H-5'), 3.65 (m, 1H, H-5'), 3.88 (s, 1H, H-4'), 4.45 (t, 
J = 6.8 Hz, 1H, H-2'), 4.86 (s, 1H, OH-3'), 5.45 (d, J = 6.4 Hz, 1H, OH-2'), 5.68 (br s, 1H, 
OH-5'), 5.90 (d, J = 7.7 Hz, 1H, H-1'), 6.70 (br s, 1H, arom.), 6.65 (br s, 1H, arom.), 8.32 
(s, 1H, H-2), 8.48 (s, 1H, H-8), 9.90 (br s, 1H, NH), 12.38 (br s, 1H, NH). MS: m/z 348.3 
[M + H]+. Anal. calcd. for C14H17N7O4: C, 48.41; H, 4.93; N, 28.23. Found: C, 48.49; H, 
4.86; N, 28.29.  
N6-(2-Furanylmethyl)-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (29).  Reaction of 
33 ine for 4.5 h followed by  with 2-furfurylam
gel column (CHCl3-MeOH, 94:6) gave 29 lid (93% yield). 
1H-NMR (DMSO-
2
6.8 Hz, 1H, OH-2'), 5.80 (dd, J = 3.4, 8.1 Hz, 1H, OH-5'), 5.82 (d, J = 7.7 Hz, 1H, H-1'), 
6.20 (d, J = 3.0 Hz, 1H, arom.), 6.35 (dd, J = 1.7, 3.4 Hz, 1H, arom), 7.52 (d, J = 1.7 Hz, 
1H, arom.), 8.20 (s, 1H, H-2), 8.32 (br s, 1H, NH), 8.34 (s, 1H, H-8), MS: m/z 362.3 [M + 
H]
6 3
+. Anal. calcd. for C H N O : C, 53.18; H, 5.30; N, 19.38. Found: C, 53.25; H, 5.26; 
N, 19.41. 
N6
16 19 5 5
Cyclopentyl-2-chloro-9H-(3-C-methyl-β-D-ribofuranosyl)adenine (30). Reaction of 
34 with c
(CHCl3-MeOH, 97:3) gave 30 as a white solid (68% yield). 1H-NMR (DMSO-d6): δ 1.30 
(s, 3H, CH3), 1.50-2.00 (2m, 8H, cyclopentyl),3.55 (m, 2H, H-5’), 3.85 (br s, 1H, H-4’), 
4.40 (m, 2H,H-2’, CHNH), 4.87 (s, 1H, OH), 5.20 (t, J = 5.3 Hz, 1H, OH), 5.42 (d, J = 7.0 
Hz, 1H, OH). 5.80 (d, J = 8.0 Hz, 1H, H-1'), 8.35 (s and d, 2H, NH, H-8). MS: m/z 384.84 
[M + H]+. Anal. calcd. for C16H22ClN5O4: C, 50.07; H, 5.78; N, 18.25. Found: C, 50.11; H, 
5.83; N, 18.19. 
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3.6.2 Biological section  
 
 
The cell lines human myelogenous leukemia k562, human promyelocytic leukemia HL-60, 
human colon carcinoma HT-29, human colon adenocarcinoma CaCo-2, and human breast 
carcinoma MCF-7 were obtained from the American type Culture Collection (ATCC, 
Manassas, VA). K562 and HL-60 cells were maintained in RPMI 1640 medium (Gibco/ 
Life Technologies, Gaithersburg, MD) containing 10% heat-inactivated fetal bovine serum 
(FBS) (Atlanta Biologicals, Atlanta, GA) and 10000 U/L penicillin and 50 mg/L 
streptomyc
3.6.2.1 Cells and culture 
in. HT-29, CaCo-2, and MCF-7 cells were maintained in MEM with Earl’s 
ity of the tested compounds was determined by their cytotoxic action on 
ultured tumor cells. Cytotoxicity assays were conducted by tetrazolium reduction of  3-
,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
TS) with N-methylphenazonium methyl sulfate (PMS) (CellTiter Assay, Promega, 
adison, WI, U.S.A.). Logarithmically growing cells were plated in 0.1 mL aliquots in 96-
lls were plated at an initial density of about 50,000 cells/ml and 
 24 h. Cell suspensions were treated with various dilutions of 
ompounds in triplicate, mixed well and allowed to incubate for 48 h at 37 ˚C in an 
balanced salts, 10% FBS, penicillin, and streptomycin as above. Logarithmically grown 
HT-29, CaCo-2, and MCF-7 cells were incubated with 0.05% trypsin containing 1mM 
EDTA at 37°C for about 5 min until cells were no adherent  and formed a single cell 
suspension. Trypsin activity was neutralized by adding 20-fold excess of the serum-
containing medium. Cells were cultured at 37°C in an atmosphere of air and 5% CO2.
 
3.6.2.2 Cytotoxicity assays 
 
Antitumor activ
c
(4
(M
M
well microtiter plates. Ce
allowed to acclimatize for
c
atmosphere of air and 5% CO2. To the cell suspension was added 20 μL of tetrazolium 
reagent, the mixture was incubated for 3 h at 37 ˚C in an atmosphere of air and 5% CO2 
and absorbance at 490 nm was read by microplate reader. Control plates with serial 
dilutions of cell types were counted as a control for the assay. In all cases, controls 
indicated a linear response versus cell number, R2 ≥ 0.99.  
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3.6.2.3 Stability of nucleosides 3-8 in Culture Medium 
 
Stability of nucleosides 3-8 was evaluated by incubation of the compounds (50 μM) in 
MEM containing 10% fetal bovine serum (Sigma Chemical Co.)  for 72 h at 37 °C. At 
various times, 200 μl of the medium was removed and frozen. The collected samples were 
thawed, passed through 0.22-μm syringe filters and then subjected to HPLC. Samples were 
luted with a linear gradient from water to 100% methanol using a 4.6 x 250 mm Beckman 
n. A HP1090 system was used.  
entration: 100 mg/mL). After 
cubation at 37 °C for 30 min, the reaction was stopped by adding 5 μL of 1 M rhamnose 
 a Merck ”La Chrom” high-
erformance liquid chromatography (HPLC) system (Merck, Darmstadt, Germany) 
onstant ambient temperature 
ith a flow rate of 2 mL/min. The concentration of dNTPs was calculated as percent of 
total area under the curve for each sample. 
e
Ultrasphere 5-mm C18 colum
 
3.6.2.4 Analysis of intracellular dNTP pools by high performance liquid 
chromatography (HPLC). 
  
Logarithmically growing HL-60 cells (0.5 × 106 per mL) were incubated with 2.5, 5, and 
10μM 24 or 25, 50, and 100 μM 25 for 24 h. Afterward, 5 × 107 cells were separated for 
the extraction of dNTPs according to the method described by Garrett and Santi.131
Cells were centrifuged at 1800 rpm for 5 min, then resuspended in 100 μL phosphate-
buffered saline and lysed by addition of 10 μL of trichloroacetic acid and the mixture was 
vortexed for 1 min. The lysate was rested on ice for 30 min and then the protein was 
separated by centrifugation at 15000 rpm for 10 min in an Eppendorf microcentrifuge. The 
supernatant was removed and neutralized by adding 1.1 vol of Freon containing 0.5 M tri-
n-octylamine. Aliquots of 100 μL were periodated by adding 30 μL of 4 M methylamine 
solution and 10 μL of sodium periodate solution (conc
in
solution. The extracted dNTPs were measured using
p
equipped with L-7200 autosampler, L-7100 pump, L-7400 UV detector, and D-7000 
interface. Detection time was set at 80 min, with the detector operating on 280 nm for 40 
min and then switched to 260 nm for another 40 min. Samples were eluted with a 3.2 
mol/L ammonium phosphate buffer, pH 3.4 (pH adjusted by addition of 3.2 mM H3PO4), 
containing 2% acetonitrile using a 4.6 × 250 mm Partisil 10 SAX analytical column 
(Whatman Ltd., Kent, UK). Separation was performed at c
w
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Chapter 4. 
 
Sugar-modified nucleosides as 
A1 Adenosine receptor agonists 
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4.1 Introduction 
 
e therapeutic potential of chemically modified purine ribonucleosides (PNs) like 
adenosine analogues has stimulated great interest in order to develop new drugs for many 
different dise
It is known that a number of pathological affects, as well as physiological ones, are 
mediated by
The endogenous nucleoside adenosine exerts regulatory actions for many biologically 
relevant molecules, and many patho-physiological conditions are believed to be associated 
with changes of adenosine levels.  
denosine is present in every cell of the body and its cytoplasmatic concentration is tightly 
gulated.  
nder normal conditions, adenosine is continuously formed intracellularly as well as 
xtracellularly. Adenosine extracellular concentration is calculated to be in the range of 50-
00 nM, but under several adverse conditions, including ischemia, trauma, stress and 
flammation, extracellular levels of adenosine are enhanced due to increased energy 
emands and ATP metabolism. 
he intracellular production is mediated either by an intracellular 5'-nucleotidase, which 
ephosphorylates AMP132,133 or by hydrolysis of S-adenosyl-homocysteine.134 Adenosine 
enerated intracellularly is transported into the extracellular space mainly via specific bi-
irectional transporters through facilitated diffusion that efficiently evens out the intra- and 
xtracellular levels of adenosine.  
he dephosphorylation of extracellular AMP to adenosine, mediated by ecto-5'-
last step in the enzymatic chain that catalyzes the breakdown of 
xtracellular adenine nucleotides, such as ATP, to adenosine. Ectonucleotidases include 
ucleotidases.135  
MP by adenosine 
Th
ases. 
 interaction of nucleos(t)ides with the purinergic receptors. 
A
re
U
e
2
in
d
T
d
g
d
e
T
nucleotidase, is the 
e
ectonucleoside triphosphate diphosphohydrolases, also known as ecto-apyrases, (e.g. 
CD39), which can hydrolyze ATP or ADP, ectonucleotide pyrophosphatase/phospho-
diesterases and 5'-n
When adenosine levels in the extracellular space are high, the nucleoside is transported 
into cells by means of transporters. It is then phosphorylated to A
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kinase136 or degradated to inosine by adenosine deaminase (ADA).137
The biological action of adenosine was first identified in the cardiovascular system by 
Drury and Szent – Gyorgyi in 1929,138 who reported the effect of adenosine on the heart 
only late in the 1980s in the United States.139,140
ly studied.141 A1 and A3 ARs primarily couple to the Gi/G0 
s many characteristics with other mammalian GPCRs. 
e been developed on 
β -AR is 1.56 Å, which indicates a 
rate, atrioventricular conduction and blood pressure, but its clinical usefulness has been 
recognized 
The functions of adenosine are mediated through binding interactions with adenosine 
receptors (ARs), which are part of the superfamily of G-protein coupled receptors 
(GPCRs). There are four known subtypes of ARs, classified as A1, A2A, A2B, and A3 each 
one having a unique pharmacological profile, tissue distribution and effector coupling.  
AR signaling has been extensive
proteins, which mediates the inhibition of adenylyl cyclase, and A2A and A2B ARs couple 
to Gs proteins, which activate adenylyl cyclase leading to an increase in intracellular 
cAMP. In addition, the A2B AR couples to Gq proteins which stimulate phospholipase C 
activity and subsequently the protein kinase C activity and intracellular calcium 
mobilization. 
Adenosine receptors, like other GPCRs are integral membrane proteins. Such 
macromolecules are not easily amenable to crystallization and hence to precise structure 
elucidation through X-ray diffraction. However, the suggestion that the GPCR family bears 
structural homology to a membrane-bound protein i.e. mammalian rhodopsin, has been an 
impetus to the current understanding of receptor structure. Rhodopsin, a G-protein-coupled 
receptor, is of similar size and share
It has the typical seven-transmembrane alfa-elical architecture and binds retinal, its 
endogenous ligand, in the cavity formed by the barrel-like arrangement of the seven 
transmembrane domains. Therefore, a number of receptor models hav
the basis of rhodopsin. Recently Kobilka et al.142 reported the first X-ray structure of the 
human β2-adrenergic receptor (β2-AR). The data show that the overall topology of b-Rho 
and β2-AR are quite similar. The root mean square deviation (RMSD) for the Cα backbone 
of the transmembrane region between rhodopsin and 2
very similar arrangement of the TM helices.  
ARs display the topology typical of GPCRs. These receptors share a central core domain 
of seven transmembrane helices, with each TM composed of 20-25 amino acids, connected 
by three intracellular (IL1, IL2 and IL3) and three extracellular (EL1, EL2 and EL3) loops. 
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Two cysteine residues (one in TM3/EL1 interface and one in EL2) form a disulfide bond 
which is critical for the folding and for the stabilization of a limited number of 
conformations of these seven TMs.143 Beside sequence variations, GPCRs differ in the 
length and function of their N-terminal extracellular domain, their C-terminal intracellular 
domain and their intracellular loops. Each of these domains confers specific properties to 
these receptor proteins. GPCRs can exist as dimers or as part of larger oligomeric 
 to the apical membrane of the umbrella cell 
n the basolateral membrane of umbrella 
complexes, and many studies have intimated the existence of heterodimeric GPCR 
pairings. Determination of the prevalence and relevance of these complexes in native 
tissues and the implications of heterodimerization for pharmacology and potentially for 
drug design is still a key issue.144  
The adenosine receptors are present on virtually every tissue and are often co-expressed in 
the same cell type, and their activation is predominantly responsible for the wide variety of 
effects produced by Adenosine throughout several organ systems.145 However, receptor 
subtype distribution and densities vary greatly.  
The A1 AR is found in high density in the brain (cortex, hippocampus), and in lower 
density in peripheral organs and tissues, such as heart, kidney, lung, and fat cells.146  
The A2A AR is less widely expressed, with greatest density in the striatum, nucleus 
accumbens and olfactory tubercle. The A2B and A3 are expressed at low density in most 
brain regions and are implicated in purinergic signaling in neuronal – glial interactions.  
In the bladder, A1 are predominantly localized
layer, whereas A , A  and A  are localized o2A 2B 3
cells and the plasma membrane of the underlying cell layers. A1, A2A and A2B are all 
expressed on normal human airway smooth muscle cells, and both A1 and A2A are highly 
expressed in gastric mucosa. A2A are also widely distributed in the immune cells, such as T 
cells and macrophages. A3 are abundantly expressed in various blood cells, such as 
neutrophils and eosinophils. Various subtypes of ARs have also been detected in the heart, 
blood vessels, kidney and other organs throughout the body.147,148
The wide and abundant distribution of these receptors suggests that they potentially play a 
critical role in the body and thus, potentially useful therapeutic agents may be developed 
based on the AR distribution and function.149
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4.2 Adenosine receptor agonists 
 
A large number of ligands have been synthesized over the last two decades, providing 
agonists and antagonists that are more or less selective for the known receptor subtypes. 
However, very few compounds have received regulatory approval. Therefore new selective 
and potent agonists and antagonists at the human receptor subtypes are needed for a 
s 8 only 
al 
onosubstitution at N  of adenosine with bulky residues, 
6 6
N
specific therapeutic application. 
Most of the agonists of adenosine receptors so far known are adenosine derivative ;14
in 2004 IJzerman et al.150 reported the first example of  nonadenosine agonists for the 
human A2B receptor. 
Adenosine, marketed as ADENOCARD®, is currently used in the treatment of paroxysm
supraventricular tachycardia (PSVT). However, the nucleoside also produces side effects 
(e.g., vasodilatation) as a result of the widespread distribution of adenosine receptors and 
its lack of receptor subtype selectivity. These side effects are limited by adenosine’s short 
half-life which results from its rapid breakdown in plasma by ADA.151 From several 
studies resulted that four positions in the molecule of adenosine may be modified to 
increase affinity to specific receptor subtypes without destroying the agonistic activity: the 
2'- and the 5'- position of the ribose, the 2- and N6-positions of the purine ring.  
 
 
 
 
N
 
 
 
 
 
Substitution at the N6-position 
 
The first known subtype-selective adenosine derivatives were modified at the N6-position 
and showed A1 selectivity.152 M 6
such as cycloalkyl, bicicloalkyl [N -cyclopentyladenosine (CPA), N -endo-2-
N
N
NH2
O
OHHO
HO
2'3'5'
2
6
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norbornyladenosine (S-ENBA)] or phenylalkyl [N6-(R)-1-methyl-2-phenylethyladenosine 
(R-PIA)] enhances A1 affinity and may lead to A1-selective AR agonists (Figure 16).153,154  
N
N
In a series of 1-deaza analogues of adenosine it turned out that 2-chloro substitution in 
addition to an N6-cyclopentyl increases A1 selectivity.155 The respective modification in 
adenosine led to the development by Grifantini et al. of 2-chloro-N6-cyclopentyladenosine 
(CCPA) as the most potent and selective A1 receptor ligand characterized in rat brain.113,156
Although this holds true for the human receptors as well (>3000-fold A1- selective vs. 
A2A), the A1 selectivity compared to the A3 adenosine receptor is only about 50- to 70 
fold.157  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 16. Structures of some selective A1 agonists. 
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2'-Modification and substitution at the N6-position 
he ribose
denosine receptors, and 2'-, 3'-, and 5'-hydroxyl groups contribute markedly to the 
otency of adenosine derivatives as agonists.158-160 In fact, removal of the 2'- and 3'-
ydroxyl groups led to a large decrease in affinity and a loss of intrinsic activity. 
 1998 Franchetti et al.127 studied a series of 2'-C-methyl derivatives of A1, A2A, and A3-
lective AR agonists in order to investigate the subdomain that binds the ribose moiety. In 
articular, the 2'-C-methyl analogues of CPA, CCPA, adenosine-5'-ethyluronamide 
ECA), and N6-(3-iodobenzyl)-5'-(N-methylcarbamoyl)adenosine (IB-MECA) have been 
nthesized and their binding affinities at A1 and A2A receptors in bovine brain 
embranes and at A3 in rat testis membranes were determined. 
'-C-Methyl-substituted analogues of the A1-selective agonists CPA, (R)-PIA, and CCPA 
ere slightly less potent at A1 receptors (Ki values in the low-nanomolar range) than the 
arent compounds (Ki values in the subnanomolar range), but their affinities for A2A and 
3 receptors were very low. Thus, the 2'-C-methyl modification may serve as a means of 
creasing A1 selectivity in general. The most potent compound at A1 receptors proved to 
e 2-chloro-2'-C-methyl-N6-cyclopentyladenosine (2'-Me-CCPA, Figure 16) (Ki = 1.8 nM) 
hich was 2166-fold selective for A1 vs A2A and 2777-fold for A1 vs A3. In functional 
ssay, 2'-Me-CCPA inhibited forskolin-stimulated adenylyl cyclase activity with an IC50 
alue of 13.1 nM, acting as a full agonist. 
Moreover, 2'-M uman adenosine receptor, 
ith a 2903-fold and 341-fold selectivity vs A2A and A3 ARs, respectively.122
161 estigated the effect of 2'-Me-CCPA on 
ociceptive responses. 
 
T  recognition domain appears to be of considerable importance for activity at 
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eCCPA proved to be a potent A1 agonist also vs h
w
Recently, Grifantini et al. reported a study that inv
n
Systemic and intra-periaqueductal grey (PAG) administrations of 2'-Me-CCPA generated a 
dose-dependent antinociceptive effect in healthy and formalin-treated rats. These data are 
in agreement with evidence that adenosine A1 receptor agonists have been implicated in 
purine-induced antinociception.162
Subcutaneous injection of formalin generates typical biphasic nocifensive behaviour 
characterized by an early phase (0–7 min), a quiescent interphase, and a second prolonged 
phase (15–55 min). The intra-PAG and systemic administrations of 2'-Me-CCPA both 
elicited a significant and dose-dependent decrease in the second phase of formalin test, 
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whereas only the intra-PAG microinjection of the highest dose of 2'-Me-CCPA partly 
decreased the early phase. These effects are both inhibited by 8-cyclopentyl-1,5-
oxamides is shown by those with small alkyl 
6
n  enhance the 
ine derivative NECA (adenosine-5'-ethyluronamide) was originally 
164
 a rather dramatic manner. The first agonist with high 
6
s the A3 subtype.
-4-Aminobenzyladenosine-5'-N-methyluronamide (AB-MECA) is the most A3-selective 
6 ld selectivity compared to the A1 and 
2A subtypes, respectively. In particular the compounds with Ki-values at A3 receptors in 
dipropylxanthine (DPCPX), a selective A1 receptor antagonist, but not by the A2A receptor 
antagonist 1,3-dimethyl-1-propargyl-xanthine (DMPX). This study confirms the role of A1 
ARs in modulating pain. 
 
5'-Modification and substitution at the N6-position 
 
Replacement of the -CH2OH group of adenosine or adenosine analogues with an N-alkyl 
5'-carboxamide group (5'-uronamide modification) resulted in potent agonists. The highest 
agonistic activity of the adenosine-5'-carb
groups or a cyclopropyl group. Depending on the substituents at N  or C2 positions of the 
adenine moiety, the adenosine-5'-uronamide a alogues have been reported to
158,163affinity as agonists at A2A or A3 adenosine receptors.
The prototypical adenos
considered to be an A2-selective compound,  but turned out to be a non selective agonist 
with high affinity at other receptor subtypes as well.165,166  
The introduction of N6-substituent into 5'-modified adenosine derivatives may change the 
receptor affinity and selectivity in
affinity for A3 adenosine receptors were such compounds bearing N -benzyl substituents in 
addition to 5'-modification.167 The preferred 5'-modification is the 5'-N-methyluronamide 
which resulted in the highest A3 potency compared to other modifications in this position 
of adenosine. Several compounds of a series of N6-benzyl-5'-N-methyl-
carboxamidoadenosines (MECA) exhibit nanomolar affinity for the rat A3 receptor. N-3-
Iodobenzyladenosine-5'-N-methyluronamide (IB-MECA) is about 50-fold selective 
compared to the A1 and A2A receptor subtypes.167  The affinity of IB-MECA for the human 
A3 receptor is similar to the rat data whereas the human A1 receptor binds IB-MECA with 
almost the same affinity a 168
6N
N -benzyl derivative of MECA with 70- and 170-fo
A
the low nanomolar range exhibit also high affinity at A1 receptors. An interesting 
observation is that 2-chloro substitution of IB-MECA reduces both A1 and A3 affinity 
 72
whereas the same modification of CPA results in an increase of the potency at A1 receptors 
with no change of A3 affinity. 
 
5'-Modification and substitution at the 2-position 
 
The first adenosine derivative with some A2A selectivity was 2-(phenylamino)adenosine 
(CV-1808).165 Further evaluation of 2-substitution led to the development of the NECA 
ENECA) exhibits a 36-fold A2A selectivity 
derivative CGS-21680 (2-[p-(2-carboxyethyl)phenethylamino]adenosine-5'-N-ethylurona-
mide) as an A2A-selective agonist which was 140-fold selective vs A1 adenosine receptors 
in a rat model.166 However, data at human receptors show a tremendous species variation 
for the A1 receptor with an over ten fold higher affinity of this compound for the human 
subtype.168 In addition, with a similar affinity of CGS-21680 for A3 receptors it can not 
longer be considered to be an A2A-selective agonist. It is, however, still the ligand of 
choice to distinguish A2A  and A2B mediated effects.  
Substitution of the 2-position of NECA with alkynyl chains results in a decrease of A1 
affinity and a concomitant increase of the potency at A2A receptors.169
Of this series of 2-substituted compounds tested at the rat receptors 2-hexynyl-NECA (2-
hexyn-1-yl-adenosine-5'-N-ethyluronamide, H
compared to the A1 subtype. 
This selectivity is less pronounced for the human adenosine receptor subtypes.  
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4.3 A1 Adenosine receptor agonists 
 
The A1 receptor is the most comprehensively studied adenosine receptor subtype. It has 
been purified, cloned and sequenced from several species including humans.170-172  
T
Cardiovascular 
Because the wide distribution of A1 AR in both CNS and peripheral tissues, various are the 
effects mediated by A1 AR in many systems (Table 4).  
 
able 4.   A1 Adenosine receptor mediated effects in various systems  
CNS 
Decreased transmitter release Negative Inotropy (Atrial) 
Decreased locomotor activity Negative Chronotropy 
Sedation Negative Dromotropy 
Anticovulsant Renal 
Metabolic Decreased GFR 
Anti-lipolytic Mesangial cell contraction 
Increase insulin sensitivity Inhibition of renin release 
Gastro-Intestinal Antidiuresis 
Inhibition of acid secretion Vasoconstriction of afferent artery 
 
Therefore, A1 AR agonists may provide benefit for many deseases, in particular in 
al supraventricular tachycardia (PSVT); atrial fibrillation (AF); type 2 diabetes 
2D); dental and neuropathic pain, and angina.  
lthough the existence of A  ARs  has been known for more than 25 years and its 
eloped, no drug acting directly and selectively 
n this receptor has yet been introduced into therapy. The greatest problem consists in the 
 its lack of selectivity, due to its 
odulation of all four AR subtypes, do not permit its use for other therapeutic 
paroxysm
(T
A 1
medicinal chemistry is particularly well dev
o
side effects, due to wide distribution in the body of A1 ARs and the difficulty of getting 
ligands to target only a particular organ or tissue.  
As previously described, adenosine itself has been used in the treatment of acute 
supraventricular tachycardia but its short half-life and
m
applications.  
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The first A1 AR agonists to make it to clin enosine) were the 
denoson173-175
tructure feature that imparts high  for the A1 AR comes 
ophilic substituent: N6-(R)-3 yl for Tecadenoson (A1 AR Ki 
d N6–cyclopentyl for Selodeno = 6 nM) (Figure 17). Both 
ar some resemblance to CPA nces are found in 
PA that impart beneficial pharmacological and pharmaceutical 
 the furan oxygen of Tec avorable for imparting enhanced 
dditional solub amide of 
elodenoson is favorable for both A1 AR  and A3 AR affinities. Both compounds were 
ical development (beside ad
i.v. antiarrhythmic agents Teca  and Selodenoson.176  
The key s  affinity and selectivity
from the N6 lip -tetrahydrofuran
= 3 nM) an son (A1 AR Ki 
compounds be , but key structural differe
each molecule relative to C
properties: namely, adenoson is f
binding selectivity and a ility, while the 5'-N-ethylcarboxy
S
found to be safe and well-tolered in Phase I clinical trials.  
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        Tecadenoson                                Selodenoson                 CVT-3619                             
    Phase III-PSVT                            Phase II- PSVT 
    CV Therapeutic                            Astellas/Aderis 
                     
                Fig. 17. Structures of Tecadenoson, Selodenoson and CVT-3619. 
xyc e erivative substituted at 
high A1 affinity (Ki = 0.97nM) and selectivity (Ki A3 = 513 nM).182
 
CVT-3619 (Figure 17), an N6-(2-hydro yclopentyl)adenosin  d
the 5’-position with a bulky group that conferred on the molecule the properties of partial 
agonist177 has been studied for its antilipolytic activity.178,179  
CV Therapeutics also synthesized a new series of nucleoside derivatives having as N6-
substituent a cycloalkyl group and a pyrazole, triazole or tetrazole in the 2-position.180 The 
best affinity and selectivity for A  AR was reached with compound (X) (Figure 18).1 181  
Recently the Inotek Pharmaceutical Corporation patented two series of N6-
cyclopentyladenosine derivatives. In the first series  a 5'-nitrooxymethyl derivative showed 
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In the second series183 the N6-substitutent was modified and compound (XI) was found to 
be one of the best (K  = 6.77 nM, K A = 28,100 nM, K  Ai i 2A i 3= 7700 nM). 
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 A  ARs agonists patented from 2005 to the present.  
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Fig. 18. Structures of some 1
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Chapter 5. 
 
Study of adenosine derivatives as potent 
and selective A1 adenosine receptor 
agonists 
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5.1. Introduction 
 
Numerous full agonists with high affinity for the A1 adenosine receptor have been 
developed during last decades, but very few erged as truly selective 
ligands for the human A1 receptor (hA1 AR). As previously described, agonists for the A1 
AR have many potential therapeu g the control of cardiac rhythm, 
attenuation of ischemia-reperfusi neuropathic pain, reduction of 
plasma lipids, reduction of intestinal peristalsis, and treatment of inflammation.184  
Moreover, adenosine and some its N6-substituted derivatives by A1 activation produce a 
ne y 
sev s 
at other on the 
developm e with 
a minimum of unwanted effects.  
One way to circumvent the side effects of full agonists is the use of A1 selective partial 
gonists, which may exploit the differences in receptor-effector coupling in various tissues 
nd can achieve selective activity in vivo.  
oreover, partial agonists may have less side effects, may act more selectively depending 
n the receptor density of a cell type,187  and may induce less receptor downregulation and 
esensitization. Thus, for example, partial agonists selective for the A1 AR inhibit lipolysis 
 vivo while are devoid of cardiovascular effects.188  
ome N6-cycloalkyl- or bicycloalkyl derivatives and 5'-chloro-5'-deoxy analogues were 
tivity for rat brain membrane A1 AR.122,181,189
 
-hydroxy group in adenosine analogues is not essential 
r receptor binding and activation of A1 AR. Furthermore, 5'-modified selective A1 
gonists could be more druggable than 5'-unmodified analogues since normal 
bonucleosides may be phosphorylated by adenosine kinases and in consecutive steps by 
ucleotide kinases to 5'-mono-, 5'-di-, or 5'-triphosphate derivatives, respectively, and 
with P2Y receptors and/or other biological targets. Moreover, the 
ent of 5'-hydroxyl group by a chlorine atom confers to these nucleosides greater 
compounds have em
tic applications includin
on injury, reduction of 
uroprotective effect.185 Unfortunately, the clinical use of A1 agonists is hampered b
ere cardiovascular side effects caused by the strong hypotensive action and side effect
 organs.186 Thus, the therapeutic use of an A1 agonist is highly dependent 
ent of strategies to achieve selective action of the drug on the targeted tissu
a
a
M
o
d
in
S
found to have affinity and selec
These results indicated that, the 5'
fo
a
ri
n
subsequently interact 
replacem
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stability versus purine nucleoside metabolizing enzymes such as adenosine deaminase and 
purine nucleoside phosphorylase.190
On the basis of these findings, in the second part of my PhD project new adenosine 
derivatives were designed and synthesized to investigate the influence of the substituents at 
5'-position of selected A1 agonists on the affinity at adenosine receptors. 
In particular the research work comprised:  
1) synthesis of 5'-carbamoyl and 5'-thionocarbamoyl derivatives of N6-substituted 2'-C-
from different species; 
2) synthesis, of  5'-chloro-5'-deoxy-N
methyladenosine and their affinity and efficacy evaluation at adenosine receptor subtypes 
6-substituted adenosine and 2'-C-methyladenosine  
derivatives and their 2-chloro analogues. These compounds were evaluated for affinity and 
efficacy at all four human adenosine receptor subtypes. 
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5.2 5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as 
selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity 
for A  receptor from different species.191   1
 
5.2.1 Aim of the research 
 
In the search for potent and selective A1 AR agonists, the research group in which I 
pentyl-adenosine (2'-Me-CCPA) 
merged as a potent and highly selective full agonist at rat, bovine and human A1 vs A2A, 
2B and A3 ARs.
122,127
mong the N6-amino substituted adenosine analogues, tecadenoson (N-[3-(R)-
trahydrofuranyl]-6-aminopurine riboside, CVT-510), a derivative structurally related to 
PA that proved to be a full agonist selective for the A1 AR,  is in phase III trials for the 
eatment of paroxysmal supraventricular tachycardia (PSVT) and for its conversion to 
nus rhythm without lowering blood pressure.192
e Tecadenoson derivatives modified at 5'-position such as 5'-carbamates, 5'-
ionocarbamates, or 5'-aromatic ethers and sulfide derivatives, demonstrated high affinity 
r the A1 AR and less than full efficacy resulting in A1 partial agonists that can be used to 
rovide ventricular rate control during atrial fibrillation.193,194
n the basis of these findings, a series of 2'-C-methyl-analogues of N6-
yclopentyladenosine, such as 2'-Me-CPA, 2'-Me-CCPA and of N6-[(R)-3-
trahydrofuranyl]-analogues substituted at the 5'-position with a carbamoyl or 
thionocarbamoyl group were synthesized. These compounds were evaluated for binding 
ffinity at bovine, porcine, and human ARs and for relative intrinsic efficacy, in 
omparison to that of 2' or 5'-unmodified analogues. 
attended my PhD course, has previously investigated a series of 2'-C-methyl-analogues of 
selective A1 AR agonists such as (R)-PIA, CPA, and CCPA.  
As reported above, 2-chloro-2'-C-methyl-N6-cyclo
e
A
A
te
C
tr
si
Som
th
fo
p
O
c
te
a
c
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5.2.2 Chemistry 
 
The synthesis of the 5'-carbamates and 5'-thionocarbamates 35-44 and 45-58 was showed 
in Scheme 4. 2'-C-Methyladenosine and the 2-chloro analogues substituted in the N6-amino 
group [2'-Me-CPA (61)127 2'-Me-CCPA (62),127 and the N6-tetrahydrofuranyl analogues 2'-
Me-tecadenoson (63) and 2-Cl-2'-Me-tecadenoson (64)]  were obtained by nucleophilic 
displacement of the 6-chlorine atom of 6-chloro-9H-[(2-C-methyl)-2,3,5-tri-O-benzoyl-β-
D-ribofuranosyl]purine (59)127 or the 2-chloro analogue 60,127 with an excess of 
cyclopentylamine or (R)-tetrahydro-3-furylamine in ethanol, followed by deprotection of 
the ribose moiety in basic condition. The obtained compounds 61-64 were then converted 
into the 2',3'-isopropylidene derivatives 65-68 by treatment with 2,2-dimethoxypropane 
and camphorsulfonic acid in acetone. Reaction of 65-68  with carbonyl- or 
iocarbonyldiimidazole and then with an excess of 
in good yield. Deisopropylidation of 69-92 
 N6-cyclopentylamino-purine nucleosides 
ino analogues 45-58. Tecadenoson and 2-
reviously reported in literature,195,196 and 
 
 
O
HN
th  appropriate amines gave the 
corresponding 5'-carbamoyl derivatives 69-92 
with 70% formic acid afforded the 5'-substituted
35-44 and the N6-(R)-tetrahydro-3-furanylam
chloro-tecadenoson were also synthesized as p
used as reference compounds. 
OHHO
N
N N
N
R1
CH3
O
O
HN
R2
X
45,46 R1 = H,  R2 =  CH3, X = O or S 
47,48 R1 = H,  R2 = n(C3H7), X = O or S
HN
O
N
N N
N
49,50 R1 = H,  R2 = CH2C6H5, X = O or S
51,52 R1 = Cl, R2 = CH3, X = O or S 
53,54 R1 = Cl, R2 = n(C3H7), X = O or S
55,56 R1 = Cl, R2 = CH2C6H5, X = O or S
57,58 R1 = Cl, R2 = C5H9, X = O or S
OHHO
R1
CH3
X
O
HN
R2
  35,36 R  = H,   R 6H5, X = O or S
3, X = O or S
  39,40 R  = Cl,  R n(C H )  X = O or S
1 2 = CH2C
  37,38 R1 = Cl,  R2 = CH  
1 2 = 3 7 ,
  41,42 R1 = Cl,  R2 = CH2C6H5, X = O or S
  43,44 R1 = Cl,  R2 = C5H9, X = O or S
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OOBzBzO
N
N N
BzO
N
Cl
R1
     
59 R1 = H
60 R1 = Cl
O
OHHO
N
N N
N
NHR
HO
R1
61 (R1 = H), 62 (R1 = Cl), R 
63 (R1 = H), 64 (R1 = Cl), R 
N N
NHR
= cyclopentyl 6
= (R)-3-tetrahydrofuranyl
O
OO
N N
HO
R1
65 (R1 = H), 66 (R1 = Cl), R = cyclopentyl
67 (R1 = H), 68 (R1 = Cl), R = (R)-3-tetrahydro
iii
furanyl
CH3 CH3
CH3
i, ii
O
OHHO
N
N N
N
HN
R1
CH3 O
HN
R2
O
OHHO
N
N N
N
HN
R1
CH3
69,70 R1 = H, R = cyclopentyl, R2= CH2C6H5, X = O
71,78 R1 = Cl, R = cyclopentyl, R  = CH3, n(C3H7),    
         CH2C6H5, or C5H , X = O or S
79,84 R1 = H, R = (R)-3-tetrahydrofuranyl, R2 = CH3, 
          n(C3H7), CH2C6H5, or C5H9, X = O or S
85-92 R1 = Cl, R = (R)-3-tetrahyd ofuranyl, R2 = CH3
          n(C3H7), CH2C6H5, or C5H9, X = O or S
  or S
2           
9
         
r ,         
  35,36 R1 = H,  R2 = CH2C6H5, X = O or S
  37,38 R1 = Cl, R2 = CH3, X = O or S
  39,40 R1 = Cl, R2 = n(C3H7), X = O or S
  41,42 R1 = Cl, R2 = CH2C6H5, X = O or S
  43,44 R1 = Cl, R2 = C5H9, X = O or S
45,46 R1 = H, R2 =  CH3, X = O or S 
47,48 R1 = H, R2 = n(C3H7), X = O or S
49,50 R1 = H, R2 = CH2C6H5, X = O or S
51,52 R1 = Cl, R2 = CH3, X = O or S 
53,54 R1 = Cl, R2 = n(C3H7), X = O or S
55,56 R1 = Cl, R2 = CH2C6H5, X = O or S
57,58 R1 = Cl, R2 = C5H9, X = O or S
O
iv, v
vi O
OO
N
N N
N
NHR
R1
CH3
X
X
O
HN
R2
X
O
HN
R2
Reagents and conditions: (i) RNH2, C2H5OH, reflux; (ii) CH3ONa, CH3OH a r thio CDI, 
THF a. r.t.; (v) R2NH, r.t.; (vi) 70% HCOOH, Δ.
Scheme 4
, r.t.; (iii) 2,2-dimethoxypropane, camphorsulfonic acid, cetone, Δ; (iv) CDI o
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5.2.3 Biological evaluation  
 
Radioligand binding assays on bovine and porcine brain membranes, [35S]GTPγS 
binding assay and adenylyl cyclase assay at porcine brain membranes were carried out 
by Prof. Martini C. (Dipartimento di Neurobiologia, Farmacologia e Biotecnologia, 
University of Pisa, Italy).  Binding assay and adenylyl cyclase assay at cloned human 
ARs were carried out by Prof. Klotz N.-H. (Institut fur Pharmakologie und Toxikologie, 
Universitat Wurzburg, Germany). 
The di- and trisubstituted 2’-C-methyl-purine nucleosides 35-58, 63, and 64 were tested 
in radioligand binding assays to determine their affinities at A1 and A2A ARs from 
bovine and porcine brain cortical and striatum membranes utilizing the agonists 
[3H]CCPA for A1 receptor and [
3H]CGS21680 for A2A subtype (Table 5).  
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Table 5. Binding affinit
membranes. 
 
y of compounds 35-58, 63, and 64 in radioligand assays at bovine and porcine cortical (A1), and striatum (A2a) 
O
OHHO
N
N N
N
HN
R1
R2
R3O O
OHHO
N
N N
N
HN
R1
R2
O
OR3
35-44, CPA, CCPA
2'-Me-CPA, 2'-Me-CCPA
4 -58, 63, 64, tec
2-Cl-tecadenoso
ent at 10
5
 
                                             Ki (nM) or % displacem
                
Compd               R1      R2        R3  bA1a                    pA1a          
 
  35  H       CH3 CONHCH2C6H5  538   2,052 
  36  H CH3 CSNHCH2C6H5  457   1,026 
  37  Cl CH3     CONHCH3                156     72  
  38  Cl CH3 CSNHCH3                    66     13     
  39  Cl CH3 CONH(CH2)2CH3      65   513     
  40  Cl CH3 CSNH(CH2)2CH3      75   337            
  41  Cl CH3 CONHCH2C6H5     57   410    
  42  Cl CH3 CSNHCH2C6H5      42   380     
  43  Cl CH3 CONHC5H9     66   370    
  44  Cl CH3 CSNHC5H9     80   380    
  45  H CH3 CONHCH3  923   760      
  46  H CH3 CSNHCH3  615   173    
  47  H CH3 CONH(CH2)2CH3      930   3,879 
  48  H CH3 CSNH(CH2)2CH3  770   3,200     
  49  H CH3 CONHCH2C6H5  2,308     16,200    
adenoson
n
 
-5 M 
           pA bA2Ab   
        0%  
 11,000   
       16%  
 15,000    
        9% 
      0% 
 19,300 
   7,900       
 12,750     
   8,092       
    13% 
    21% 
        0% 
        0% 
      15% 
2A
b            
     14% 
     21% 
  24% 
   9,200  
   8,700  
     0% 
      28% 
      15% 
   4,700  
   6,845  
   3%   
   4% 
      12%  
        5%  
      12% 
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  continued 
 
 50   H CH3 CSNHCH2C6H5  2,703        9,800           5%        7%  
  51  Cl CH3 CONHCH3   769       534      14%       2%  
  52  Cl CH3 CSNHCH3    615       276          15%       9% 
  53  Cl CH3 CONH(CH2)2CH3  460 1,848                  0%         9%   
  54     Cl CH3 CSNH(CH2)2CH3            313     1,450    10,000                      13,000  
  55     Cl CH3 CONHCH2C6H5     384       4,100         0%            1% 
  56     Cl CH3 CSNHCH2C6H5     230     2,870         9%                     14,100  
  57  Cl CH3 CONHC5H9     307     1,850           12%              29% 
  58     Cl CH3 CSNHC5H9     460      2,053         7%           16%                         
’-Me-CPA     H CH3 H 
CCPA  Cl H H    0.34     0.3       730                           650  
Tecadenoson H H H      3.1             7.6         7,300                 9,756  
           % 
Tecade son       
64                                 1%  
f cortical ranes expressed as n nM (n =
f stri Ki in nM (
CPA  H H H      0.4            0.53                    1,220                           810                                            
2      4.4            10.0                      7,230                      11,370  
        
2’-Me-CCPA     Cl CH3 H                                         1.8             3.6               4,560                      12,000   
 
63   H CH3 H   13.6      150          0%          13
2-Cl- no  Cl      H H                                         1.7              6.6             4,689           27%
Cl CH3 H  13.0        67              7% 
  
a Displacement of speci ic [3H]CCPA binding in bovine or porcine  memb K  i  3).  i
b Displacement of speci ic [3H]CGS21680 binding in bovine or porcine atum membranes expressed as n = 3). 
 85
Some representative compounds were also evaluated for affinity at human A1, A2A, A2B, 
and A3 ARs  CPA, C A, 2'-Me-CPA (61), 2'-Me-CCPA (62), tecadenoson, and 2-chloro-
tecadenoson  were tested as refere compounds.  
Affinity o that the replacement of the N6-
cyclopenty d 2 -CCPA with the (R)-3-
tetrahyd rany so compounds 63 and 64) 
resulted in a decre i finit ceptor. a n showed only slightly 
different affinity toward the A1 A an in branes with Ki values of 
3.1 and o porcine A1 AR appeared 
to be sim 2
A similar lack of species selectivity for bovine vs porcine A as also shown by CPA, 
CCPA, 2'-Me-CPA, 2'-Me-CCPA -Cl-tecadenoson, w  2'-C-methyl-derivatives 
63 and 64 exhibited 11- and 5-fold differences in K s ctively, between the two 
species.
The 5'-c d ty for both bovine and 
porcine A AR com e  A1 selectivity of these 
compounds vs the A2A receptor was retained. T methyl-carbamate and 
thionoca c l-2’-C-methyladenosine 
(compounds 37 and respectively) showed the best affinity at porcine A1 AR (Ki values 
of 72 and 13 nM, respectively)  while the N tr a logues 51 and 52 proved 
to be less fine. l-carbamate nd t ocar  42 had the best affinity 
at bovin f 57 an  nM ecti  general, comparing the 
oxo- vs ith the e alkyl chain length, only in the case of 
compou rv th the thionocarbamate 
derivative m am e in h i
Within n -carbamoyl and 5'-
thionoca v AR with the following  
trend: benzyl ≥ propyl ≥ cyclopentyl yl, w   receptor the trend was 
me l > lope benz
In the trah anyl l c te 46 and the 2-chloro 
de tiv  i = 173 and 276 nM, 
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respectively), while at bovine A1 receptor the most affine compound was the 5'-benzyl-
thionocarbamate 56 (Ki = 230 nM).  
In general it was observed that in 5'-carbamoyl derivatives of the N6-cyclopentyl series the 
41, 46, 63 and 64 was also determined, and compared to the level of maximal stimulation 
 values in the nanomolar 
mmon for A1 AR agonists and has been  shown in particular for adenylyl cyclase 
113,197
 
replacement of the hydrogen with a chlorine atom at the 2-position of the purine ring 
induces an increase in affinity at both bovine and porcine A1 AR (compare 35 and 36 with 
41 and 42); this was not always observed in the N6-tetrahydrofuranyl series. 
The intrinsic activities of tecadenoson, 2-Cl-tecadenoson and selected compounds 37, 38, 
of agonist-induced [35S]GTPγS binding in porcine brain membranes by the full agonist 
CPA (Table 6). Tecadenoson and 2-Cl-tecadenoson showed EC50
range, while the 2'-C-methyl analogues 63 and 64 proved to be much less potent. For these 
compounds a discrepancy between the EC50 and Ki values was detected. This discrepancy 
is quite co
inhibition vs radioligand binding as reported by Klotz et al.
Among the 5'-carbamates, compounds 37 and 38 showed the best EC50 values (165 and 
326 nM, respectively). The 5'-carbamates and thionocarbamates 37, 38, 41 and 46 turned 
out to be partial agonists with 54 to 64% of CPA’s maximal efficacy, while Tecadenoson, 
2-Cl-tecadenoson and the 2'-C-methyl analogues 63 and 64 proved to be full agonists 
(Table 6).  
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Table 6. EC50 values and maximum level of G-protein activation of selected compounds as 
35 o
 
determined by [ S]GTPγS binding t  porcine brain membranes (n = 3) 
 
lso determined (Table 7). 
6
ces a moderate reduction of the affinity at  human A1 receptor (compare 
ompounds 63 and 64 to tecadenoson and 2-Cl-tecadenoson). Thus, 2'-Me-tecadenoson 
nd 2-Cl-2'-Me-tecadenoson turned out to be very selective compounds (> 4,761- to > 
,451-fold A1 vs human A2A, and > 211- to > 288-fold A1 vs A3 receptors, respectively). 
he 5'-thionocarbamates 38 and 52 showed the best affinity at hA1 AR receptor with Ki 
alues of 350 and 840 nM, respectively, but their selectivity proved to be reduced in 
omparison to the non-carbamoylated analogues. Moreover, all tested compounds showed 
 very poor activity at A2B receptor.  
  Compd          EC50 (nM)     efficacy (%) 
 
                                       CPA                                   7.9 ± 1              100 
Tecadenoson      31.6 ± 3               101 ± 1 
2-Cl-Tecadenoson          18.3 ± 2                 97 ± 3 
37         165 ± 18               61 ± 3 
38         326 ± 26               64 ± 2 
41           5,000 ± 478            54 ± 2 
46      2,400 ± 190             56 ± 2 
63           3,620 ± 358             95 ± 4 
64           2,760 ± 293             96 ± 3 
 
 
aMeasurement of the stimulation of binding of [35S]GTPγS (0.3 nM) to G- protein-coupled A1 AR 
in porcine cortical membranes induced by the test compounds (1 nM-10 μM) as % of CPA.  
 
 
The affinity of selected compounds (37, 38, 51, 52, 63, and 64) at human A1, A2A, A2B, and 
A3 adenosine receptor subtypes expressed in CHO cells was a
With the exception of tecadenoson, the N -(R)-3-tetrahydrofuranylamino derivatives 
showed only 2.3- to 5-fold lower affinity at human A1 AR in comparison with the 
corresponding N6-cyclopentyl analogues.  
It was confirmed that the introduction of a methyl group in the 2'-position of the ribose 
moiety indu
c
a
6
T
v
c
a
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Table 7. Binding affinity of N6-cyclopentyl-, and N6-[(R)-3-tetrahydrofuranyl]-2'-C-methyl adenosine 
derivatives at human A1, an A3 a
                                       M)    Selectivity  
 
  Compd                                      A2Ab            A3/A1        A2A/A3
  
 CPA                                          4            19.1           18.5 
 CCPA                                     53              55 
  2'-Me-CPA                           10 0            194.4         11.8 
28.1 
2-Cl-Tecadenoson       1.87          4,590           34,600        211          2,455           112.8          21.7 
1.
8,900         4,470        >6,451        288.4         >22.4 
aDisplacement of [ H]CCPA binding in CHO cells, stably transfected with human recombinant A1 
ade n 
reco c d 
stim th 
hum
 AR of the three species that was porcine > bovine > 
uman. 
 
 A2A, A2B, d denosine receptor subtypes. 
  
         
               Ki  (n                                                    
  A1a       A2Bc          A3b        A /A   2A 1
2.25 79       18,600         43             353    
  0.8        3       18,800         42             2,875    2, 00 
4.52 ,40       26,800        879           2,301  
  2'-Me-CCPA                 3.3           9,580          37,600        1,150        2,903     348             8.3 
  Tecadenoson                2.05          6,390          25,800         227          3,117          110.7          
  
    37                            1,118         10,400      >100,000        8,350        9.3              7.5              2 
    38                               356           8,760      >100,000        2,810       24.6     7.9           3.1 
    51                            4,770     >100,000     >100,000        30,800      >20.9     6.4             >3.2 
    52                               837         15,900     >100,000        12,10        19               14.5          1.3 
    63                              21.0     >100,000         35,500        4,440        >4,761        211.4         >22.5 
    64                              15.5     >100,000        1
 
3
nosine receptor. b Displacement of [3H]NECA binding in CHO cells stably transfected with huma
mbinant A2A or A3 adenosine receptors. EC50 values (nM) are reported for the agonist-mediate
ulation of adenylyl cyclase activity in a membrane preparation of CHO cells, stably transfected wi
an recombinant A2B receptor subtype. 
 
 
With regard to species selectivity of the tested compounds, 2'-C-methyl-tecadenoson (63) 
and the 2-chloro analogue 64 appeared to be less affine at porcine than at bovine and 
human A1 ARs. In the case of the 5'-carbamates and 5'-thiocarbamates, compounds 37, 38, 
51 and 52 showed their affinity at A1
h
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5.3. N6-Cycloalkyl-, and N6-bicycloalkyl-C5'(C2')-modified adenosine 
erivatives as high affinity and selective agonists at human A1 Adenosine 
n 
6  a at 
, 
ts 
o-norborn-2-yl purine 
 
3 
d
Receptor198  
 
5.3.1. Aim of the research 
 
As reported above, to address the problem of side effects of A1 AR agonists several purine 
ribofuranoside derivatives have been investigated as A1 partial agonists endowed with a 
191,199potentially more favourable clinical suitability.  Adenosines bearing 5'-modification i
conjunction with an N -substituent have previously been shown to act s partial agonists 
the A1 AR.122,181,187,189   
Based on these findings, in the search for new potent and selective human A1 AR agonists
we synthesized a series of 5'-chloro-5'-deoxy derivatives of the selective A1 AR agonis
CPA, CCPA, 2'-Me-CPA (61), 2'-Me-CCPA (62) and N6-(±)-end
ribonucleoside analogues (compounds 93-100) that were evaluated for affinity and
selectivity at all cloned human adenosine receptor subtypes. The ability of selected 
compounds to inhibit forskolin-stimulated cAMP production via human A1 and A
receptor was also studied in comparison with the full agonists CCPA and NECA 
respectively. 
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Cl
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R1 R1
93 R = H,  R1 = H
94 R = Cl, R1 = H
97 R = H,  R1 = CH3
98 R = Cl, R1 = CH3
  95 R = H,  R1 = H
  96 R = Cl, R1 = H
  99 R = H,  R1 = CH3
100 R = Cl, R1 = CH3
 
CPA and (±)-ENBA into their 5'-Cl-5'-deoxy-derivatives using SOCl  in 
  HMPA. 
 
 
 
 
 
 
 
 
 
 
5.3.2 Chemistry 
 
Compounds 93 (5'-Cl-CPA) and 94 (5'-Cl-(±)-ENBA), previously reported by van der 
Wenden187 and Trivedi et al.189 respectively, were prepared following a different route as 
described in Scheme 5. Reaction of CPA or (±)-ENBA, with SOCl2, in acetonitrile in 
presence of pyridine, gave the desired compounds  93 and 94  in good yield. Conversion of 
2
hexamethylphosphoramide (HMPA) as descrived in literature by Klotz et al.156 for CCPA 
 because the high toxicity ofwas avoided
 
RR
101 R = cyclopentyl
102 R = endo-2-norbornyl
i
N
N N
N
O
OHHO
HO
NH NH
N
N N
N
Cl O
OHHO
93 R = cyclopentyl
94 R = endo-2-norbornyl
Scheme 5
Reagents and conditions:(i) SOCl2, pyridine, CH3CN, -5°C to r. t.
 91
 92
The synthesis of 2-chloro-analogues 95 and 96 (Scheme 6) was carried out starting from  
2,6-dichloro-9H-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)purine (103) that was prepared as 
reported  by Hou et al.200 Nucleophilic displacement of the chlorine atom in 6-position of 
compound 103 by cyclopentyl or (±)-endo-2-norbornyl-amine in absolute ethanol, 
followed by sugar deblocking with methanolic ammonia gave CCPA (104) and 105, 
respectively.  Compounds 104 and 105  were protected as 2',3'-isopropylidene derivatives  
106 and 107 using camphorsulfonic acid and 2,2-dimethoxypropane in acetone at 55 °C. 
Conversion of 106 and 107  to 5'-chloro derivatives  108 and 109 was performed by 
treatment with thionyl chloride, in the presence of pyridine as described for compounds 93 
and 94. Finally, deprotection of 108 and 109 with 70% formic acid at 40 °C furnished the 
5'-chloro-5'-deoxy-derivatives 95 and 96.  
Scheme 6 
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104 R = cyclopentyl
105 R = endo-2-norbornyl
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 Reagents and conditions: (i) RNH2, EtOH, Δ; (ii) NH3/MeOH, r. t.; (iii) 2,2-dimethoxypropane,
phorsulfonic acid, (CH3)2CO, Δ; (iv) SOCl2, pyridine, CH3CN , -5 °C to  r.t.; (v) HCOOH (70%), 40 °C.
iv
cam
N
N
O
OHHO
HO
Cl
NH
R
103
N
N N
N
O
OO
Cl
Cl
NH
R
N
N N
N
O
OHHO
Cl
Cl
NH
R
v
107 R = endo-2-norbornyl
108 R = cyclopentyl
109 R = endo-2-norbornyl
95 R = cyclopentyl
96 R = endo-2-norbornyl
 
 
106 R = cyclopentyl
he synthesis of compounds 97-100 begins with the 6-chloro- or 2,6-dichloro-9H-(2-C-
ethyl-2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)purine (59 and 60, respectively). (Scheme 
T
m
7). The protected 6-chloro-, and 2,6-dichloro-9H-(2-C-methyl-2,3,5-tri-O-benzoyl-β-D-
ribofuranosyl)purine were prepared as previously reported by Franchetti et al.127  
Reaction of 59 and 60 with cyclopentylamine or (±) endo-2-norbornylamine followed by 
sugar deblocking in basic conditions furnished compounds 61-62 and 110-111  in high 
yield. Compounds 61-62, 110-111 were protected in the corresponding 2',3'-isopropylidene 
derivatives 65-66 and  112-113 that were converted into the 5'-chloro-5'-deoxy-derivatives 
as descrived above. Finally, deisopropylidenation of 114-117 in acid conditions, gave the 
desired compounds 97-100. 
Scheme 7 
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59 R = H
60 R = Cl
  61 R = cyclopentyl, R1 = H
  62 R = cyclopentyl, R1 = Cl
110 R = endo-2-norbornyl, R1 = H
111 R = endo-2-norbornyl, R1 = Cl
 65  R = cyclopentyl, R1 = H
 66  R = cyclopentyl, R1 = Cl
112 R = endo-2-norbornyl, R1= H
113 R = endo-2-norbornyl, R1 = Cl
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  97  R = cyclopentyl, R1 = H
  98  R = cyclopentyl, R1 = Cl
  99  R = endo-2-norbornyl, R1 = H
  100 R = endo-2-norbornyl, R1 = Cl
R
 Reagents and conditions: (i) RNH2, EtOH, Δ; (ii) NH3/MeOH, r.t.; (iii) 2,2-dimethoxypropane,
camphorsulfonic acid, (CH3)2CO, Δ; (iv) SOCl2, pyridine, CH3CN,  -5 °c to r.t.; (v) HCOOH (70%), 40 °C.
O
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OO
  114 R = cyclopentyl, R1 = H
  115 R = cyclopentyl, R1 = Cl
  116 R = endo-2-norbornyl, R1 = H
  117 R = endo-2-norbornyl, R1 = Cl
 
Reference compounds CPA, CCPA, 2'-Me-CPA, 2'-Me-CCPA, and (±)-ENBA, were 
 93
synthesized as reported in the literature.113,127,189
 
5.3.3 Biological evaluation 
 
The synthesized compounds were evaluated at the human recombinant adenosine 
receptors, stably transfected into Chinese hamster ovary (CHO) cells, utilizing radioligand 
binding assays for A1, A2A, and A3 ARs or adenylyl cyclase activity assay  for A2B.156,191 
The biological evaluation was carried out by Prof. Klotz  K.-N. (University of  Würzburg ).  
[3H]CCPA, [3H]NECA and [3H]HEMADO were used as radioligands for human A1, A2A 
and A3 ARs, respectively. In the case of A2B subtype, Ki values were calculated from IC50 
values determined by inhibition of NECA-stimulated adenylyl cyclase activity.168  
The affinity of the compounds was compared to the reference compounds CPA, CCPA, 2'-
Me-CPA, 2'-Me-CCPA, (±)-ENBA, (Table 8). 
 94
Table 8. Bind
         
ing affini y at humt an A 2A, A3 adenosine receptor subtypes.           
N
N
1, A A2B and 
NH
N
N
O
OHHO
R1
R2
R
NH
N
NN
N
O
OHHO
R1
R2
R
93,95, 
2'-Me-C
97, 98, CPA, CCPA,
PA, 2'-Me-CCPA
94,96, 99, 100, 110, 111,
(  )-ENBA, 2-Cl-(  )-ENBA
 
   
                                   Ki  (nM)                                                        
t
 R2            A1
a         A2A
b A2B
c     A3
b             A2A/A1      A3/A1  
 H      0.59             837                 3,210            376 1,470         637 
 H       0.51         1,340                 2,740      1,290          2,630      2,530         
 Cl            1.56           2,160                 4,830         417            1,380         267           
 Cl       1.61           2,050             >10,000      1,410          1,270         875       
 H              28.4     >100,000             >10,000      6,740            >3,520         237  
 CH Cl              12.8                16,200         >10,000      3,030            1,770         237       
 H       9.13          24,000            >10,000    11,600            2,630      1,270    
 Cl        9.16          31,600              >10,000          5,900           3,450         644            
     H      4.09            8,780    >10,000                 2,520 2,150  616 
     Cl      6.96          11,800  >10,000                 4,490 1,700  645 
H      2.25           794       18,600                  43    353           19 
CCP   H Cl      0.8             2,300       18,800          42 2,875     53 
   
 
Selectivi y 
 
   Compd
 
   93
   94   
   95  
   96
   97  
   98
   99  
 100  
 110     
 111    
CPAd  
Ad 
              
          
  
  
  
  
  
  
  
  
  
  
  
  
   R   R1 
   H   Cl 
   H   Cl 
   H   Cl 
   H   Cl 
CH3   Cl 
3   Cl 
CH3   Cl 
CH3   Cl 
CH3     OH 
CH3     OH 
   H OH 
 OH 
(±)-E H    0.54               1,270            4,930                 101         2,350         187   NBA    H OH   
 95
continued 
       
2-Cl-(±)-ENBA     H OH Cl              0.71                  797          >10,000                 129           1,120          182           
5 
8
2'-Me-CPAd CH3 OH H       4.5         10,400    26,800                  879   2,301   19
2'-Me-CCPAd  CH3 OH Cl                3.3             9,580       37,600               1,150   2,903   34
  
 
a Displacement of [3H]CCPA binding in CHO cells stably transfected with human recombinant A1 adenosine receptor.  
b Displacement of [3H]NECA binding in CHO cells stably transfected with human recombinant A1 or A3 
adenosine receptors.   
c Ki values were calculated from IC50 values determined by inhibition of NECA-stimulated adenylyl cyclase activity. 
d Data are from reference 191.  
 
 
 
 96
Among the tested compounds only 93, 94, 95 and (±)-ENBA showed interaction with hA2B 
receptor with Ki values of 3.2, 4.8, 2.7, and 4.9 μM, respectively. 
All the compounds 93-100 showed high affinity and selectivity for human A1 receptor. The 
5'-chloro-5'-deoxy derivatives of CPA (5'Cl-CPA, 93) and (±)-ENBA (5'Cl5'd-(±)-ENBA, 
95) displayed the highest affinity at subnanomolar range for the hA1 AR (Ki = 0.5 nM) and 
relevant selectivity vs hA2A and hA3 Ars, while the corresponding 2-chloro analogues 
(compounds 94 and 96) showed a slight lower affinity and selectivity. A similar 
modification in the ribose-modified C2'-methyl analogues resulted in a moderate decrease 
in affinity at all human AR subtypes; however, these compounds showed an A1 selectivity 
similar to that of parent adenosine analogues. 
These data are in accord to that previously reported by us for the C2'-methyl analogues of 
N6-substituted adenosine that were found to have a decreased affinity, in particular at A3 
ARs, resulting in more A1 selective agonists122,127 (e.g., compare CPA and (±)-ENBA with 
2'-Me-CPA and 2'-Me-(±)ENBA (110), respectively). Among the 5'-chloro-5'-deoxy- and 
2,5'-dichloro-5'-deoxy-C2'-methyl-adenosine derivatives, the most interesting compounds 
appeared to be the N6-(±)-endo-norbornyl analogues 99 and 100, that showed good A1 
affinity (Ki = 9.13 and 9.16 nM, respectively), and A1 selectivity vs A2A = 2,630 and 3,450,  
and vs A3 = 1,270 and 644, respectively. 
 
5.3.3.1 Adenylyl cyclase activity  
 
The ability of selected compounds (93-96 and 110, (±)-ENBA and 2-Cl-(±)-ENBA) to 
inhibit forskolin-stimulated cAMP production via human A1 receptor was studied in 
comparison with the full agonist CCPA. The functional assay showed that all these 
compounds are full agonists on the basis of their adenylyl cyclase inhibitory activity. The 
ability of the selected compounds 93, 94, CPA and (±)-ENBA to inhibit forskolin-
stimulated cAMP production via human A3 AR was also studied in comparison with the 
A3 agonist NECA. The functional assay showed that the 5'-chloro-5'-deoxy derivatives 93 
and 94 behave as antagonists, while the corresponding parent compounds CPA and (±)-
ENBA are partial agonists compared with NECA that proved to be a full agonist.  
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5.4 Molecular Modeling 
 
In order to explain why the replacement of the OH group in 5'-position in N6-substituted 
adenosine analogues with a chlorine is tolerated at human A1 AR but is scarcely tolerated 
at hA3 AR, a molecular docking and dynamic simulation analysis of CPA, (±)-ENBA, 93 
and 94 was performed at the hom y models of both ARs built using bovine rhodopsin 
(b-Rho) crystal structure as a temp . The results indicated that the adenine moiety of the 
ligands had a similar position and orientation inside the putative hA1 AR binding site, 
defined by TMIII, TMV, TMVI and TMVIII. In particular, the N6-substituent of the 
ligands was oriented toward TMV hereas the ribose ring was placed between helices 
TMIII and TMVII with the 5'-substituent pointing toward the intracellular part of the 
receptor. Figures 19 and 20 show t inding mode of CPA, (±)-ENBA, 93 and 94 into the 
hA1 AR model as the average structure calculated on the last 200 ps of the production step. 
It was found that the 5’-OH of CPA and (±)-ENBA accepted a H-bond from the Thr91 
(3.36) OH group in line with the site mutagenesis studies. As regards compound 93 and 94, 
the chlorine atom at 5' position was too far away from Thr91 (3.36) OH group to accept an 
effective H-bond. Nevertheless, MD simulations indicated that it could still accept a H-
bond from the W247 (6.48) indole , thus explaining the high hA1 AR affinity displayed 
by these compounds.  
 
olog
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Fig. 19. On the left,  (extracellular)  view  of CPA (top, yellow)  and ENBA (bottom, orange)  
complexed with the  hA1 AR model.  On the right, schem
CPA (top) and ENBA (bottom) obtained after doc
atic representation of the binding mode of 
king simulation. The green arrows correspond to 
the putative H-bonds. The critical residues involved in interactions with the ligand are colored in 
blue. 
 
 
 
Fig. 20. On the left, (extracellular) view of compounds 93 (top, magenta)  and 94 (bottom, cyan) 
complexed with the hA1 AR model. On the right, schematic representation of the binding mode of 
93 (top)  and 94  (bottom) obtained after docking simulation. The green arrows correspond to the 
putative H-bonds. The critical residues involved in interactions  with the ligand are colored in 
 
blue. 
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g. 21. On the left, (extracellular)  orange)  
mplexed with the hA3 AR model.  On the right,  schematic  representation  of the binding mode 
of CPA (top) and ENBA (bottom) obtained afte
to the putative H-bonds. The critical residues involved 
blue. 
 
 
The lower affinity of CPA and ENBA for hA
these ligands  to establish efficient  H-bonds in particu
His272 (7.43) imidazole ring (Figure 21). W
and 94 in complex with the hA3  
was probably due in particular to the unabil   
to donate a H-bond  to T94 (3.36), unlike CPA and ENBA, which possess a 5'-OH group 
yet able to make this interaction, so explaining the higher A1 vs A3 selectivity of the 5'-
chloro compounds.  
 
Fi
co
view of CPA (top, yellow) and ENBA (bottom,
r docking simulation. The green arrows correspond 
in interactions with the ligand are colored in 
3 AR may be explained by the inability of 
lar between 3'-OH substituent and 
hen analyzing trajectories of derivatives 93 
AR a weakness of the polar interactions was observed. This
ity of chlorine atom at 5' position  of  93 and 94
 99
 100
5.5 Conclusions 
 
The work developed in the second part of m
derivatives as new potent and selective A
In conclusion, in the series of 5'-carbam C-
methyl analogues of the A1 adenosine recepto
chloro-tecadenoson, it was found N6-
positions of purine moiety and at C-2  of ribofuranose ring resulted in some cases 
 different affinity profiles at the a nosine receptors from bovine, porcine, and human 
ompared to the 5'-unsubstituted pa -
tetrahydrofuranyl analogues 
However, the tested nucleosides re
porcine receptors and versus A2A, A2B
The 5'-carbamoyl and 5'-thionocarbamoyl 
Me-CCPA, 37, 38, 41 and tecadenos t 
the porcine A1 AR. 
In the series of 5'-chloro-5'-deoxy-N6
adenosine derivatives the replacemen of 5'-hydroxyl group by a chlorine afforded full 
agonists endowed with similar affinity and increased selectivity for hA1 AR when 
compared with the parent 5'-OH analogues. A similar modification in 2'-C-methyl 
analogues slightly reduced the affinity but maintained the A1 selectivity.  
The 5'-chloro-5'-deoxy derivative of (±)-ENBA (5'Cl5'd-(±)-ENBA)  proved to be the most 
potent and selective among the investigated 5'-chloro-5'-deoxy ribonucleosides. The higher 
selectivity of 5'-chloro-5'-deoxy-modified adenosine derivatives for hA1 AR vs hA3 AR 
compared to that of the 5'-hydroxy parent compounds was rationalized by a molecular 
therapeutic potential. 
y PhD project regarded the study of adenosine 
1 adenosine receptor agonists. 
oyl and 5'-thionocarbamoyl derivatives of 2'-
r agonists, CPA, CCPA, Tecadenosn and 2-
that the combination of modifications at C-2 and 
' and C-5'
dein
species. 
5'-Carbamoyl substituents in the N6-cyclopentyl derivatives of 2'-C-methyladenosine and 
2-chloro analogue caused a decrease in affinity at A1 receptor from the various species, as 
c rent compounds. The same substituents in the N6
brought about a greater reduction in binding affinity. 
tained the A1 versus A2A selectivity at bovine and 
, and A3 human ARs. 
derivatives of the highly selective A1 receptor 2'-
on derivative 46 were found to be partial  agonists a
-cycloalkyl(bicycloalkyl)-adenosine and 2'-C-methyl-
t 
modeling study.  
Owing to the higher selectivity of 5'-chloro-5'-deoxy-adenosine derivatives for the human 
A1 receptor, this type of A1 agonists deserve further investigation to explore their 
5.6 Experimental section 
 
5.6.1 Chemistry 
 
General procedure for the amination of 59 and 60 into compounds 61-64.  
To a stirred solution of 59127 or 60127 (1.0 mmol) in absolute ethanol (20 mL), (R)-3-
aminotetrahydrofuran toluene-4-sulfonate (1.6 mmol) and TEA (4.8 mmol) were added. 
The reaction mixture was refluxed for the time reported below and concentrated in vacuo. 
The residue was dissolved in anhydrous methanol (10 mL) and treated with sodium 
ethoxide (0.5 M in MeOH) (5.8 mL) for 40 min. at room temperature. The obtained 
solution was neutralized with Dowex 50W x 8 (H+ form) ion exchange resin and the resin 
was filtered off with MeOH washing. The filtrate was evaporated to dryness and the 
residue was purified by column chromatography. 
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-β-D-ribofuranosyl)adenine (63). The 
title compound was synthesized from 59 (reaction time 17 h) and purified by 
chromatography on a silica gel column (CHCl3-MeOH, 94:6) as a white solid (95% yield). 
1H-NMR (DMSO-d6): δ 0.75 (s, 3H, CH3), 1.90-2.25 (2m, 2H, tetrahydrofuranyl), 3.55-
3.95 (3m, 7H, H-4', H-5', tetrahydrofuranyl), 4.05 (m, 1H, H-3'), 4.70 (m, 1H, NHCH), 
5.20 (m, 3H, OH), 5.95 (s, 1H, H-1'), 7.98 (d, J = 6.6 Hz, 1H, NH), 8.22 (s, 1H, H-2), 8.50 
64). The title compound was synthesized from 60 (reaction time 3 h) and purified by 
romatography on a silica gel column (CHCl3-MeOH, 93:7) as a white solid (83% yield). 
2,127 63, or 64 (1.0 mmol), 2,2-dimethoxypropane (18.1 mmol) and 
m
(s, 1H, H-8). MS: m/z 352.2 [M + H]+. Anal. calcd. for  C15H21N5O5: C, 51.28; H, 6.02; N, 
19.33. Found: C, 51.20; H, 6.12; N, 19.89.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-β-D-ribofuranosyl)adenine 
(
ch
1H-NMR (DMSO-d6) δ 0.78 (s, 3H, CH3), 2.0-2.20 (2m, 2H, tetrahydrofuranyl), 3.60-4.0 
(4m, 8H, H-3', H-4', H-5', tetrahydrofuranyl), 4.65 (m, 1H, NHCH), 5.20 (m, 2H, OH), 
5.30 (s, 1H, OH), 5.83 (s, 1H, H-1'), 8.50 (s and d, 2H, H-8, NH). MS: m/z 386.2 [M + H]+. 
Anal. calcd. for C15H20ClN5O5: C, 46.70, H, 5.22; N, 18.15. Found: C, 46.75; H, 5.18; N, 
18.10.  
General procedure for the synthesis of the 2',3'-O-isopropylidene derivatives 65-68. A 
mixture of  61,127 6
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camphorsulfonic acid (1.0 mmol) in anhydrous acetone (10 mL) was stirred at 55 °C for 
e time reported below. The solvent was removed in vacuo and the residue was purified 
osyl)adenine 
J = 7.0 Hz, 1H, NH), 8.15 (s, 1H, H-2), 8.28 (s, 1H, H-8). MS: m/z 
4:6) gave 66 as a white foam 
), 4.40 (m, 1H, NHCH), 4.58 (d, J = 2.2 Hz, 1H, H-3'), 5.26 (t, J = 5.6 
63 (reaction time 
3 (s, 1H, H-1'), 8.02 (d, J = 6.6 Hz, 1H, NH), 8.22 (s, 1H, H-2), 8.36 (s, 
th
by column chromatography. 
N6-Cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-β-D-ribofuran
(65). The title compound was obtained starting from 61 (reaction time 4 h). 
Chromatography on a silica gel column (CHCl3-MeOH, 99:1) gave 65 as a white foam 
(84% yield). 1H-NMR (DMSO-d6): δ 1.08 (s, 3H, CH3), 1.32, 1.50 (2s, 6H, CH3), 1.50-
1.78 (m, 6H, cyclopentyl), 1.90 (m, 2H, cyclopentyl), 3.65 (m, 2H, H-5'), 4.20 (m, 1H, H-
4'), 4.50 (m, 1H, NHCH), 4.55 (d, J = 2.2 Hz, 1H, H-3'), 5.38 (t, J = 5.3 Hz, 1H, OH), 6.18 
(s, 1H, H-1'), 7.75 (d, 
390.3 [M + H]+. Anal. calcd. for C19H27N5O4: C, 58.60; H, 6.99; N, 17.98. Found: C, 
58.63, 6.92 H, N, 17.88.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-β-D-ribofurano-
syl)adenine (66). The title compound was synthesized starting from 62 (reaction time 4 h). 
Chromatography on a silica gel column (CHCl3-EtOAc, 9
(77% yield). 1H-NMR (DMSO-d6): δ 1.10 (s, 3H, CH3), 1.35, 1.55 (2s, 6H, CH3), 1.50-
1.72 (2m, 6H, cyclopentyl), 1.92 (m, 2H, cyclopentyl), 3.70 (q, J = 4.5 Hz, 2H, H-5'), 4.23 
(pseudo q, 1H, H-4'
Hz, 1H, OH), 6.12 (s, 1H, H-1'), 8.36 (s and d, 2H, H-8, NH). MS: m/z 424.9 [M + H]+. 
Anal. calcd. for C19H26ClN5O4: C, 53.83; H, 6.18; N, 16.52. Found: C, 53.75; H, 6.25;  N, 
16.58.  
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-β-D-ribofura-
nosyl)adenine (67). The title compound was synthesized starting from 
4.5 h). Chromatography on a silica gel column (CHCl3-MeOH, 96:4) gave 67 as a white 
foam (76% yield). 1H-NMR (DMSO-d6): 1.10 (s, 3H, CH3), 1.35, 1.55 (2s, 6H, CH3), 2.0-
2.20 (2m, 2H, tetrahydrofuranyl), 3.60-3.95 (3m, 6H, H-5', tetrahydrofuranyl), 4.23 
(pseudo q, 1H, H-4'), 4.60 (d, J = 2.2 Hz, 1H, H-3'), 4.70 (m, 1H, NHCH), 5.40 (t, J = 5.7 
Hz, 1H, OH), 6.2
1H, H-8). MS: m/z 392.2 [M + H]+. Anal. calcd. for C18H25N5O5 : C, 55.23 ; H, 6.44; N, 
17.89. Found: C, 55.20; H, 6.46; N, 17.94. 
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2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-β-D-
ibofuranosyl)adenine (68). The title compound was obtained starting from 64 (reaction 
matography on a silica gel column (CHCl3-MeOH, 98:2) gave 68 as a 
hite foam (90% yield). 1H-NMR (DMSO-d6): δ 1.10 (s, 3H, CH3), 1.35, 1.55 (2s, 6H, 
stirred at room temperature for the time 
atography to give the 2',3'-isopropylidene-5'-substituted derivatives 35-
5
 with CDI for 8 h, followed by addition of 
n a 
, 6.49; N, 16.17.  
r
time 4.5 h). Chro
w
CH ), 1.90-2.30 (2m, 2H, tetrahydrofuranyl), 3.60-3.95 (3m, 6H, H-5', tetrahydrofuranyl), 3
4.23 (pseudo q, 1H, H-4'), 4.58 (d, J = 2.2 Hz, 1H, H-3'), 4.63 (m, 1H, NHCH), 5.27 (t, J = 
5.5 Hz, 1H, OH), 6.14 (s, 1H, H-1'), 8.40 (s, 1H, H-8), 8.58 (d, J = 6.6 Hz, 1H, NH). MS: 
m/z 426.7 [M + H]+. Anal.calc. for C18H24ClN5O5: C, 50.77; H, 5.68; N, 16.44. Found: C, 
50.70; H, 5.76;  N, 16.51.  
General procedure for the synthesis of compounds 69-92 and 35-58.  
To a solution of 31-34 (1.0 mmol) in anhydrous THF (10 mL), CDI or thio CDI (6.0 
mmol) was added and the reaction mixture was 
reported below. Then water (50 μL) was added and the solution was stirred for 30 min. 
After that, the appropriate amine (1.5 mmol) was added stirring at room temperature for 
the time reported below. The solvent was evaporated to dryness and the residue was 
purified by chrom
8. These compounds were deprotected by treatment with 70% HCOOH (10 mL) at 40 °C 
or 55 °C for various times, to give the desired compounds 1-24 after chromatographic 
purification. 
N6-Cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-benzylcarbamoyl-β-D-
ribofuranosyl)adenine (69). Reaction of 65
benzylamine and stirring for 2 h, gave 69 which was purified by chromatography o
silica gel column (CHCl3-MeOH, 99.5:0.5) as a white foam (88% yield). 
1H-NMR 
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 1.50-1.75 (m, 6H, cyclopentyl), 
1.94 (m, 2H, cyclopentyl), 4.20 (d, J = 5.9 Hz, 2H, H-5', ), 4.35 (m, 3H, H-4', CH2C6H5), 
4.50 (m, 1H, NHCH), 4.56 (br s, 1H, H-3'), 6.22 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 7.76 
(d, J = 7.3 Hz, 1H, NHCH), 7.92 (t, J = 5.9 Hz, 1H, NHCH2), 8.20 (s, 2H, H-2, H-8). MS: 
m/z 523.5 [M + H]+. Anal. calc. for C27H34N6O5: C, 62.05; H, 6.56; N, 16.08. Found: C, 
62.14; H
N6-Cyclopentyl-9H-(2-C-methyl-5-N-benzylcarbamoyl-β-D-ribofuranosyl)adenine 
(35). Reaction of 69 with HCOOH at 40 °C for 6 h, followed by chromatography on a 
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silica gel column (CHCl3-MeOH, 98:2) gave 35 as a white solid (50% yield). 
1H-NMR 
(DMSO-d6): δ 0.8 (s, 3H, CH3), 1.50-1.72 (2m, 6H, cyclopentyl), 1.94 (m, 2H, 
cyclopentyl), 4.08 (m, 2H, H-5'), 4.18 (d, J = 5.8 Hz, 2H, CH C H ), 4.22 (t, J = 6.4 Hz, 
ribofuranosyl)adenine (70). Reaction of 65 with thio CDI for 2.5 h, followed by addition 
 
3-MeOH, 99.5:0.5) as a white foam (58% yield). 
1H-NMR 
CH C H ), 6.22 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 7.75 (d, J = 8.1 Hz, 1H, NHCH), 8.18 
6 H
). Reaction of 70 with HCOOH at 40 °C for 6 h, followed by chromatography 
 1H-
-2,3-O-isopropylidene-5-N-methylcarba-
moyl-β-D-ribofuranosyl)adenine (71). Reaction of 66 with CDI for 6 h, followed by 
2 6 5   
1H, H-4'), 4.42 (d, J = 11.9 Hz, 1H, H-3'), 4.48 (m, 1H, NHCH), 5.28 (s, 1H, OH), 5.42 (d, 
J = 6.4 Hz, 1H, OH), 5.95 (s, 1H, H-1'), 7.25 (m, 5H, arom.), 7.72 (d, J = 7.9 Hz, 1H, 
NHCH), 7.85 (t, J = 5.9 Hz, 1H, NHCH2), 8.20 (s, 2H, H-2, H-8). MS: m/z 483.5 [M + 
H]+. Anal. calcd for C24H30N6O5: C, 59.74; H, 6.26; N, 17.42. Found: C, 59.66; H, 6.33; 
N,  17.55.  
N6-Cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-benzylthiocarbamoyl-β-D-
of benzylamine and stirring for 4 h, gave 70 which was purified by chromatography on a 
silica gel column (CHCl
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.35, 1.55 (2s, 6H, CH3), 1.50-1.75 (m, 6H, cyclopentyl), 
1.92 (m, 2H, cyclopentyl), 4.45 (m, 2H, H-5'), 4.60-4.78 (2m, 5H, H-3', H-4', NHCH, 
2 6 5
(s, 1H, H-2), 8.22 (s, 1H, H-8), 9.85 (t, J = 5.9 Hz, 1H, NHCH2). MS: m/z 539.5 [M + H]+. 
Anal. calcd. for C27H34N6O4S: C, 60.20; H, 6.36; N, 15.60. Found: C, 60.11; H, 6.43; N,  
15.74.  
N -Cyclopentyl-9 -(2-C-methyl-5-N-benzylthiocarbamoyl-β-D-ribofuranosyl)- 
adenine (36
on a silica gel column (CHCl3-MeOH, 98:2) gave 36 as a white solid (73% yield).
NMR (DMSO-d6): δ 0.8 (s, 3H, CH3), 1.50-1.72 (m, 6H, cyclopentyl), 1.92 (m, 2H, 
cyclopentyl), 4.10-4.35 (2m, 3H, H-4', H-5', NHCH), 4.55 (dd, J = 6.6, 12.5 Hz, 1H, H-5'), 
4.65 (d, J = 5.9 Hz, 2H, CH2C6H5), 4.88 (d, J = 10.6 Hz, 1H, H-3'), 5.30 (s, 1H, OH), 5.45 
(d, J = 6.2 Hz, 1H, OH), 5.98 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 7.75 (d, J = 7.7 Hz, 1H, 
NHCH), 8.20 (s, 1H, H-2), 8.24 (s, 1H, H-8), 9.82 (t, J = 6.2 Hz, 1H, NHCH2). MS: m/z 
499.5 [M + H]+. Anal. calcd. for C24H30N6O4S: C, 57.81; H, 6.06; N, 16.85. Found: C, 
57.75; H, 6.19; N, 16.90.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl
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addition of methylamine and stirring for 2 h, gave 71 as a white foam (62% yield) 
chromatography on a silica gel column (CHCl
after 
 with HCOOH at 55 °C for 4 h, followed by chromatography 
1H-
 
ofuranosyl)adenine (72). Reaction of 66 with thio CDI for 2 h, followed by 
 by 
6 3 3
3
n of 72 with HCOOH at 40 °C for 4 h, followed by 
lid 
3-MeOH, 99.5:0.5). 
1H-NMR (DMSO-d6): δ 
1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 1.50-1.75 (m, 6H, cyclopentyl), 1.92 (m, 2H, 
cyclopentyl), 2.58 (d, J = 4.4 Hz, 3H, NHCH3), 4.30 (m, 3H, H-4', H-5'), 4.40 (m, 1H, 
NHCH), 4.54 (d, J = 2.2 Hz, 1H, H-3'), 6.15 (s, 1H, H-1'), 7.2 (q, J = 4.4 Hz, 1H, NHCH3), 
8.20 (s, 1H, H-8), 8.38 (d, J = 7.7 Hz, 1H, NHCH). MS: m/z 481.9 [M + H]+. Anal. calcd. 
for C21H29ClN6O5: C, 52.44; H, 6.08; N, 17.47. Found: C, 52.56; H, 6.01 ; N, 17.40.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-methylcarbamoyl-β-D-ribofuranosyl)-
adenine (37). Reaction of 71
on a silica gel column (CHCl -MeOH, 97:3) gave 37 as a white solid (86% yield). 3
NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.60, 1.90 (2m, 8H, cyclopentyl), 2.55 (d, J = 4.8 
Hz, 3H, NHCH3), 4.02 (m, 2H, H-5'), 4.20 (m, 1H, H-4'), 4.40 (m, 2H, NHCH, H-3'), 5.35 
(s, 1H, OH), 5.42 (d, J = 6.2 Hz, 1H, OH), 5.85 (s, 1H, H-1'), 7.15 (q, J = 4.5 Hz, 1H, 
NHCH3), 8.20 (s, 1H, H-8), 8.38 (d, J = 7.7 Hz, 1H, NHCH). MS: m/z 441.8 [M + H]+. 
Anal. calcd. for C18H25ClN6O5: C, 49.04; H, 5.71; N,  19.06. Found: C, 49.13; H, 5.78 ; N, 
19.16.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-methylthiocarba-
moyl-β-D-rib
addition of methylamine and stirring overnight, gave 72 which was purified
chromatography on a silica gel column (CHCl3-MeOH, 99:1) as a white foam (92% yield). 
1H-NMR (DMSO-d ): δ 1.18 (s, 3H, CH ), 1.38, 1.56 (2s, 6H, CH ), 1.50-1.78 (m, 6H, 
cyclopentyl), 1.94 (m, 2H, cyclopentyl), 2.88 (d, J = 4.4 Hz, 3H, NHCH ), 4.42 (m, 2H, H-
5'), 4.62 (d, J = 3.3 Hz, 1H, H-3'), 4.70 (m, 2H, H-4', NHCH), 6.15 (s, 1H, H-1'), 8.22 (s, 
1H, H-8), 8.38 (d, J = 7.3 Hz, 1H, NHCH), 9.25 (q, J = 4.4 Hz, 1H, NHCH3). MS: m/z 
498.0 [M + H]+. Anal. calcd. for  C21H29ClN6O4S: C, 50.75; H, 5.88; N, 16.91. Found: C, 
50.82; H, 5.80, N, 19.96. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-methylthiocarbamoyl-β-D-ribofurano-
syl)adenine (38). Reactio
chromatography on a silica gel column (CHCl3-MeOH, 99:1) gave 38 as a white so
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(56% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.60, 1.90 (2m, 8H, cyclopentyl), 
2.86 (d, J = 4.4 Hz, 3H, NHCH3), 4.10 (m, 2H, H-5'), 4.45 (m, 2H, H-4', NHCH), 4.80  (m, 
1H, H-3'), 5.35 (s, 1H, OH), 5.48 (d, J = 6.2 Hz, 1H, OH), 5.86 (s, 1H, H-1'), 8.22 (s, 1H, 
H-8), 8.35 (d, J = 8.1 Hz, 1H, NHCH), 7.25 (q, J = 4.4 Hz, 1H, NHCH3). MS: m/z 457.9 
[M + H]+. Anal. calcd. for  C18H25ClN6O4S: C, 47.31;  H, 5.51; N, 18.39. Found: C, 47.45; 
H, 5.65; N,  18.51.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-propylcarba-
moyl-β-D-ribofuranosyl)adenine (73). Reaction of 66 with CDI for 3 h, followed by 
 
 (39). Reaction of 73 with HCOOH at 40 °C for 4 h, followed by chromatography 
). 1H-
+
nd stirring for 1 h, gave 74 as a white foam (91% yield) after 
 7.3 
addition of propylamine and stirring for 2 h, gave 73 which was purified by
chromatography on a silica gel column (CHCl3) as a white foam (92% yield). 
1H-NMR 
(DMSO-d6): δ 0.82 (t, J = 7.3 Hz, 3H, CH2CH3), 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, 
CH3), 1.50-1.78 (m, 6H, cyclopentyl), 1.94 (m, 2H, cyclopentyl), 2.95 (q, J = 6.8 Hz, 2H, 
CH2CH3), 3.60 (q, J = 6.6 Hz, 2H, NHCH2), 4.20-4.45 (m, 4H, H-4', H-5', NHCH), 4.55 
(br s, 1H, H-3'), 6.15 (s, 1H, H-1'), 7.35 (t, J = 5.7 Hz, 1H, NHCH2), 8.20 (s, 1H, H-8), 
8.38 (d, J = 7.7 Hz, 1H, NHCH). MS: m/z 510 [M + H]+. Anal. calcd. for  C23H33ClN6O5: 
C,  54.27; H, 6.53; N, 16.51. Found: C, 54.17; H, 6.60; N, 16.60.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-propylcarbamoyl-β-D-ribofuranosyl)-
adenine
on a silica gel column (CHCl3-MeOH, 99:1) gave 39 as a white solid (87% yield
NMR (DMSO-d6): δ 0.82 (s and t, 6H, CH3, CH2CH3), 1.40 (q, J = 7.0 Hz, 2H, CH2CH3), 
1.50-1.78 (m, 6H, cyclopentyl), 1.94 (m, 2H, cyclopentyl), 2.95 (q, J = 6.6 Hz, 2H, 
NHCH2), 4.02 (br s, 2H, H-5'), 4.20 (m, 1H, H-4'), 4.40 (m, 2H, H-3', NHCH), 5.35 (s, 1H, 
OH), 5.40 (pseudo t, 1H, OH), 5.86 (s, 1H, H-1'), 7.30 (t, J = 5.9 Hz, 1H, NHCH2), 8.20 (s, 
1H, H-8), 8.38 (d, J = 7.7 Hz, 1H, NHCH). MS: m/z 469.9 [M + H] . Anal. calcd. for  
C20H29ClN6O5: C, 51.23; H, 6.23; N, 17.92. Found: C, 51.26; H, 6.18; N, 17.82.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-propylthiocarba-
moyl-β-D-ribofuranosyl)adenine (74). Reaction of 66 with thio CDI for 6 h, followed by 
addition of propylamine a
chromatography on a silica gel column (CHCl3). 
1H-NMR (DMSO-d6): δ 0.85 (t, J =
Hz, 3H, CH2CH3), 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 1.50-1.78 (m, 6H, 
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cyclopentyl), 1.92 (m, 2H, cyclopentyl), 2.95 (q, J = 6.8 Hz, 2H, CH2CH3), 3.70 (q, J = 6.6 
Hz, 2H, NHCH2), 4.20-4.45 (m, 4H, H-4', H-5', NHCH), 4.70 (m, 1H, H-3'), 6.15 (s, 1H, 
H-1'), 8.40 (s, d, 2H, H-8, NHCH), 9.38 (t, J = 6.0 Hz, 1H, NHCH2). MS: m/z 526.1 [M + 
H]+. Anal. calcd. for  C23H33ClN6O4S : C, 52.61; H, 6.33; N, Found: C, 52.70; H, 6.29; N, 
16.10.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-propylthiocarbamoyl-β-D-ribofurano-
syl)adenine (40). Reaction of 74 with HCOOH at 55 °C for 2 h, followed by 
d 
6 H
ine (75). Reaction of 66 with CDI for 8 h, followed by addition of 
+
 75 with HCOOH at 55 °C for 6 h, followed by chromatography 
-
4.45 (m, 2H, H-3', H-4'), 5.35 (s, 1H, OH), 5.45 (m, 1H, OH), 5.86 (s, 1H, H-1'), 7.28 (m, 
chromatography on a silica gel column (CHCl3-MeOH, 99.5:0.5) gave 40 as a white soli
(55% yield). 1H-NMR (DMSO-d6): δ 0.82 (s and t, 6H, CH3, CH2CH3), 1.44-1.74 (m, 8H, 
CH2CH3, cyclopentyl), 1.94 (m, 2H, cyclopentyl), 3.30 (q, J = 6.6 Hz, 2H, NHCH2), 4.10 
(m, 2H, H-5'), 4.45 (m, 2H, H-4', NHCH), 4.85 (d, J = 11.7 Hz, 1H, H-3'), 5.40 (s, 1H, 
OH), 5.50 (pseudo t, 1H, OH), 5.90 (s, 1H, H-1'), 8.25 (s, 1H, H-8), 8.40 (d, J = 7.7 Hz, 
1H, NHCH),  9.32 (t, J = 5.9 Hz, 1H, NHCH2). MS: m/z 486.0 [M + H]+. Anal. calcd. for 
C20H29ClN6O4S: C, 49.53, H, 6.03; N,17.33. Found: C, 49.55; H, 6.0; N, 17.37. 
2-Chloro-N -cyclopentyl-9 -(2-C-methyl-2,3-O-isopropylidene-5-N-benzylcarbamoyl-
β-D-ribofuranosyl)aden
benzylamine and stirring for 2 h, gave 75 which was purified by chromatography on a 
silica gel column (CHCl3-MeOH, 99.5:0.5) as a white foam (87% yield). 
1H-NMR 
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 1.50-1.76 (m, 6H, cyclopentyl), 
1.94 (m, 2H, cyclopentyl), 4.20 (d, J = 5.9 Hz, 2H, CH2C6H5), 4.35 (m, 4H, H-4', H-5', 
NHCH), 4.55 (br s, 1H, H-3'), 6.15 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 7.95 (t, J = 5.9 Hz, 
NHCH2), 8.20 (s, 1H, H-8), 8.40 (d, J = 7.7 Hz, 1H, NHCH). MS: m/z 558.0 [M + H] . 
Anal. calcd. for  C27H33ClN6O5: C, 58.22; H, 5.97; N, 15.09. Found: C, 58.10; H, 6.04; N, 
15.14. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-benzylcarbamoyl-β-D-ribofuranosyl)-
adenine (41). Reaction of
on a silica gel column (CHCl3-MeOH, 97:3) gave 41 as a white solid (77% yield). 
1H
NMR (DMSO-d6): δ 0.8 (s, 3H, CH3), 1.46-1.76 (m, 6H, cyclopentyl), 1.94 (m, 2H, 
cyclopentyl), 4.02 (m, 2H, H-5'), 4.20 (d, J = 6.2 Hz, 2H, CH2C6H5), 4.25 (m, 1H, NHCH), 
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5H, arom.), 7.88 (m, NHCH2), 8.23 (s, 1H, H-8), 8.38 (d, J = 8.1 Hz, 1H, NHCH). MS: m/z 
518.0 [M + H]+. Anal. calcd. for C24H29ClN6O5: C, 55.76; H,  5.65; N, 16.25. Found: C, 
55.70; H, 5.78; N, 16.32.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-benzylthiocarba-
moyl-β-D-ribofuranosyl)adenine (76). Reaction of 66 with thio CDI for 5 h, followed by 
addition of benzylamine and stirring for 1 h, gave 76 as a white foam (77% yield) after 
2 (2m, 6H, cyclopentyl), 
), 
8 (s, 3H, 
 
chromatography on a silica gel column (CHCl3). 
1H-NMR (DMSO-d6): δ 1.20 (s, 3H, 
CH3), 1.38, 1.56 (2s, 6H, CH3), 1.50-1.75 (m, 6H, cyclopentyl), 1.94 (m, 2H, cyclopentyl), 
4.45 (m, 2H, H-5'), 4.60-4.80 (2m, 5H, H-3', H-4', CH2C6H5, NHCH), 6.15 (s, 1H, H-1'), 
7.28 (m, 5H, arom.), 8.25 (s, 1H, H-8), 8.40 (d, J = 8.8 Hz, 1H, NHCH), 9.88 (t, J = 5.9 
Hz, 1H, NHCH2). MS: m/z 574.1 [M + H]+. Anal. calcd. for  C27H33ClN6O4S: C, 56.58; H, 
5.80; N, 14.66. Found: C, 56.50; H, 5.71; N, 14.56.  
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-benzylthiocarbamoyl-β-D-ribofurano-
syl)adenine (42). Reaction of 76 with HCOOH at 55 °C for 3.5 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 97:3) gave 42 as a white solid 
(80% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.50-1.7
1.95 (m, 2H, cyclopentyl), 4.12 (m, 2H, H-5'), 4.20 (m, 1H, NHCH), 4.52 (m, 1H, H-4'
4.65 (m, 2H, CH2C6H5), 4.88 (d, J = 11.9 Hz, 1H, H-3'), 5.38 (s, 1H, OH), 5.50 (d, J = 6.4 
Hz, 1H, OH), 5.86 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 8.23 (s, 1H, H-8), 8.38 (d, J = 7.6 
Hz, 1H, NHCH), 9.82 (t, J = 5.9 Hz, 1H, NHCH2). MS: m/z 534.0 [M + H]
+. Anal. calcd. 
for  C24H29ClN6O4S: C, 54.08; H, 5.48; N, 15.77. Found: C, 54.18; H, 5.44; N, 15.72. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-cyclopentylcarba-
moyl-β-D-ribofuranosyl)adenine (77). Reaction of 66 with CDI for 3 h, followed by 
addition of cyclopentylamine and stirring overnight, gave 77 as a white foam (93% yield) 
after chromatography on a silica gel column (CHCl3). 
1H-NMR (DMSO-d6): δ 1.1
CH3), 1.38 (s, 3H, CH3), 1.30-1.50 (2m, 4H, cyclopentyl), 1.54 (s, 3H, CH3), 1.50-1.78
(3m, 10H, cyclopentyl), 1.95 (m, 2H, cyclopentyl), 3.78 (m, 1H, NHCH), 4.30 (2m, 3H, H-
5', NHCH), 4.40 (m, 1H, H-4'), 4.54 (d, J = 2.3 Hz, 1H, H-3'), 6.15 (s, 1H, H-1'), 7.35 (d, J 
= 7.4 Hz, 1H, NHCH), 8.20 (s, 1H, H-8), 8.40 (d, J = 7.4 Hz, 1H, NHCH). MS: m/z 536.0 
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[M + H]+. Anal. calcd. for C25H35ClN6O5 : C, 56.12; H, 6.59; N, 15.71. Found: C, 56.22; 
H, 6.43; N, 15.88. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-cyclopentylcarbamoyl-β-D-ribofurano-
syl)adenine (43). Reaction of 77 with HCOOH at 40 °C for 2 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 98:2) gave 43 as a white solid 
, 
SO-d6): δ 
c
1
, 4H, cyclopentyl), 4.12 (m, 2H, H-5'), 4.30 (m, 1H, NHCH), 4.40 (m, 2H, H-4', 
), 
+
N -(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-methylcarba-
(58% yield). 1H-NMR (DMSO-d6): δ 0.8 (s, 3H, CH3), 1.30-2.0 (2m, 16H, cyclopentyl)
3.75 (m, 1H, NHCH), 4.0-4.22 (m, 3H, H-5', NHCH), 4.40 (m, 2H, H-3', H-4'), 5.35 (s, 
1H, OH), 5.45 (pseudo t, 1H, OH), 5.86 (s, 1H, H-1'), 7.30 (d, J = 7.3 Hz, 1H, NHCH), 
8.20 (s, 1H, H-8), 8.40 (d, J = 8.1 Hz, 1H, NHCH). MS: m/z 496.0 [M + H]+. Anal. calcd. 
for  C22H31ClN6O5: C, 53.38; H, 6.31; N, 16.99. Found: C, 53.33; H, 6.28; N, 16.94. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-cyclopentylthio-
carbamoyl-β-D-ribofuranosyl)adenine (78). Reaction of 66 with thio CDI for 4 h, 
followed by addition of cyclopentylamine and stirring overnight, gave 78 as a white foam 
(95% yield) after chromatography on a silica gel column (CHCl3). 
1H-NMR (DM
1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 1.46-1.74 (m, 12H, cyclopentyl), 1.90 (m, 4H, 
yclopentyl), 3.70 (m, 1H, NHCH), 4.20-4.45 (m, 4H, H-4', H-5', NHCH), 4.70 (m, 1H, H-
3'), 6.15 (s, 1H, H-1'), 7.15 (d, J = 7.1 Hz, 1H, NHCH), 8.22 (s, 1H, H-8), 9.35 (d, J = 7.0 
Hz, 1H, NHCH). MS: m/z 552.1 [M + H]+. Anal. calcd. for C25H35ClN6O4S: C, 54.49; H, 
6.40; N, 15.25. Found: C, 54.32; H, 6.49; N,   15.37. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-N-cyclopentylthiocarbamoyl-β-D-ribo-
furanosyl)adenine (44). Reaction of 78 with HCOOH at 55 °C for 2 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 99.5:0.5) gave 44 as a white solid 
(50% yield). H-NMR (DMSO-d6): δ 0.82 (s, 3H, CH3), 1.40-1.78 (m, 12H, cyclopentyl), 
1.94 (m
NHCH), 4.82 (br d, J = 12.1 Hz, 1H, H-3'), 5.38 (s, 1H, OH), 5.50 (pseudo t, 1H, OH
5.88 (s, 1H, H-1'), 8.22 (s, 1H, H-8), 8.38 (d, J = 7.7 Hz, 1H, NHCH), 9.30 (d, J = 7.3 Hz, 
1H, NHCH). MS: m/z 512.0 [M + H] . Anal. calcd. for  C22H31ClN6O4S: C, 51.71; H, 
6.11; N, 16.44. Found: C, 51.63; H, 6.18; N, 16.53.  
6
moyl-β-D-ribofuranosyl)adenine (79). Reaction of 67 with CDI for 8 h, followed by 
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addition of methylamine and stirring overnight, gave the 79 as a white foam (72% yield) 
after chromatography on a silica gel column (CHCl -MeOH, 96:4). 3
1H-NMR (DMSO-d ): 
δ 1.12 (s, 3H, CH ), 1.32, 
6
3 1.52 (2s, 6H, CH3), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 2.58 
-
 3H, CH3), 2.0, 2.20 (2m, 2H, 
, 
+
6
J H J
furanosyl)adenine (46). Reaction of 80 with HCOOH at 55 °C for 3 h, followed by 
(d, J = 4.4 Hz, 3H, NHCH3), 3.60-3.95 (m, 4H, tetrahydrofuranyl), 4.30 (m, 3H, H-4', H
5'), 4.58 (d, J = 1.8 Hz, 1H, H-3'), 4.70 (m, 1H, NHCH), 6.22 (s, 1H, H-1'), 7.20 (q, J = 4.7 
Hz, 1H, NHCH3), 8.0 (d, J = 5.7 Hz, 1H, NHCH), 8.22 (s, 2H, H-2, H-8). MS: m/z 448.5 
[M + H]+. Anal. calcd. for  C20H28N6O6 : C, 53.56; H, 6.29; N, 18.74. Found: C, 53.43; H, 
6.38; N, 18.79.  
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-5-N-methylcarbamoyl-β-D-ribofurano-
syl)adenine (45). Reaction of 79 with HCOOH at 55 °C for 3.5 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 96:4) gave 45 as a white solid 
(71% yield). 1H-NMR (DMSO-d6): δ 0.8 (s,
tetrahydrofuranyl), 2.55 (d, J = 4.0 Hz, 3H, NHCH3), 3.58-3.95 (m, 4H, tetrahydrofuranyl)
4.05 (m, 2H, H-5'), 4.20 (m, 1H, H-4'), 4.40 (d,  J = 12.5 Hz, 1H, H-3'), 4.65 (m, 1H, 
NHCH), 5.30 (s, 1H, OH), 5.42 (d,  J = 5.9 Hz, 1H, OH), 5.96 (s, 1H, H-1'), 7.15 (q, J = 
4.7 Hz, 1H, NHCH3), 8.0 (d, J = 5.7 Hz, 1H, NHCH), 8.22 (s, 1H, H-2), 8.24 (s, 1H, H-8). 
MS: m/z 409.4 [M + H] . Anal. calcd. for C17H24N6O6: C, 49.99; H, 5.92; N, 20.58. 
Found: C, 49.90; H, 5.97; N, 20.68.  
N -(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-methylthio-
carbamoyl-β-D-ribofuranosyl)adenine (80). Reaction of 67 with thio CDI for 8 h, 
followed by addition of methylamine and stirring overnight, gave 80 as a white foam (93% 
1yield) after chromatography on a silica gel column (CHCl3-MeOH, 99:1). H-NMR 
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 2.0, 2.20 (m, 2H, 
tetrahydrofuranyl), 2.86 (d, J = 4.8 Hz, 3H, NHCH3), 3.60-3.95 (m, 4H, tetrahydrofuranyl), 
4.45 (m, 1H, H-5'), 4.62 (d, J = 2.6 Hz, 1H, H-3'), 4.70 (m, 4H, H-4', H-5', NHCH), 6.25 (s, 
1H, H-1'), 8.05 (d,  = 5.7 Hz, 1H, N CH), 8.25 (s, 2H, H-2, H-8), 9.28 (q,  = 4.8 Hz, 1H, 
NHCH3). MS: m/z 465.4 [M + H]
+. Anal. calcd. for  C20H28N6O5S: C, 51.71; H, 6.07; N, 
18.09. Found: C, 51.59; H, 6.19; N, 18.16. 
 N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-5-N-methylthiocarbamoyl-β-D-ribo-
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chromatography on a silica gel column (CHCl3-MeOH, 95:5) gave 46 as a white solid 
(63% yield). 1H-NMR (DMSO-d6): δ 0.8 (s, 3H, CH3), 2.0, 2.20 (2m, 2H, 
 
β ed by 
r 
C ,
8N6O6: C, 52.28; H, 6.47; N, 19.25. 
tetrahydrofuranyl), 2.86 (d, J = 4.4 Hz, 3H, NHCH3), 3.58-3.98 (m, 4H, tetrahydrofuranyl),
4.15 (m, 2H, H-5'), 4.50 (m, 1H, H-4'), 4.70 (m, 1H, NHCH), 4.85 (d, J = 12.5 Hz, 1H, H-
3'), 5.32 (s, 1H, OH), 5.46 (d, J = 6.2 Hz, 1H, OH), 6.0 (s, 1H, H-1'), 8.0 (d, J = 5.7 Hz, 
1H, NHCH), 8.25 (s, 2H, H-2, H-8), 9.25 (q, J = 4.4 Hz, 1H, NHCH3). MS: m/z 425.5 [M 
+ H]+. Anal. calcd. for  C17H24N6O5S: C, 48.10; H, 5.70; N, 19.80. Found: C, 48.17; H, 
5.60; N, 19.86.  
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-propylcarba-
moyl- -D-ribofuranosyl)adenine (81). Reaction of 67 with CDI for 6 h, follow
addition of propylamine and stirring for 1 h, gave 81 as a white foam (68% yield) afte
chromatography on a silica gel column (CHCl3-MeOH, 96:4). 
1H-NMR (DMSO-d6): δ 
0.82 (t, J = 7.3 Hz, 3H, CH2CH3), 1.18 (s, 3H, CH3), 1.38 (s and m, 5H, CH3, CH2CH3), 
1.56 (s, 3H, CH3), 2.05, 2.20 (2m, 2H, tetrahydrofuranyl), 2.95 (q, J = 6.6 Hz, 2H, 
CH2CH2CH3), 3.58-3.96 (m, 4H, tetrahydrofuranyl), 4.30 (m, 3H, H-4', H-5'), 4.56 (d, J = 
2.2 Hz, 1H, H-3'), 4.70 (m, 1H, NHCH), 6.24 (s, 1H, H-1'), 7.38 (t, J = 5.5 Hz, 1H, 
NHCH2), 8.05 (d, J = 5.9 Hz, 1H, NHCH), 8.22 (s, 1H, H-2), 8.26 (s, 1H, H-8). MS: m/z 
477.5 [M + H]+. Anal. calcd. for C22H32N6O6: C, 55.45; H, 6.77; N, 17.64. Found: C, 
55.55; H, 6.70; N, 17.54.  
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-5-N-propylcarbamoyl-β-D-ribofurano-
syl)adenine (47). Reaction of 81 with HCOOH at 55 °C for 7 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 95:5) gave 47 as a white solid 
(70% yield). 1H-NMR (DMSO-d6): δ 0.8 (s and t, 6H, CH3, CH2CH3), 1.38 (m, 2H, 
CH2CH3), 1.98, 2.20 (2m, 2H, tetrahydrofuranyl), 2.90 (q, J = 6.6 Hz, 2H, NHCH2), 3.58-
3.96 (m, 4H, tetrahydrofuranyl), 4.0-4.20 (m, 3H, H-4', H-5'), 4.40 (d, J = 11.7 Hz, H-3'), 
4.70 (m, 1H, NHCH), 5.30 (s, 1H, OH), 5.42 (d, J = 6.2 Hz, 1H, OH), 5.95 (s, 1H, H-1'), 
7.28 (t, J = 4.7 Hz, 1H, NHCH2), 8.0 (d, J = 6.2 Hz, 1H, NH H)  8.22 (s, 2H, H-2, H-8). 
MS: m/z 437.5 [M + H]+. Anal. calcd. for C19H2
Found: C, 52.26; H, 6.51; N, 19.35. 
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 N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-propylthio-
carbamoyl-β-D-ribofuranosyl)adenine (82). Reaction of 68 with thio CDI for 8 h, 
followed by addition of propylamine and stirring overnight, gave 82 as a white foam (64% 
yield) after chromatography on a silica gel column (CHCl3-MeOH, 99:1). 
1H-NMR 
(DMSO-d6): δ 0.85 (t, J = 7.3 Hz, 3H, CH2CH3), 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, 
CH3), 1.50 (m, 2H, CH2CH3), 2.05, 2.20 (2m, 2H, tetrahydrofuranyl), 3.35 (q, J = 6.6 Hz, 
2H, NHCH2), 3.58-3.96 (m, 4H, tetrahydrofuranyl), 4.45 (m, 2H, H-5'), 4.62 (d, J = 3.0 Hz, 
1H, H-3'), 4.72 (m, 2H, H-4', NHCH), 6.26 (s, 1H, H-1'), 8.05 (d, J = 5.9 Hz, 1H, NHCH), 
 
 4.84 (d, J = 10.6 Hz, 1H, H-3'), 5.40 (br s, 2H, OH), 
), 
H), 6.25 (s, 1H, H-1'), 7.28 (m, 5H, 
16.02. Found: C, 59.46; H, 6.19; N, 16.12.  
8.26 (s, 1H, H-2), 8.28 (s, 1H, H-8), 9.40 (t, J = 5.9 Hz, 1H, NHCH2). MS: m/z 492.6 [M +
H]+. Anal. calcd. for  C22H32N6O5S: C,53.64; H, 6.55; N, 17.06. Found: C, 53.54; H, 6.61; 
N, 17.13.  
 N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-5-N-propylthiocarbamoyl-β-D-ribo-
furanosyl)adenine (48). Reaction of 82 with HCOOH at 55 °C for 4 h, gave 48 which was 
purified by chromatography on a silica gel column (CHCl3-MeOH, 96:4) as a white foam 
(62% yield). 1H-NMR (DMSO-d6): δ 0.8 (s, 3H, CH3), 0.84 (t, J = 7.3 Hz, CH2CH3), 1.50 
(m, 2H, CH2CH3), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.30 (t after exchange with D2O, 
J = 6.9 Hz, 2H, NHCH2), 3.58-3.95 (m, 4H, tetrahydrofuranyl), 4.15 (m, 2H, H-5'), 4.50 
(m, 1H, H-4'), 4.70 (m, 1H, NHCH),
6.0 (s, 1H, H-1'), 8.03 (d, J = 5.5 Hz, 1H, NHCH), 8.25 (s, 1H, H-2), 8.27 (s, 1H, H-8
9.30 (t, J =  5.9 Hz, 1H, NHCH2). MS: m/z 453.6 [M + H]+. Anal. calcd. for C19H28N6O5S: 
C, 50.43; H, 6.23; N, 18.57. Found: C, 50.40; H, 6.31; N, 18.64.  
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-benzylcarba-
moyl-β-D-ribofuranosyl)adenine (83). Reaction of 67 with CDI for 9 h, followed by 
addition of benzylamine and stirring overnight, gave 83 as a white foam (92% yield) after 
chromatography on a silica gel column (CHCl3-MeOH, 98:2). 
1H-NMR (DMSO-d6): δ 
1.16 (s, 1H, CH3), 1.35, 1.56 (s, 6H, CH3), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.60-3.90 
(m, 4H, tetrahydrofuranyl), 4.20 (d, J = 6.2 Hz, 2H, CH2C6H5), 4.35 (m, 3H, H-4', H-5'), 
4.58 (d, J = 2.1 Hz, 1H, H-3'), 4.72 (m, 1H, NHC
arom.), 7.94 (t, J = 6.0 Hz, 1H, NHCH2), 8.04 (d, J = 4.4 Hz, 1H, NHCH). 8.24 (s, 2H, H-
2, H-8). MS: m/z 525.5 [M + H]+. Anal. calcd. for C26H32N6O6: C, 59.53; H, 6.15; N, 
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 N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-5-N-benzylcarbamoyl-β-D-ribofurano-
syl)adenine (49). Reaction of 83 with HCOOH at 55 °C for 2 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 96:4) gave 15 as a white solid 
(60% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 2.0, 2.18 (2m, 2H, 
tetrahydrofuranyl), 3.60-3.95 (m, 4H, tetrahydrofuranyl), 4.18 (m, 5H, CH2C6H5, H-4', H-
5'), 4.45 (d, J = 10.6 Hz, 1H, H-3'), 4.70 (m, 1H, NHCH), 5.30 (s, 1H, OH), 5.42 (d, J = 5.9 
Hz, 1H, OH), 5.97 (s, 1H, H-1'), 7.25 (m, 5H, arom.), 7.85 (t, J = 6.2 Hz, 1H, NHCH2), 8.0 
(d, J = 6.6 Hz, 1H, NHCH), 8.22 (s, 2H, H-2, H-8). MS: m/z 485.4 [M + H]+. Anal. calcd. 
nyl-9H-(2-C-methyl-5-N-benzylthiocarbamoyl-β-D-ribofura-
y 
yl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
methylcarbamoyl-β-D-ribofuranosyl)adenine (85). Reaction of 68 with CDI for 6 h, 
for C23H28N6O6: C, 57.02; H, 5.82; N, 17.35. Found: C, 57.08; H, 5.84; N, 17.30. 
N6-(R)-3-Tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-benzylthio-
carbamoyl-β-D-ribofuranosyl)adenine (84). Reaction of 67 with thio CDI for 9 h, 
followed by addition of benzylamine and stirring overnight, gave 84 as a white foam (92% 
yield) after chromatography on a silica gel column (CHCl3). 
1H-NMR (DMSO-d6): δ 1.18 
(s, 1H, CH3), 1.38, 1.58 (s, 6H, CH3), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.60-3.95 (m, 
4H, tetrahydrofuranyl), 4.44 (m, 2H, H-5'), 4.60-4.80 (2m, 5H, H-3', H-4', CH2C6H5, 
NHCH), 6.25 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 8.0 (d, J = 5.9 Hz, 1H, NHCH), 8.22 (s, 
2H, H-2, H-8), 9.82 (t, J = 5.7 Hz, 1H, NHCH2). MS: m/z 541.5 [M + H]+. Anal. calcd. for 
C26H32N6O5S: C, 57.76; H, 5.96; N, 15.54. Found: C, 57.61; H, 6.04; N, 15.43.  
N6-(R)-3-Tetrahydrofura
nosyl)adenine (50). Reaction of 84 with HCOOH at 55 °C for 4.5 h, followed b
chromatography on a silica gel column (CHCl3-MeOH, 97:3) gave 50 as a white solid 
(60% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 2.0, 2.20 (2m, 2H, 
tetrahydrofuranyl), 3.60-3.95 (m, 4H, tetrahydrofuranyl), 4.20 (m, 2H, H-5'), 4.50 (m, 1H, 
H-4'), 4.60 (br s, 2H, CH2C6H5), 4.70 (m, 1H, NHCH), 4.88 (d, J = 11.7 Hz, 1H, H-3'), 
5.32 (s, 1H, OH), 5.50 (d, J = 6.0 Hz, 1H, OH), 5.98 (s, 1H, H-1'), 7.28 (m, 5H, arom.), 8.0 
(d, J = 5.7 Hz, 1H, NHCH), 8.22 (s, 1H, H-2), 8.26 (s, 1H, H-8), 9.82 (t, J = 5.7 Hz, 1H, 
NHCH2). MS: m/z 501.5 [M + H]
+. Anal. calcd. for C23H28N6O5S: C, 55.19 ; H, 5.64, N, 
16.79. Found: C, 55.24; H, 5.57; N, 16.62.  
2-Chloro-N6-(R)-3-tetrahydrofuran
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followed by addition of methylamine and stirring for 2 h, gave 85 as a white foam (93
yield) after chromatography on a silica gel column (CHCl
% 
d by chromatography on a silica gel column (CHCl3-MeOH, 96:4) as a white 
2H, 
-MeOH, 99:1). 1H-NMR 
3
3-MeOH, 98:2). 
1H-NMR 
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 2.0, 2.20 (m, 2H, 
tetrahydrofuranyl), 2.58 (d, J = 4.4 Hz, 3H, NHCH3), 3.58-3.94 (m, 4H, tetrahydrofuranyl), 
4.30 (m, 3H, H-4', H-5'), 4.55 (d, J = 2.2 Hz, 1H, H-3'), 4.62 (m, 1H, NHCH), 6.15 (s, 1H, 
H-1'), 7.20 (q,  J = 4.8 Hz, 1H, NHCH3), 8.24 (s, 1H, H-8), 8.60 (d, J = 5.7 Hz, 1H, 
NHCH). MS: m/z 483.9 [M + H]+. Anal. calcd. for C20H27ClN6O6: C, 49.74, H, 5.63; N, 
17.40. Found: C, 49.80; H, 5.58; N, 17.46.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-methylcarbamoyl-β-D-
ribofuranosyl)adenine (51). Reaction of 85 with HCOOH at 55 °C for 6 h, gave 51 which 
was purifie
solid (69% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 2.0, 2.20 (m, 
tetrahydrofuranyl), 2.58 (d, J = 4.0 Hz, 3H, NHCH3), 3.60-3.96 (m, 4H, tetrahydrofuranyl), 
4.05 (m, 2H, H-5'), 4.20 (m, 1H, H-4'), 4.40 (d,  J = 11.2 Hz, 1H, H-3'), 4.62 (m, 1H, 
NHCH), 5.38 (s, 1H, OH), 5.45 (br s, 1H, OH), 5.9 (s, 1H, H-1'), 7.18 (m, 1H, NHCH3), 
8.24 (s, 1H, H-8), 8.60 (d, J = 5.7 Hz, 1H, NHCH). MS: m/z 443.9 [M + H]+. Anal. calcd. 
for C17H23ClN6O6: C, 46.11; H, 5.23; N, 18.97. Found: C, 46.18 ; H, 5.19 H; N, 18.86.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
methylthiocarbamoyl-β-D-ribofuranosyl)adenine (86). Reaction of 68 with thio CDI for 
6.5 h, followed by addition of methylamine and stirring for 2 h, gave 86 as a white foam 
(69% yield) after chromatography on a silica gel column (CHCl3
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 2.0, 2.20 (m, 2H, 
tetrahydrofuranyl), 2.86 (d, J = 4.0 Hz, 3H, NHCH3), 3.58-3.96 (m, 4H, tetrahydrofuranyl), 
4.45 (m, 1H, H-4'), 4.62 (d, J = 2.9 Hz, 1H, H-3'), 4.70 (m, 3H, H-5', NHCH), 6.15 (s, 1H, 
H-1'), 8.24 (s, 1H, H-8), 8.60 (d, J = 6.2 Hz, 1H, NHCH), 9.28 (q, J = 4.4 Hz, 1H, 
NHCH3). MS: m/z 499 [M + H]
+. Anal. calcd. for C20H27ClN6O5S: C, 48.14; H, 5.45; N, 
16.84. Found: C, 48.10; H, 5.52; N, 16.79.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-methylthiocarbamoyl-β-D-
ribofuranosyl)adenine (52). Reaction of 86 with HCOOH at 55 °C for 3 h, followed by 
chromatography on a silica gel column (CHCl -MeOH, 94:6) gave 52 as a white solid 
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(88% yield). 1H-NMR (DMSO-d6): δ 0.8 (s, 3H, CH3), 2.0, 2.20 (m, 2H
tetrahydrofuranyl), 2.86 (d, J = 4.0 Hz, 3H, NHCH
, 
m (77% 
R 
llowed by 
 
,
denine (88). Reaction of 68 with thio CDI for 
foam 
3), 3.58-3.96 (m, 4H, tetrahydrofuranyl), 
4.12 (m, 2H, H-5'), 4.60 (m, 2H, H-4', NHCH), 4.85 (m, 1H, H-3'), 5.40 (s, 1H, OH), 5.50 
(pseudo t, 1H, OH), 5.90 (s, 1H, H-1'), 8.30 (s, 1H, H-8), 8.62 (d, J = 5.7 Hz, 1H, NHCH), 
9.25 (q, J = 4.4 Hz, 1H, NHCH3). MS: m/z 459.9 [M + H]+. Anal. calcd. for 
C17H23ClN6O5S: C, 44.49; H, 5.05; N, 18.31. Found: C, 44.51; H, 5.00; N, 18.23. 
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
propylcarbamoyl-β-D-ribofuranosyl)adenine (87). Reaction of 68 with CDI for 7 h, 
followed by addition of propylamine and stirring for 1 h, gave 87 as a white foa
yield) after chromatography on a silica gel column (CHCl3-MeOH, 98:2). 
1H-NM
(DMSO-d6): δ 0.82 (t, J = 7.3 Hz, 3H, CH2CH3), 1.18 (s, 3H, CH3), 1.40 (s and q, 5H, 
CH3, CH2CH3), 1.56 (s, 3H, CH3), 2.0, 2.20 (m, 2H, tetrahydrofuranyl), 2.95 (q, J = 6.6 
Hz, 2H, NHCH2), 3.58-3.96 (m, 4H, tetrahydrofuranyl), 4.30 (m, 3H, H-4', H-5'), 4.56 (br 
s, 1H, H-3'), 4.62 (m, 1H, NHCH), 6.16 (s, 1H, H-1'), 7.36 (t, J = 5.9 Hz, 1H, NHCH2), 
8.24 (s, 1H, H-8), 8.60 (d, J = 6.2 Hz, 1H, NHCH). MS: m/z 511.9 [M + H]+. Anal. calcd. 
for C22H31ClN6O6: C, 51.71; H, 6.11; N, 16.45. Found: C, 51.68; H, 6.17; 16.40 N.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-propylcarbamoyl-β-D-
ribofuranosyl)adenine (53). Reaction of 87 with HCOOH at 55 °C for 3 h, fo
chromatography on a silica gel column (CHCl3-MeOH, 96:4) gave 53 as a white solid
(75% yield). 1H-NMR (DMSO-d6): δ 0.80 (s and t, 6H, CH3, CH2CH3), 1.40 (m, 2H, 
CH2CH3), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 2.92 (q, J = 6.6 Hz, 2H, NHCH2), 3.58-
3.94 (m, 4H, tetrahydrofuranyl), 4.0 (m  2H, H-5'), 4.20 (m, 1H, H-4'), 4.40 (d, J = 11.0 
Hz, H-3'), 4.60 (m, 1H, NHCH), 5.38 (s, 1H, OH), 5.45 (pseudo t, 1H, OH), 5.90 (s, 1H, 
H-1'), 7.30 (t, J =  5.9 Hz, 1H, NHCH2), 8.25 (s, 1H, H-8), 8.60 (d, J = 5.7 Hz, 1H, 
NHCH). MS: m/z 471.9 [M + H]+. Anal. calcd. for C19H27ClN6O6: C, 48.46; H, 5.78; N, 
17.85. Found: C, 48.38; H, 5.84; N, 17.80. 
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
propylthiocarbamoyl-β-D-ribofuranosyl)a
6 h, followed by addition of propylamine and stirring overnight, gave 88 as a white 
(75% yield) after chromatography on a silica gel column (CHCl3-MeOH, 98:2). 
1H-NMR 
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(DMSO-d6): δ 0.82 (t, J = 7.3 Hz, 3H, CH2CH3), 1.18, 1.38 (s, 6H, CH3), 1.54, (s and q, 
3H, CH3, CH2CH3), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.30 (t after exchange with D2O, 
J = 6.9 Hz, 2H, NHCH2), 3.58-3.94 (m, 4H, tetrahydrofuranyl), 4.44 (m, 2H, H-5'), 4.60 (d, 
J = 3.0 Hz, 1H, H-3'), 4.70 (m, 2H, H-4', NHCH), 6.16 (s, 1H, H-1'), 8.26 (s, 1H, H-8), 
8.58 (d, J = 5.9 Hz, 1H, NHCH), 9.35 (t, J = 5.5 Hz, 1H, NHCH2). MS: m/z 528.1 [M + 
H]+. Anal. calcd. for C22H31ClN6O5S: C, 50.14; H, 5.93 15.94 N. Found: C, 50.02; H, 
5.99; N, 15.97.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-propylthiocarbamoyl-β-D-
ich 
 15.09.  
ribofuranosyl)adenine (54). Reaction of 88 with HCOOH at 55 °C for 3 h, gave 54 wh
was purified by chromatography on a silica gel column (CHCl3-MeOH, 98:2) as a white 
solid (59% yield). 1H-NMR (DMSO-d6): δ 0.80 (s and t, 6H, CH3, CH2CH3), 1.50 (m, 2H, 
CH2CH3), 1.95, 2.20 (2m, 2H, tetrahydrofuranyl), 3.30 (t after exchange with D2O, J = 6.9 
Hz, 2H, NHCH2), 3.58-3.94 (m, 4H, tetrahydrofuranyl), 4.12 (m, 2H, H-5'), 4.48 (m, 1H, 
H-4'), 4.62 (m, 1H, NHCH), 4.84 (d, J = 12.2 Hz, 1H, H-3'), 5.36 (s, 1H, OH), 5.48 
(pseudo t, 1H, OH), 5.88 (s, 1H, H-1'), 8.25 (s, 1H, H-8), 8.58 (d, J = 5.7 Hz, 1H, NHCH), 
9.30 (t, J =  5.5 Hz, 1H, NHCH2). MS: m/z 487.9 [M + H]+. Anal. calcd. for  
C19H27ClN6O5S: C, 46.86; H, 5.59; N, 17.26. Found: C, 46.73; H, 5.65; N,   17.29.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
benzylcarbamoyl-β-D-ribofuranosyl)adenine (89). Reaction of 68 with CDI for 5 h, 
followed by addition of benzylamine and stirring for 1.5 h, gave 89 as a white foam (55% 
yield) after chromatography on a silica gel column (CHCl3-MeOH, 97:3). 
1H-NMR 
(DMSO-d6): δ 1.15 (s, 1H, CH3), 1.35, 1.54 (2s, 6H, CH3), 1.95, 2.20 (2m, 2H, 
tetrahydrofuranyl), 3.58-3.92 (m, 4H, tetrahydrofuranyl), 4.20 (m, 3H, H-4', H-5'), 4.32 (m, 
2H, CH2C6H5), 4.55 (d, J = 2.1 Hz, 1H, H-3'), 4.60 (m, 1H, NHCH), 6.16 (s, 1H, H-1'), 
7.25 (m, 5H, arom.), 7.90 (t, J = 5.7 Hz, 1H, NHCH2), 8.25 (s, 1H, H-8), 8.58 (d, J = 5.9 
Hz, 1H, NHCH). MS: m/z 560.1 [M + H]+. Anal. calcd. for C26H31ClN6O6: C, 55.86; H, 
5.59; N, 15.03. Found: C, 55.72; H, 5.67; N,
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-benzylcarbamoyl-β-D-
ribofuranosyl)adenine (55). Reaction of 89 with HCOOH at 55 °C for 8 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 95:5) gave 55 as a white solid 
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(58% yield). 1H-NMR (DMSO-d6):  0.80 (s, 3H, CHδ
, 53.17; 
1
5.55; N, 14.73.  
β
chromatography on a silica gel column (CHCl -MeOH, 98:2) gave 56 as a white solid 
δ
5.08; N, 15.71. Found: C, 51.50; H, 5.17; N, 
3), 2.0, 2.20 (2m, 2H, 
tetrahydrofuranyl), 3.58-3.95 (m, 4H, tetrahydrofuranyl), 4.08 (m, 2H, H-5'), 4.20 (m, 2H, 
CH2C6H5), 4.28 (m, 1H, H-4'), 4.45 (d, J = 10.6 Hz, 1H, H-3'), 4.62 (m, 1H, NHCH), 5.38 
(s, 1H, OH), 5.48 (pseudo t, 1H, OH), 5.90 (s, 1H, H-1'), 7.30 (m, 5H, arom.), 7.88 (t, J = 
5.6 Hz, 1H, NHCH2), 8.28 (s, 1H, H-8), 8.58 (d, J = 5.7 Hz, 1H, NHCH). MS: m/z 519.9 
[M + H]+. Anal. calcd. for C23H27ClN6O6: C, 53.23; H, 5.24; N, 16.19. Found: C
H, 5.35; N, 16.15.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
benzylthiocarbamoyl-β-D-ribofuranosyl)adenine (90). Reaction of 68 with thio CDI for 
6 h, followed by addition of benzylamine and stirring for 1.5 h, gave 90 as a white foam 
(53% yield) after chromatography on a silica gel column (CHCl3-MeOH, 97:3). H-NMR 
(DMSO-d6): δ 1.20 (s, 1H, CH3), 1.38, 1.56 (2s, 6H, CH3), 2.0, 2.20 (2m, 2H, 
tetrahydrofuranyl), 3.58-3.95 (m, 4H, tetrahydrofuranyl), 4.46 (m, 1H, H-4'), 4.55-4.80 (m, 
5H, H-3', H-5', CH2C6H5, NHCH), 6.18 (s, 1H, H-1'), 7.26 (m, 5H, arom.), 8.30 (s, 1H, H-
8), 8.62 (d, J = 5.9 Hz, 1H, NHCH), 9.88 (t, J = 5.7 Hz, 1H, NHCH2), MS: m/z 576.1 [M + 
H]+. Anal. calcd. for C26H31ClN6O5S: C, 54.30; H, 5.43; N, 14.61. Found: C,  54.21; H, 
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-benzylthiocarbamoyl- -D-
ribofuranosyl)adenine (56). Reaction of 90 with HCOOH at 55 °C for 2 h, followed by 
3
(60% yield). 1H-NMR (DMSO-d6):  0.80 (s, 3H, CH3), 2.0, 2.20 (2m, 2H, 
tetrahydrofuranyl), 3.58-3.95 (m, 4H, tetrahydrofuranyl), 4.08 (m, 2H, H-5'), 4.30 (m, 1H, 
H-4'), 4.60 (m, 3H, NHCH, CH2C6H5), 4.85 (d, J = 11.7 Hz, 1H, H-3'), 5.38 (s, 1H, OH), 
5.50 (m, 1H, OH), 5.90 (s, 1H, H-1'), 7.30 (m, 5H, arom.), 8.28 (s, 1H, H-8), 8.60 (d, J = 
5.7 Hz, 1H, NHCH), 9.85 (t, J = 5.7 Hz, 1H, NHCH2). MS: m/z 536.1 [M + H] . Anal. 
calcd. for C
+
23H27ClN6O5S: C, 51.63; H, 
15.79.  
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N-
cyclopentylcarbamoyl-β-D-ribofuranosyl)adenine (91). Reaction of 68 with CDI for 7 h, 
followed by addition of cyclopentylamine and stirring overnight, gave 91 as a white foam 
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(97% yield) after chromatography on a silica gel column (CHCl3-MeOH, 98:2). 
1H-NMR 
(DMSO-d6): δ 1.15 (s, 3H, CH3), 1.38, 1.56 (2s, 6H, CH3), 1.42-1.60 (m, 6H, cyclopentyl), 
1.76 (m, 2H, cyclopentyl), 1.95, 2.20 (2m, 2H, tetrahydrofuranyl), 3.58-3.92 (m, 5H, 
NHCH, tetrahydrofuranyl), 4.20-4.35 (2m, 3H, H-4', H-5'), 4.55 (d, J = 2.7 Hz, 1H, H-3'), 
4.62 (m, 1H, NHCH), 6.15 (s, 1H, H-1'), 7.32 (d, J = 7.0 Hz, 1H, NHCH), 8.22 (s, 1H, H-
8), 8.58 (d, J = 6.3 Hz, 1H, NHCH). MS: m/z 538.0 [M + H]+. Anal. calcd. for 
C24H33ClN6O6: C, 53.68; H, 6.19; N, 15.65. Found: C, 53.79; H, 6.10 ; N, 15.72. 
-
I for 
thyl-5-N-cyclopentylthiocarbamoyl- 
or 3 
 2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-5-N-cyclopentylcarbamoyl-β-
D-ribofuranosyl)adenine (57). Reaction of 91 with HCOOH at 55 °C for 5 h, followed by 
chromatography on a silica gel column (CHCl3-MeOH, 98:2) gave 57 as a white solid 
(54% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.30-1.80 (3m, 8H, cyclopentyl), 
2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.58-3.95 (m, 5H, NHCH, tetrahydrofuranyl), 4.05 
(m, 2H, H-5'), 4.20 (m, 1H, H-4'), 4.40 (br d, 1H, H-3'), 4.60 (m, 1H, NHCH), 5.32 (s, 1H, 
OH), 5.42 (pseudo t, 1H, OH), 5.88 (s, 1H, H-1'), 7.26 (d, J = 7.7 Hz, 1H, NHCH), 8.25 (s, 
1H, H-8), 8.58 (d, J = 6.2 Hz, 1H, NHCH). MS: m/z 486.0 [M + H]+. Anal. calcd. for 
C21H29ClN6O6: C, 50.76; H, 5.88; N, 16.91. Found: C,   50.61; H, 5.97; N, 16.96. 
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-N
cyclopentylthiocarbamoyl-β-D-ribofuranosyl)adenine (92). Reaction of 68 with CD
12 h, followed by addition of cyclopentylamine and stirring overnight, gave 92 as a white 
foam (79% yield) after chromatography on a silica gel column (CHCl3). 
1H-NMR (DMSO-
d6): δ 1.20 (s, 3H, CH3), 1.38, 1.58 (2s, 6H, CH3), 1.42-1.70 (m, 9H, cyclopentyl), 1.90 (m, 
2H, cyclopentyl), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.58-3.92 (m, 4H, 
tetrahydrofuranyl), 4.30 (m, 1H, NHCH), 4.45 (m, 1H, H-4'), 4.60-4.80 (m, 4H, H-3', H-5', 
NHCH), 6.18 (s, 1H, H-1'), 8.30 (s, 1H, H-8), 8.60 (d, J = 6.9 Hz, 1H, NHCH), 9.40 (d, J = 
7.0 Hz, 1H, NHCH). MS: m/z 554 [M + H]+. Anal. calcd. for  C24H33ClN6O5S: C, 52.12; 
H, 6.01; N, 15.19. Found: C, 52.18; H, 5.96; N, 15.31. 
2-Chloro-N6-(R)-3-tetrahydrofuranyl-9H-(2-C-me
β-D-ribofuranosyl)adenine (58). Reaction of 90 (1.0 mmol) with HCOOH at 55 °C f
h, followed by chromatography on a silica gel column (CHCl3-MeOH, 99:1) gave 58 as a 
white solid (55% yield). 1H-NMR (DMSO-d6): δ 0.82 (s, 3H, CH3), 1.40-1.70 (m, 6H, 
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cyclopentyl), 1.90 (m, 2H, cyclopentyl), 2.0, 2.20 (2m, 2H, tetrahydrofuranyl), 3.58-3.95 
(m, 4H, tetrahydrofuranyl), 3.88 (m, 2H, tetrahydrofuranyl), 4.12 (m, 2H, H-5'), 4.30 (m, 
1H, NHCH), 4.45 (m, 1H, H-4'), 4.62 (m, 1H, NHCH), 4.85 (br d, J = 11.4 Hz, 1H, H-3'), 
5.45 (br s, 2H, OH), 5.88 (s, 1H, H-1'), 8.28 (s, 1H, H-8), 8.60 (d, J = 7.0 Hz, 1H, NHCH),  
9.30 (d, J = 7.7 Hz, 1H, NHCH). MS: m/z 513 [M + H]+. Anal. calcd. for C21H29ClN6O5S: 
C, 49.17; H, 5.69 H, 16.38  N. Found: C,   49.12 C, 5.77 H,  16.49 N.  
General procedure for the synthesis of compounds 93 and 94.  
(1.0 
i
ynthesized from 101. Chromatography on a silica gel column (CHCl3-
), 4.45-4.55 (m
N -(±)-endo-Norbornyl-9H-(5-chloro-5-deoxy-β-D-ribofuranosyl)adenine (94). The 
94 1 d  δ 1.33 
Commercially available N6-cyclopentyladenosine (CPA, 101) or compound 102 
mmol) in dry acetonitrile (10 mL) under nitrogen atmosphere, was stirred while cooling to 
-5 °C. SOCl2 (3.0 mmol) was added dropwise followed by dry pyridine (2.0 mmol). After 
30 min., the mixture was stirred at room temperature. The procedure was repeated after 6 h 
and the m xture was stirred at room temperature overnight. Water was added (5 mL), the 
solution was neutralized with NH4OH (30%) and extracted with CH2Cl2 (3 x 10 mL). The  
organic layer was dried (Na2SO4), and the solvent was evaporated to dryness. The residue 
was purified by chromatography on silica gel column as reported below. 
N6-Cyclopentyl-9H-(5-chloro-5-deoxy-β-D-ribofuranosyl)adenine (93). The title 
compound was s
MeOH, 95:5) gave 93 as a white solid (64% yield). 1H-NMR (DMSO-d6): δ 1.50-1.60 (m, 
4H, cyclopentyl), 1.64-1.74 (m, 2H, cyclopentyl), 1.88-1.98 (m, 2H, cyclopentyl), 3.82 
(dd, J = 6.4, 11.5 Hz, 1H, H-5'), 3.92 (dd, J = 5.1, 11.5 Hz, 1H, H-5'), 4.07 (q, J = 5.8 Hz, 
1H, H-4'), 4.20 (q,  J = 5.1 Hz, 1H, H-3' , 1H, NHCH), 4.75 (q, J = 5.6 Hz, 
1H, H-2'), 5.45 (d, J = 5.6 Hz, 1H, OH), 5.58 (d, J = 6.4 Hz, 1H, OH), 5.93 (d, J = 5.6 Hz, 
1H, H-1'), 7.75 (d, J = 7.3 Hz, 1H, NH), 8.20 (br s, 1H, H-2), 8.32 (s, 1H, H-8). MS: m/z 
354.9 [M + H]+. Anal. calcd. for  C15H20ClN5O3: C, 50.92; H, 5.70; N, 19.79. Found: C, 
50.85; H, 5.74; N, 17.78.  
6
title compound was synthesized from 102. Chromatography on a silica gel column 
(CHCl3-MeOH, 99:1) gave as a white solid (58% yield). H-NMR (DMSO- 6):
(m, 3H, norbornyl), 1.45 (m, 3H, norbornyl), 1.52 (m, 1H, norbornyl), 1.93 ( m, 1H, 
norbornyl), 2.14 (br s, 1H, norbornyl), 2.55 (br s, 1H, norbornyl), 3.85 (m, 1H, H-5'), 4.01 
(m, 1H, H-5'), 4.16 (m, 1H, H-4'), 4.23 (m, 1H, H-3'), 4.38 (m, 1H, NHCH), 4.72 (q, J = 
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5.4 Hz, 1H, H-2'), 5.42 (d, J = 5.5 Hz, 1H, OH), 5.61 (d, J = 5.3 Hz, 1H, OH), 5.91 (d, J = 
6.1 Hz, 1H, H-1'), 7.81 (d, J = 7.1 Hz, 1H, NH), 8.21 (br s, 1H, H-2), 8.38 (s, 1H, H-8). 
MS: m/z 380.9 [M + H]+. Anal. calcd. for  C17H22ClN5O3: C, 53.75; H, 5.84; N, 18.44. 
Found: C, 53.85; H, 5.81; N, 18.51.  
General procedure for N6-amination (compounds 105 and 110, 111). To a stirred 
solution of 2,6-dichloro-9H-(2,3,5-O-acetyl-β-D-ribofuranosyl)purine (103),200 6-chloro-
9H-(2-C-methyl-2,3,5-O-benzoyl-β-D-ribofuranosyl)purine127 or 59 or 2,6-dichloro-9H-
e 
compound was obtained from 103 (reaction time 3 h). Chromatography on a silica gel 
colum  (CHCl -MeOH, 96:4) gave as a white solid (90% yield). H-NMR (DMSO-
% yield). 1H-NMR (DMSO-
d
(2-C-methyl-2,3,5-O-benzoyl-β-D-ribofuranosyl)purine9 (60) (1.0 mmol) in absolut
ethanol (20 mL) cyclopentylamine or (±)-endo-norborn-2-ylamine hydrochloride (2.0 
mmol) (anhydrous triethylamine only in the case of compound 105 (5.8 mmol)) were 
added. The reaction mixture was refluxed for the time reported below and concentrated in 
vacuo. The residue was dissolved in methanol saturated with ammonia (25 mL) and stirred 
at room temperature overnight. Evaporation of the solvent to dryness gave a residue which 
was purified by column chromatography. 
2-Chloro-N6-(±)-endo-norbornyl-9H-(β-D-ribofuranosyl)adenine (105). The title 
n 105 13
d6): δ 1.25 (m, 3H, norbornyl), 1.40 (m, 3H, norbornyl), 1.50-1.65 (2m, 1H, norbornyl), 
1.90 (m, 1H, norbornyl), 2.16 (br s, 1H, norbornyl), 2.52 (br s, 1H, norbornyl), 3.52 (m, 
1H, H-5'), 3.64 (m, 1H, H-5'), 3.92 (m, 1H, H-4'), 4.10 (q, J = 4.9 Hz, 1H, H-3'), 4.24 (m, 
1H, NHCH), 4.50 (q, J = 5.6 Hz, 1H, H-2'), 5.05 (t, J = 5.8 Hz, 1H, OH), 5.40 (d, J = 5.1 
Hz, 1H, OH), 5.45 (dd, J = 3.2, 6.2 Hz, 1H, OH), 5.80 (d, J = 6.0 Hz, 1H, H-1'), 8.40 (s and 
d, 2H, NH, H-8). MS: m/z 396.7 [M + H]+. Anal. calcd. for  C17H22ClN5O4: C, 51.58; H, 
5.60; N, 17.69. Found: C, 51.61; H, 5.54; N, 17.72.  
 N6-(±)-endo-Norbornyl-9H-(2-C-methyl-β-D-ribofuranosyl)adenine (110). The title 
compound was synthesized from 59 (reaction time 3.5 h). Chromatography on a silica gel 
column (CHCl -MeOH, 93:7) gave 110 as a white solid (903
6): δ 0.78 (2s, 3H, CH3), 1.28 (m, 3H, norbornyl), 1.44 (m, 3H, norbornyl), 1.60 (m, 1H, 
norbornyl), 1.90 (m, 1H, norbornyl), 2.16 (br s, 1H, norbornyl), 2.52 (s, 1H, norbornyl), 
3.63 (m, 1H, H-5'), 3.82 (m, 1H, H-5'),  3.88 (m, 1H, H-4'), 4.05 (m, 1H, H-3')  4.35 (m, 
1H, NHCH), 5.40 (m, 3H, OH), 5.95 (s, 1H, H-1'), 7.75 (t, J = 6.0 Hz, 1H, NH), 8.18 (s, 
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1H, H-2), 8.45 (s, 1H, H-8). MS: m/z 376.5 [M + H]+. Anal. calcd. for C18H25N5O4: C, 
57.59: H, 6.71; N, 18.65. Found: C, 57.63; H, 6.67; N,   18.59.  
2-Chloro-N6-(±)-endo-norbornyl-9H-(2-C-methyl-β-D-ribofuranosyl)adenine (111). 
The title compound was synthesized from 60 (reaction time 2 h) and purified by 
chromatography on a silica gel column (CHCl3-MeOH, 97:3) gave 111 as a white solid 
(97% yield). 1H-NMR (DMSO-d6): δ 0.80 (2s, 3H, CH3), 1.28 (m, 3H, norbornyl), 1.44 
, norbornyl), 2.16 (br s, 
52.75; H, 5.90; N, 17.09. Found: C, 52.84; H, 5.87; N, 17.12.  
ompounds 65-68, 
 
(m, 3H, norbornyl), 1.50-1.63 (2m, 1H, norbornyl), 1.90 (2m, 1H
1H, norbornyl), 2.52 (br s, 1H, norbornyl), 3.66 (m, 1H, H-5'), 3.80 (m, 1H, H-5'), 3.88 (m, 
1H, H-4'), 4.0 (dd, J = 7.3, 9.0 Hz, 1H, H-3'),  4.24 (m, 1H, NHCH), 5.16 (m, 1H, OH), 
5.22 (d, J = 6.4 Hz, 1H, OH), 5.32 (d, J = 3.4 Hz, 1H, OH), 5.82 (s, 1H, H-1'), 8.38 (m, 1H, 
NH), 8.50 (s, 1H, H-8). MS: m/z 410.7 [M + H]+. Anal. calcd. for  C18H24ClN5O4: C, 
General procedure for the synthesis of 2',3'-O-isopropylidene derivatives 106, 107 
112, and 113. Compounds  106, 107, 112, and 113 were synthesized starting from CCPA 
104, 105, 110, and 111, following the general procedure reported for  c
(see section 5.2). 
2-Chloro-N6-cyclopentyl-9H-(2,3-O-isopropylidene-β-D-ribofuranosyl)adenine (106).
The title compound was synthesized from 104 (reaction time 2 h). Chromatography on a 
silica gel column (CHCl3-MeOH, 99:1) gave 106 as a white solid (75% yield). 
1H-NMR 
(DMSO-d6): 1.30, 1.50 (2s, 6H, CH3), 1.55 (m, 4H, cyclopentyl), 1.68 (m, 2H, 
cyclopentyl), 1.92 (m, 2H, cyclopentyl), 3.52 (m, 2H, H-5'), 4.18 (m, 1H, H-4'), 4.40 (m, 
1H, NHCH), 4.92 (dd, J = 2.6, 6.0 Hz, 1H, H-3'), 5.08 (pseudo t, 1H, OH), 5.26 (dd, J  = 
3.0, 6.0 Hz, 1H, H-2'), 6.04 (d, J = 2.6 Hz, 1H, H-1'), 8.35 (s, d, 2H, H-8 and NH). MS: m/z 
410.8 [M + H]+. Anal. calcd. for  C18H24ClN5O4: C, 52.75; H, 5.90; N, 17.09  N. Found: C, 
52.69; H, 5.94; N, 17.12.  
2-Chloro-N6-(±)-endo-norbornyl-9H-(2,3-O-isopropylidene-β-D-ribofuranosyl)- 
adenine (107). The title compound was synthesized from 105 (reaction time 3 h). 
Chromatography on a silica gel column (CHCl3-MeOH, 98:2) gave 107 as a white solid 
(80% yield). 1H-NMR (DMSO-d6): δ 1.26 (m, 3H, norbornyl), 1.28, 1.50 (2s, 6H, CH3), 
1.40 (m, 3H, norbornyl), 1.60 (m, 1H, norbornyl), 1.90 (m, 1H, norbornyl), 2.16 (br s, 1H, 
norbornyl), 2.52 (s, 1H, norbornyl), 3.50 (m, 2H, H-5'), 4.20 (m, 1H, H-4'), 4.24 (br s,  1H, 
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NHCH), 4.90 (m, 1H, H-3'), 5.06 (pseudo t, 1H, OH), 5.25 (m, 1H, H-2'), 6.05 (d, J = 2.6 
Hz, 1H, H-1'), 8.32 (s, 1H, H-8), 8.38 (d, J = 6.4 Hz, 1H, NH), MS: m/z 436.9 [M + H]+. 
Anal. calcd. for C20H26ClN5O4: C, 55.11; H, 6.01; N, 16.07. Found: C,   55.13; H, 5.96; N, 
16.10.  
N6-(±)-endo-Norbornyl-9H-(2-C-methyl-2,3-O-isopropylidene-β-D-ribofuranosyl)- 
adenine (112). The title compound was synthesized from 110 (reaction time 7 h). 
Chromatography on a silica gel column (CHCl3-MeOH, 99.5:0.5) gave 112 as a white 
solid (50% yield). 1H-NMR (DMSO-d6): δ 1.10 (2s, 3H, CH3), 1.25 (m, 3H, norbornyl), 
1.35, 1.55 (2s, 6H, CH3), 1.45 (m, 3H, norbornyl),  1.60 (m, 1H, norbornyl), 1.90 (m, 1H, 
norbornyl), 2.18 (br s, 1H, norbornyl), 2.52 (br s, 1H, norbornyl), 3.70 (dq, J = 12.4 Hz, 
2H, H-5'), 4.22 (m, 1H, H-4'), 4.35 (br s, 1H, NHCH), 4.58 (d, J = 2.1 Hz, 1H, H-3'), 5.40 
(br s, 1H, OH), 6.22 (s, 1H, H-1'), 7.80 (d, J =  6.5 Hz, 1H, NH), 8.20 (s, 1H, H-2), 8.32 (s, 
1H, H-8). MS: m/z 416.5 [M + H]+. Anal. calcd. for C21H29N5O4: C, 60.71; H, 7.03; N, 
16.85. Found: C, 60.75; H, 7.03; N, 16.80. 
2-Chloro-N6-(±)-endo-norbornyl-9H-(2-C-methyl-2,3-O-isopropylidene-β-D-ribofura-
nosyl)adenine (113). The title compound was synthesized from 111 (reaction time 3 h) 
and purified by chromatography on a silica gel column (CHCl -MeOH, 99.5:0.5) gave 113
as a white solid (95% yield). 
3  
6 3
1H, OH), 6.12 (s, 1H, H-1'), 8.36 (s, 1H, H-8), 8.42 (d, J = 6.8 Hz, 1H, NH). MS: m/z 
450.9 [M + H] . Anal. calcd. for C H ClN O : C, 56.06; H, 6.27; N, 15.56. Found: C, 
General procedure for the synthesis of compounds 108, 109, 114, and 117. Compounds 
atmosphere, were stirred cooling to -5 °C. SOCl2 (3.0 mmol) was added dropwise followed 
1H-NMR (DMSO-d ): δ 1.12 (2s, 3H, CH ), 1.28 (m, 3H, 
norbornyl), 1.35, 1.55 (2s, 6H, CH3), 1.44 (m, 3H, norbornyl), 1.60 (m, 1H, norbornyl), 
1.90 (m, 1H, norbornyl), 2.16 (br s, 1H, norbornyl), 2.52 (br s, 1H, norbornyl), 3.70 (m, 
2H, H-5'), 4.25 (m, 2H, NHCH, H-4'), 4.57 (d, J = 2.1 Hz, 1H, H-3'), 5.25 (t, J = 5.6 Hz, 
+
21 28 5 4
56.09; H, 6.31; N, 15.59. 
65, 66,191 106, 107, 112, and 113,191 (1.0 mmol) in dry acetonitrile (10 mL) under nitrogen 
by dry pyridine (2.0 mmol). After 30 minutes, the reaction mixture was stirred at room 
temperature. The procedure was repeated after 6 h and the mixture was stirred at room 
temperature overnight. Water was added (5 mL), the solution was neutralized with 
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NaHCO3 (1 M) and extracted with CH2Cl2 (3 x 10 mL). The organic layer was dried 
(Na2SO4), and the solvent was evaporated to dryness. The residue was purified by column 
3; H, 5.47 ; N, 16.39. 
3
1H, H-5'), 4.32 (m, 1H, H-4'), 4.40 (m, 1H, NHCH), 5.0 (dd, J = 2.8, 6.2 Hz, 1H, H-3'), 
  
N -Cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-chloro-5-deoxy-β-D-ribo-
furanosyl)adenine (114). The title compound was synthesized from 65.  
white 
3.0 Hz, 1H, H-3'), 6.30 (s, 1H, H-1'), 7.80 (d, J = 6.4 Hz, 1H, NH), 8.20 (2s, 2H, H-2, H-
chromatography as reported below. 
2-Chloro-N6-cyclopentyl-9H-(2,3-O-isopropylidene-5-chloro-5-deoxy-β-D-ribofura- 
nosyl)adenine (108). The title compound was synthesized from 106 and purified by 
chromatography on a silica gel column (CHCl3) gave 108 as a white solid (68% yield). 
1H-
NMR (DMSO-d6): δ 1.33, 1.55 (2s, 6H, CH3), 1.55 (m, 4H, cyclopentyl), 1.70 (m, 2H, 
cyclopentyl), 1.92 (m, 2H, cyclopentyl), 3.76 (dd, J = 6.0, 11.1 Hz, 1H, H-5'), 3.86 (dd, J = 
7.0, 11.0 Hz, 1H, H-5'), 4.34 (m, 1H, H-4'), 4.40 (m, 1H, NHCH), 5.0 (dd, J = 2.8, 6.2 Hz, 
1H, H-3'), 5.36 (dd, J  = 2.3, 6.2 Hz, 1H, H-2'), 6.16 (d, J = 2.1 Hz, 1H, H-1'), 8.32 (s, 1H, 
H-8), 8.40 (d, J = 7.3 Hz, 1H, NH). MS: m/z 429.4 [M + H]+. Anal. calcd. for  
C18H23Cl2N5O3: C, 50.48; H, 5.41; N, 16.35  N. Found: C, 50.4
2-Chloro-N6-(±)-endo-norbornyl-9H-(2,3-O-isopropylidene-5-chloro-5-deoxy-β-D-
ribofuranosyl)adenine (109). The title compound was synthesized from 107 
Chromatography on a silica gel column (CHCl ) gave 109 as a white foam (70% yield). 
1H-NMR (DMSO-d6): δ 1.28 (m, 3H, norbornyl), 1.38, 1.55 (2s, 6H, CH3), 1.40 (m, 3H, 
norbornyl), 1.60 (m, 1H, norbornyl), 1.90 (m, 1H, norbornyl), 2.18 (br s, 1H,  norbornyl), 
2.52 (s, 1H, norbornyl), 3.75 (dd, J = 6.8, 11.1 Hz, 1H, H-5'), 3.85 (dd, J = 7.0, 11.0 Hz, 
5.32 (dd, J = 2.3, 6.2 Hz, 1H, H-2'), 6.15 (d, J = 2.1 Hz, 1H, H-1'), 8.30 (s, 1H, H-8), 8.40 
(d, J = 7.3 Hz, 1H, NH). MS: m/z 455.4 [M + H] . Anal. calcd. for  C+ 20H25Cl2N5O3: C, 
52.87; H, 5.55; N, 15.41. Found: C, 52.83; H, 5.61; N, 15.38.  
191
6
Chromatography on a silica gel column (CHCl3-MeOH, 99.5:0.5) gave 114 as a 
foam (52% yield). 1H-NMR (DMSO-d6): δ 1.20 (s, 3H, CH3), 1.40, 1.55 (2s, 3H, CH3), 
1.56 (m, 4H, cyclopentyl), 1.70 (m, 2H, cyclopentyl), 1.92 (m, 2H, cyclopentyl), 4.02 (dq, 
J = 11.1 Hz, 2H, H-5'), 4.33 (dt, J = 6.3 Hz, 1H, H-4'), 4.50 (m, 1H, NHCH), 4.63 (d, J = 
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8). MS: m/z 408.9 [M + H]+. Anal. calcd. for C19H26ClN5O3: C, 55.95; H, 6.42; N, 17.17. 
Found: C, 55.88; H, 6.53; N, 17.21. 
2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-chloro-5-deoxy-β-D-
ribofuranosyl)adenine (115). The title compound was synthesized from 66.191 
R 
), 1.30 (m, 3H, norbornyl), 1.35, 1.55 (2s, 6H, 
 
nyl), 1.60 (m, 1H, norbornyl), 1.90 (m, 1H, norbornyl), 2.15 (br 
Chromatography on a silica gel column (CHCl3) gave 115 as a foam (50% yield). 
1H-NM
(DMSO-d6): δ 1.18 (s, 3H, CH3), 1.40, 1.56 (2s, 6H, CH3), 1.54 (m, 4H, cyclopentyl), 1.70 
(m, 2H, cyclopentyl), 1.90 (m, 2H, cyclopentyl), 4.0 (dq, J = 11.5 Hz, 2H, H-5'), 4.35 (q, J 
= 7.3 Hz, 1H, H-4'), 4.40 (m, 1H, NHCH), 4.60 (d, J = 3.0 Hz, 1H, H-3'), 6.20 (s, 1H, H-
1'), 8.25 (s, 1H, H-8), 8.40 (d, J = 7.7 Hz, 1H, NH). MS: m/z 443.4 [M + H]+. Anal. calcd. 
for C19H25Cl2N5O3: C, 51.59; H, 5.69; N, 15.83.  Found: C, 51.52; H, 5.66; N, 15.79.  
N6-(±)-endo-Norbornyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-chloro-5-deoxy-β-D-
ribofuranosyl)adenine (116). The title compound was synthesized from 112 
Chromatography on a silica gel column (CHCl3) gave 116 as a white solid (60% yield). 
1H-NMR (DMSO-d6): δ 1.20 (2s, 3H, CH3
CH3), 1.42 (m, 3H, norbornyl), 1.60 (m, 1H, norbornyl), 1.90 (m, 1H, norbornyl), 2.15 (br
s, 1H, norbornyl), 2.52 (br s, 1H, norbornyl), 4.0 (dq, J = 10.5 Hz, 2H, H-5'), 4.35 (m, 2H, 
NHCH, H-4'), 4.65 (d, J = 2.6 Hz, 1H, H-3'), 6.28 (s, 1H, H-1'), 7.85 (br s, 1H, NH), 8.20 
(2s, 2H, H-2, H-8). MS: m/z 434.9 [M + H]+. Anal. calcd. for  C21H28ClN5O3: C, 58.13; H, 
6.50; N, 16.14. Found: C, 58.17; H, 6.44; N, 16.22. 
2-Chloro-N6-(±)-endo-norbornyl-9H-(2-C-methyl-2,3-O-isopropylidene-5-chloro-5-
deoxy-β-D-ribofuranosyl)adenine (117). The title compound was synthesized from 113. 
Chromatography on a silica gel column (CHCl3) gave 117 as a white foam (69% yield). 
1H-NMR (DMSO-d6): δ 1.20 (s, 3H, CH3), 1.30 (m, 3H, norbornyl), 1.40, 1.55 (2s, 6H, 
CH3), 1.42 (m, 3H, norbor
s, 1H, norbornyl), 2.52 (s, 1H, norbornyl), 4.0 (dq, J = 10.7 Hz, 2H, H-5'), 4.25 (m, 1H, 
NHCH), 4.35 (m, 1H, H-4'), 4.60 (d, J = 3.0 Hz, 1H, H-3'), 6.20 (s, 1H, H-1'), 8.25 (s, 1H, 
H-8), 8.45 (d, J = 6.8 Hz, 1H, NH). MS: m/z 469.4 [M + H]+. Anal. calcd. for 
C21H27Cl2N5O3: C, 58.85; H, 5.81; N, 14.95. Found: C, 58.77 ; H, 5.83; N, 14.91. 
General procedure for the synthesis of compounds 95, 96, 97-100. Compounds 108, 
109 and  114-117 (1.0 mmol) were treated with HCOOH 70% in water (10 mL) and the 
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mixture was stirred at 40 °C for the time reported below. The solvent was evaporated in 
vacuo and the residue was coevaporated several times with CH3OH, then purified by 
column chromatography. 
6N -Cyclopentyl-9H-(5-chloro-5-deoxy-β-D-ribofuranosyl)adenine (95). The tit
compound was synthesized from 109 (reaction time 4 h). Chromatography on a silica gel 
column (CHCl
le 
1
N endo H β
(96). The title compound was synthesized from 109 (reaction time 6 h). Chromatography 
1H-
orbornyl), 1.90 (2m, 1H, norbornyl), 2.16 (br s, 1H, norbornyl), 2.52 (br s, 1H, 
norbornyl), 3.84 (m ,
16.90. Found: C, 49.22; H, 5.14; N, 16.87. 
N -Cyclopentyl-9H-(2-C-methyl-5-chloro-5-deoxy-β-D-ribofuranosyl)adenine (97). 
 6 h). Chromatography on a 
silica gel column (CHCl -MeOH, 99:1) gave 97 as a white foam (60% yield). H-NMR 
(CDCl ): δ 1.05 (s, 3H, CH ), 1.52-1.82 (m, 6H, cyclopentyl), 2.15 (m, 2H, cyclopentyl), 
3-MeOH, 99:1) gave 95 as a white foam (73% yield). H-NMR (DMSO-d6): 
δ 1.51-2.03 (large m, 8H, cyclopentyl), 3.90 (m, 2H, H-5'), 4.11 (m, 1H, H-4'), 4.18 (m, 
1H, H-3'), 4.43 (m, 1H, NHCH ), 4.66 (m, 1H, H-2'), 5.45 (d, J = 5.1 Hz, 1H, OH), 5.62 (d, 
J = 5.9 Hz, 1H, OH), 5.87 (d, J = 5.9 Hz, 1H, H-1'), 8.38 (s, 2H, H-8+NH). MS: m/z 389.3 
[M + H]+. Anal. calcd. for C15H19Cl2N5O3: C, 46.40; H, 4.93; N, 18.04. Found: C, 46.48; 
H, 4.87; N, 18.10. 
2-Chloro- 6-(±)- -norbornyl-9 -(5-chloro-5-deoxy- -D-ribofuranosyl)adenine 
on a silica gel column (CHCl3-MeOH, 98:2) gave 96 as a white foam (60% yield). 
NMR (DMSO-d6): δ 1.28 (m, 3H, norbornyl), 1.43 (m, 3H, norbornyl), 1.50-1.65 (2m, 1H, 
n
, 1H  H-5'), 3.92 (m, 1H, H-5'), 4.08 (q, J = 5.6 Hz, 1H, H-4'), 4.16 (m, 
1H, H-3'), 4.24 (m, 1H, NHCH), 4.64 (m, 1H, H-2'), 5.48 (d, J = 5.1 Hz, 1H, OH), 5.62 (d, 
J = 6.0 Hz, 1H, OH), 5.85 (d, J = 6.0 Hz, 1H, H-1'), 8.37 (s, 1H, H-8), 8.40 (d, J = 6.8 Hz, 
1H, NH). MS: m/z 415.3 [M + H]+. Anal. calcd. for  C17H21Cl2N5O3: C, 49.29; H, 5.11; N, 
6
The title compound was synthesized from 114 (reaction time
3
1
3 3
3.88 (dd, J = 4.9, 11.7 Hz, 1H, H-5'), 3.94 (dd, J = 4.7, 11.0 Hz, 1H, H-5'), 4.15 (br s, 1H, 
H-4'), 4.35 (q, J = 5.1 Hz, 1H, H-3'), 4.60 (m, 1H, NHCH), 5.60 (br s, 1H, OH), 5.85 (br s, 
1H, OH), 6.0 (s, 1H, H-1'), 8.0 (br s, 2H, H-2, NH), 8.38 (s, 1H, H-8). MS: m/z 368.8 [M + 
H]+. Anal. calcd. for C16H22ClN5O3: C, 52.24; H, 6.03; N, 19.04. Found: C, 52.20; H, 
6.07; N, 19.08. 
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2-Chloro-N6-cyclopentyl-9H-(2-C-methyl-5-chloro-5-deoxy-β-D-ribofuranosyl) 
adenine (98). The title compound was synthesized from 115 (reaction time 12 h). 
 h). 
d 
5-chloro-5-deoxy-β-D-ribofura-
h). 
Chromatography on a silica gel column (CH3Cl-MeOH, 99:1) gave 98 as a white foam 
(70% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.50 (m, 4H, cyclopentyl), 1.70 
(m, 2H, cyclopentyl), 1.90 (m, 2H, cyclopentyl), 3.98-4.10 (m, 4H, H-5', H-4', H-3'), 4.40 
(m, 1H, NHCH), 5.40 (s, 1H, OH), 5.52 (d, J = 6.4 Hz, 1H, OH), 5.90 (s, 1H, H-1'), 8.24 
(s, 1H, H-8), 8.35 (d, J = 6.8 Hz, 1H, NH). MS: m/z 403.3 [M + H]+. Anal. calcd. for 
C16H21Cl2N5O3: C, 47.77; H, 5.26; N, 17.41. Found: C, 47.79; H, 5.28; N,   17.45. 
N6-(±)-endo-Norbornyl-9H-(2-C-methyl-5-chloro-5-deoxy-β-D-ribofuranosyl)- 
adenine (99). The title compound was synthesized from 116 (reaction time 10
Chromatography on a silica gel column (CH3Cl-MeOH 98:2) gave 99 as a white soli
(67% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.28 (m, 3H, norbornyl), 1.44 (m, 
3H, norbornyl), 1.60 (m, 1H, norbornyl), 1.90 (m, 1H, norbornyl), 2.16 (br s, 1H, 
norbornyl), 2.52 (br s, 1H, norbornyl), 4.0 (m, 2H, H-5'), 4.08 (m, 1H, H-4'), 4.14 (m, 1H, 
H-3'), 4.34 (m, 1H, NHCH), 5.35 (s, 1H, OH), 5.48 (d, J = 6.4 Hz, 1H, OH), 5.98 (s, 1H, 
H-1'), 7.80 (br s, 1H, NH), 8.20 (s, 1H, H-2), 8.22 (s, 1H, H-8). MS: m/z 394.9 [M + H]+. 
Anal. calcd. for C18H24ClN5O3: C, 54.89; H, 6.14; N, 17.78. Found: C,   54.92; H, 6.10; N, 
17.75.  
2-Chloro-N6-(±)-endo-norbornyl-9H-(2-C-methyl-
nosyl)adenine (100). The title compound was synthesized from 117 (reaction time 7 
Chromatography on a silica gel column (CH3Cl-MeOH, 99:1) gave 100 as a white solid 
(81% yield). 1H-NMR (DMSO-d6): δ 0.80 (s, 3H, CH3), 1.25 (m, 3H, norbornyl), 1.40 (m, 
3H, norbornyl), 1.60 (2m, 1H, norbornyl), 1.90 (2m, 1H, norbornyl), 2.16 (br s, 1H, 
norbornyl), 2.52 (br s, 1H, norbornyl), 4.0 (m, 4H, H-5', H-4', H-3'), 4.25 (br s, 1H, 
NHCH), 5.40 (s, 1H, OH), 5.50 (d, J = 6.0 Hz, 1H, OH), 5.90 (s, 1H, H-1'), 8.28 (s, 1H, H-
8), 8.40 (d, J = 6.4 Hz, 1H, NH). MS: m/z 429.3 [M + H]+. Anal. calcd. for  
C18H23Cl2N5O3: C, 50.47; H, 5.41; N, 16.35  N. Found: C, 50.53; H, 5.37; N, 16.39. 
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5.6.2 Biological section 
 
5.6.2.1 Radioligand binding assays 
°C for 120 min in 0.5 mL of 50 mM Tris/HCl buffer, pH 7.7, containing 
he 
6
compounds at A AR were determined with [ H]CGS21680 in striatal bovine and porcine 
ing to the method of Bradford.203
35 205
ogenized with a Teflon pestle in a Potter 
Elvehjem glass homogenizer in 0.32 M sucrose (9 mL of sucrose/ g of tissue) and 
 
Affinities of new synthesized compounds at A1 AR were determined with [3H]CCPA in 
cortical bovine and porcine membranes. Cerebral cortex membranes were prepared as 
described by Lohse et al.201
The [3H]CCPA binding assay was performed according to Klotz et al.113 with minor 
modifications. 
Briefly, the [3H]CCPA binding assay was performed by incubating aliquots of cortical 
membrane homogenate (0.04 and 0.12 mg/protein for bovine and porcine membranes, 
respectively) at 25 
1 mM EDTA, 2 mMMgCl2, with 1 nM[3H]CCPA and a range of concentrations of t
tested compounds (1 nM–10 lM). The tested compounds were dissolved in DMSO and the 
percentage of organic solvent did not exceed 2% of final assay volume. Nonspecific 
binding was determined in the presence of 20 μM of (R)-N -phenylisopropyladenosine 
((R)-PIA). The incubation was stopped by sample filtration under vacuum through GF/C 
glass fiber filters. After two washes with 4 mL of ice-cold buffer, the filters were placed in 
vials containing 4 mL of scintillation cocktail and the radioactivity was counted using a 
scintillation counter (Tri-Carb 2800 TR, Perkin-Elmer). Affinities of the new synthesized 
2A
3
membranes as described by Jarvis et al.202
Protein concentration was estimated accord
The experiments (n = 4), carried out in triplicate, were analyzed by an iterative curve 
fitting procedure (GraphPad, Prism program, San Diego, CA),which provided IC50 and 
SEM values for tested compounds.IC50 values were converted to Ki values according to the 
equation of Cheng and Prusoff.204  
 
5.6.2.2 [35S]GTPγS membrane binding assay 
 
[ S]GTPγS binding was performed as previously described  with minor modifications. 
Briefly, the porcine cerebral cortex was hom
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centrifuged at 1000g for 10 min at 4° C. The supernatant was centrifuged at 46,000g
min at 4° C and the resulting pellet was suspended in 50 mM Tris/HCl, pH 7.4, 
homogenized, and recentrifuged at 46,000g for 20 min at 4° C. The final pellet was used 
immediately or stored at -80° C until binding assays. For the radioligand binding assay, the 
incubation mixture contained, in a total volume of 100 lL, 50 mM Tris/HCl, pH 7.4, 1 mM 
EDTA, 5 mM MgCl
 for 20 
lg/protein of membranes, which were pre-incubated for 15 min with 3 mU/mL ADA at 37° 
 SEM. Intrinsic activities are expressed as relative to CPA. 
 
ed by 
onlinear curve fitting with the program SCTFIT.206
2, 10 lM GDP, 1 mM dithiothreitol, 100 mM NaCl, 0.2 U/mL ADA, 
0.3 nM [35S]GTPγS, 0.5% bovine serum albumin, and a range of concentrations of tested 
compounds (1 nM–10 lM). The incubation (45 min at 25° C) was started by addition of 7.5 
C. Incubations were terminated by rapid filtration under vacuum through glass fiber filters 
(Whatman GF/C), followed by three washes with 50 mM Tris/HCl, 5 mM MgCl2, pH 7.4, 
cold buffer. The filters were placed in vials containing 4 mL of scintillation cocktail and 
the radioactivity was counted using a scintillation counter (Tri-Carb 2800 TR, Perkin-
Elmer). 
Non-specific binding was measured with 10 lM unlabeled GTPγS and was less than 10% 
of total binding. Protein concentration was estimated according to the method of 
Bradford.203
The EC50 values were derived from three independent experiments and are presented as 
means ±
 
 
5.6.2.3 Binding assay and adenylyl cyclase assay at cloned human adenosine receptors 
Ki-values were determined in competition experiments with membranes from CHO cells 
stably transfected with the individual human adenosine receptor subtypes.168
For A1 receptors 1 nM [3H]CCPA was used as a radioligand, [3H]NECA was used for the 
A2A (30 nM), [3H]NECA (10 nM) and [3H]HEMADO were used for the A3 subtype. In the 
case of A2B receptor, Ki values were calculated from IC50 values determined by inhibition 
of NECA-stimulated adenylyl cyclase activity.168 All binding data were calculat
n
 128
The functional activity of selected derivatives at A1 receptor was determined in adenylyl 
yclase experiments. The inhibition of forskolin-stimulated adenylyl cyclase via A1 and A3 
arlier.197,207
c
receptors was measured as described e
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